Genetics in the workplace: implications for occupational safety and health by National Institute for Occupational Safety and Health Genetics Working Group.
G e n e t ic s  in  t h e  
W o r k p la c e
I m p l i c a t i o n s  f o r  O c c u p a t i o n a l  
S a f e t y  a n d  H e a l t h
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention 
National Institu te for Occupational Safety and Health W o r k p l a c eSafety and Health
G E N E T I C S  IN T H E  W O R K P L A C E
I m p l i c a t i o n s  f o r  O c c u p a t i o n a l  S a f e t y  a n d  H e a lt h
Department of Health and Human Services 
Centers for Disease Control and Prevention 
National Institute for Occupational Safety and Health 
Genetics Working Group
ORDERING INFORMATION
To receive NIOSH documents or more information about occupational safety and health 
topics, please contact NIOSH:
Telephone: I-8OO-CDC-INFO (1-800-232-4636) 
TTY:1-888-232-6348 
E-mail: cdcinfo@cdc.gov
or visit the NIOSH Web site at www.cdc.gov/niosh
For a monthly update on news at NIOSH, subscribe to NIOSH eNews by visiting www/cdc. 
gov/niosh/eNews.
This docum ent is in  the public dom ain and m ay be freely  copied  or reprin ted
Disclaimers
Mention of any company or product does not constitute endorsement by NIOSH.
Citations to web sites external to NIOSH do not constitute NIOSH endorsement of the 
sponsoring organizations or their programs or products. Furthermore, NIOSH is not 
responsible for the content of these web sites.
DHHS (NIOSH) Publication Number 2010-101
November 2009
i i G e n e tic s  in  th e  W o r k p la c e
FOREWORD
The purpose of this document is to consolidate the diverse literature and opinions on 
genetics in the workplace, to flag important issues, and to provide some considerations 
for current and future research and practice. Recent advances in understanding the hu­
man genome have created opportunities for disease prevention and treatment. Even 
though the focus of attention on applications of genetic discoveries has been largely 
outside of the workplace, genetic information and genetic testing are impacting today’s 
workplace.
The issues related to genetic information and genetic testing in the workplace have the 
potential to affect every worker in the United States. This NIOSH document provides 
a discussion on the benefits, limitations, and risks of genetic information and genetic 
tests. Anecdotal evidence already exists of employers inappropriately using genetics 
tests. Although genetic technology is becoming widely available, a serious knowl­
edge gap on the part of consumers of this technology is a concern. Basic information 
on genetics, genetic research, genetic testing, genetic information, informed consent, 
privacy, confidentiality, technological advances based on genetics, notification, data 
management, and discrimination need to be discussed. The passage of the Genetic In­
formation Nondiscrimination Act of 2008 has abated some concerns about the misuse 
of genetic information. This NIOSH document provides information on these issues 
to help the reader be made more aware of the multitude of scientific, legal, and ethical 
issues with regard to the use of genetics in occupational safety and health research and 
practice.
This document has been written to appeal to both targeted and broad audiences. Oc­
cupational safety and health professionals and practitioners interested in the use of 
genetic information in the workplace will be most informed by the chapters on the role 
of genetic information in the workplace, health records, genetic monitoring, genetic 
screening, and the ethical, social, and legal implications of this information. Academ­
ics and researchers will be especially interested in the chapter on incorporating genet­
ics into occupational health research. Employers, workers, and other lay readers will 
likely find the chapters on health records and ethical, social, and legal implications of 
genetic information in the workplace provide the most information. Regardless of spe­
cific reader interest levels, the goal of this document is to draw attention to the many 
gaps in knowledge about the use of genetic information and to stimulate dialogue on 
its use in the workplace.
John Howard, M.D.
Director
National Institute for Occupational Safety and Health 
Centers for Disease Control and Prevention
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ABBREVIATIONS AND ACRONYMS
AAOHN American Association of Occupational Health Nurses, Inc.
ACCE analytic validity, clinical validity, clinical utility, and ethical, legal, and
social implications
ACE angiotensin I converting enzyme (peptidyl-dipeptidase A) 1
ACMG American College of Medical Genetics
ACOEM American College of Occupational and Environmental Medicine
ADA Americans With Disabilities Act of 1990
ADH alcohol dehydrogenase
ADRB3 adrenergic, beta-3-, receptor
ALAD aminolevulinate, delta-, dehydratase
AMA American Management Association
APOz apolipoprotein E
AR androgen receptor
ASHG American Society of Human Genetics
BMI body mass index
BRCA2 breast cancer gene 2, early onset
CBD chronic beryllium disease
CCND1 cyclin D1
CDKN2A cyclin-dependent kinase inhibitor 2A
CDC U.S. Centers for Disease Control and Prevention
CFR Code of Federal Regulations
CLIA Clinical Laboratory Improvement Amendment of 1988
CNV Copy number variant
CTSD cathepsin D
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1
CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1
CYP17 cytochrome P450, family 17
CYP2D6 cytochrome P450, family 2, subfamily D, polypeptide 6
CYP2E1 cytochrome P450, family 2, subfamily E, polypeptide 1
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4
DHHS U.S. Department of Health and Human Services
DNA deoxyribonucleic acid
DOE U.S. Department of Energy
DPB1 major histocompatibility complex, class II, DP beta 1
DQ major histocompatibility complex, class II, DQ
DQA1 major histocompatibility complex, class II, alpha 1
DQB1 major histocompatibility complex, class II, beta 1
DR3 major histocompatibility complex, class II, DR3
DRB1 major histocompatibility complex, class II, DR beta 1
EEOC Equal Employment Opportunity Commission
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EGP Environmental Genome Project
ERa Estrogen receptor a  (ESR1)
ERfi Estrogen receptor B (ESR2)
ERCC2 excision repair cross-complementing rodent repair deficiency, 
complementation group 2 (xeroderma pigmentosum D)
FDA U.S. Food and Drug Administration
FISH fluorescence in situ hybridization
G6PD glucose-6-phosphate dehydrogenase
GEI Genes, Environment and Health Initiative
GINA Genetic Information Nondiscrimination Act of 2008
GJB2 gap junction protein, beta 2, 26kDa (connexin 26)
GPA glycophorin A
GST glutathione S-transferase
GSTM1 glutathione S-transferase mu1
GSTP1 glutathione S-transferase pi
GSTT1 glutathione S-transferase theta 1
GWAS genome-wide association studies
HIPAA Health Insurance Portability and Accountability Act
HIV human immunodeficiency virus
HLA human leukocyte antigen
hMLHl mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)
hMSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)
HPRT hypoxanthine phosphoribosyltransferase
HuGE Human Genome Epidemiology
HuGENet Human Genome Epidemiology Network
IARC International Agency for Research on Cancer
IL-3 interleukin 3
IL-4 and 4R interleukin 4, interleukin 4 receptor
IRB institutional review board
Ki-ras Kirsten rat sarcoma viral oncogene homolog
MCP-1 monocyte chemoattractant protein-1
MIAME minimum-information-about-a-microarray experiment
MnSOD2 manganese superoxide dismutase 2
MPO myeloperoxidase
mRNA messenger ribonucleic acid
MTHFR 5,10-methylenetetrahydrofolate reductase (NADPH)
MTR 5-methyltetrahydrofolate-homocysteine methyltransferase
NAS National Academy of Sciences
NAT1 N-acetyltransferase 1 (arylamine N-acetyltransferase)
NAT2 N-acetyltransferase 2 (arylamine N-acetyltransferase)
NBAC National Bioethics Advisory Commission
NCI U.S. National Cancer Institute
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NF1 neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson 
disease)
NF2 neurofibromin 2
NIEHS U.S. National Institute of Environmental Health Sciences
NIH U.S. National Institutes of Health
NIOSH U.S. National Institute for Occupational Safety and Health
NQO1 NAD(P)H dehydrogenase, quinone 1
NRC National Research Council
OGG1 8-oxoguanine DNA glycosylase
OSH Act Occupational Safety and Health Act of 1970
OSHA U.S. Occupational Safety and Health Administration
OTA Office of Technology Assessment
PAH polycyclic aromatic hydrocarbons
PCR polymerase chain reaction
PGR progesterone receptor
PIR6.2 potassium inward-rectifier 6.2
PON1 paraoxonase 1
PPAR-y peroxisome proliferative activated receptor, gamma
PPV positive predictive value
PTEN phosphatase and tensin homolog
RFLP restriction fragment length polymorphism
RNA ribonucleic acid
ROC relative operating characteristic
SACGT Secretary’s Advisory Committee on Genetic Testing
SD standard deviation
SNP single nucleotide polymorphism
s p -b surfactant protein B
TDI toluene diisocyanate
TGFB1 transforming growth factor beta 1 - induced
TGFBR2 transforming growth factor beta receptor II
TNF-a tumor necrosis factor (TNF superfamily, member 2)
TNF-a-308 tumor necrosis factor (TNF superfamily, member 2 with a base change at 
position 308
TP53 tumor protein p53
tRNA transfer ribonucleic acid
UGT2B7 UDP-glucuronosyltransferase 2 family, polypeptide B7
Val valine
XRCC1 X-ray repair complementing defective repair in Chinese hamster cells 1
XRCC3 X-ray repair complementing defective repair in Chinese hamster cells 3
XRCC5 X-ray repair complementing defective repair in Chinese hamster cells 5
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EXECUTIVE SUMMARY
• Exposure to a workplace hazard is necessary for an occupational disease to 
occur, regardless of the genetic makeup of the person.
• The use of genetic information in occupational safety and health research and 
practice would have several real or perceived consequences.
• In occupational safety and health practice, genetic tests—whether for 
monitoring or screening—must be validated to provide reliable exposure or risk 
assessments.
• At this time, no genetic test related to an occupational disease has been 
validated or accepted for use, except the use of genetic biomarkers to measure 
the dose of a genotoxic exposure.
Major technological advances in the last few years have increased our knowledge of the 
role that genetics has in occupational diseases and our understanding of genetic compo­
nents and the interaction between genetics and environmental factors. The use of genetic 
information, along with all of the other factors that contribute to occupational morbidity 
and mortality, will play an increasing role in preventing occupational disease. However, the 
use of genetic information in occupational safety and health research and practice presents 
both promise and concerns [McCanlies et al. 2003; Kelada et al. 2003; Henry et al. 2002; 
Christiani et al. 2001; Schulte et al. 1999]. Use of genetic information raises medical, ethi­
cal, legal and social issues [Clayton 2003; Ward et al., 2002; McCunney 2002; Christiani 
et al 2001; Rothstein 2000a; Schulte et al. 1999; Lemmens 1997; Barrett et al. 1997, Van 
Damme et al. 1995; Gochfeld 1998; Omenn 1982].
The purpose of this report is to bring together the diverse literature and opinions on genet­
ics in the workplace, to highlight important issues, and to provide some considerations for 
current and future practice. Occupational safety and health professionals and practitioners 
may have particular interest in this report as the understanding of gene-environment inter­
actions at the mechanistic and population levels may result in improved prevention and 
control strategies. This report is divided into topic areas for ease of reading. Specifically, 
the role of genetic information in occupational disease is discussed in Chapter 2, followed 
in Chapter 3 by a presentation of how genetics is incorporated into occupational health 
research. Health records as a source of genetic information are discussed in Chapter 4. The 
report continues in Chapter 5 with a focus on genetic monitoring, followed in Chapter 6 by 
a theoretical discussion of genetic screening. The final chapter presents an overview of the 
most important aspects of this report, which are the ethical, social, and legal implications of 
genetics in the workplace. In addition, ethical issues specific to health records and genetic 
testing are discussed in Chapters 4 and 6, respectively. To assist our audience in finding
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additional sources of information or more in-depth discussion of the issues surrounding 
genetic information, a list of web sites is provided at the conclusion of this document.
Role of Genetic Information in Occupational Disease. The role of genetic information 
in occupational disease is being explored. The framework for considering genetics in the 
exposure to disease paradigm arose from a National Academy of Sciences review on bio­
markers [NRC 1987]. Biomarkers are measurements using biological tissues that give in­
formation about exposure, effect of exposure, or susceptibility. Evaluation of genetic dam­
age can provide information about exposure or effect of exposure. However, the presence 
of a specific genetic biomarker will not itself result in an occupational disease; exposure to 
a workplace hazard is necessary. The presence of a disease risk biomarker in the absence 
of exposure may be innocuous.
The study of biomarkers of genetic susceptibility in the context of workplace exposures 
can provide information about gene-environment interactions. One major emphasis of ge­
netic research in occupational disease has been in the area of response variability.
Extensive variability in the human response to workplace exposures has been observed. 
Genes can have multiple variations known as polymorphisms, which may contribute to 
some of this variability [Grassman et al. 1998]. Research has been conducted over the last 
approximately 30 years to identify the role of genetic polymorphisms in a wide range of 
occupational and environmental diseases, particularly those involving occupational car­
cinogens [Hornig 1988; Berg 1979]. The risk of biological effects or diseases attributable 
to an occupational exposure can be decreased, unchanged, or increased among individuals 
with certain genetic polymorphisms.
Incorporating Genetics into Occupational Health Research. The main influence on ge­
netic research with respect to occupational health is the large number of technological 
advances in molecular biology. Because of these new techniques, it is now feasible to 
evaluate the relationship of disease with individual genes and their variants or even with 
the whole genome. These technologies promise to set the stage for new discoveries in un­
derstanding mechanisms and the preclinical changes that might serve as early warnings of 
disease or increased risk [NRC 2007]. They also present difficult challenges in terms of 
handling large data sets, understanding the normal range, standardizing technologies for 
comparison and interpretation, and communicating results [King and Sinha 2001; Wittes 
and Friedman 1999].
As our understanding of the role of specific genes and their variants increases, genetic 
tests are being developed to look at specific genotypes. One critical issue in genetics is the 
validity of such genetic tests. Much contemporary genetic research involves the collection 
of biological specimens (usually DNA in white blood cells) that are then tested either for 
changes (damage) to genetic material or for genetic polymorphisms. These genetic tests, 
while useful in occupational health research, are not ready for clinical use; in other words, 
they are not validated for clinical interpretation. Validation is a process by which a test’s
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performance is measured both in the laboratory and in populations, resulting in the evalua­
tion of the clinical utility or the risks and benefits of the test. Until clinically validated, the 
information from such tests may be meaningless with regard to an individual’s health or 
risk. In contrast, genetic tests may be validated for assessing exposure or effect modifica­
tion in research even if they have no clinical utility.
Health Records: A Source of Genetic Information. Genetic tests are not the only source of 
genetic information in the workplace. Genetic information is kept in workers’ personnel 
and workplace health records [Rothenberg et al. 1997]. This information is in the family 
history of diseases with known strong genetic etiologies as well as in the results of physical 
examinations and common laboratory tests. This type of information is reported routinely 
by workers or obtained by employers from workers’ job applications, health questionnaires, 
health and life insurance applications, physicals, and workers’ compensation proceedings 
[Anderlik and Rothstein 2001]. The line between what is and is not genetic information in 
health records is unclear. States have enacted legislation with widely varying definitions 
of what constitutes genetic information from an employee’s health record. Questions con­
cerning confidentiality, privacy and security remain as the handling of health records may 
be influenced by various federal and state regulations.
Genetic Monitoring and Occupational Research and Health Practice. Genetic information 
can be a scientific tool to understand mechanisms and pathways in laboratory research and 
as independent or dependent variables in population research studies of workers. In oc­
cupational safety and health practice, genetic tests may be used in a variety of ways. As in 
other areas of health science, genetic information may be used in the differential diagnosis 
of disease, allowing clinicians to consider or exclude various diagnoses. Monitoring for 
the effects of exposure on genetic material, such as chromosomes, genes, and constituent 
deoxyribonucleic acid (DNA), has been used to evaluate risks and potential health prob­
lems for more than 50 years, particularly those from ionizing radiation [Mendelsohn 1995; 
Langlois et al. 1987; Berg 1979]. Such monitoring is not unlike monitoring for metals in 
blood, solvents in breath, or dusts in lungs and presents less ethical concern than assessing 
heritable effects [Schulte and DeBord 2000]. Tests for genetic damage have been advo­
cated as a way to prioritize exposed individuals for more thorough medical monitoring 
[Albertini 2001].
Genetic monitoring highlights the confusion that exists between individual and group risk 
assessment. Unlike other monitoring methods, the risks linked to cytogenetic changes are 
interpretable only for a group, not for an individual [Schulte 2007; Murray 1983; Lappe 
1983].
Currently, no U.S. regulations exist that mandate genetic monitoring. Questions arise 
whether genetic monitoring indicates a potential health problem, an existing health prob­
lem, or compensable damage. More research is needed to understand the science before the 
individual’s risk of disease can be interpreted from genetic monitoring results. However, 
genetic monitoring to determine exposure may be useful for the occupational health prac­
titioner.
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Theoretical Use of Genetic Screening and Occupational Health Practice. Genetic moni­
toring may have some application in occupational health practice, but perhaps the most 
controversial use of genetic information would be in making decisions about employment 
opportunities and health and life insurance coverage [Schill 2000; Bingham 1998; Van 
Damme et al. 1995; Murray 1983; Lappe 1983]. This would occur primarily as a result of 
genetic screening, in which a job (and insurance) applicant or a current worker might be 
asked to undergo genetic testing to determine if he or she has a certain genotype. However, 
the Genetic Information Nondiscrimination Act of 2008 (GINA) prohibits discrimination 
on the basis of genetic information with respect to health insurance and employment [U.S. 
Congress 2008]. Genetic screening which was not strictly prohibited by the Americans 
With Disabilities Act of 1990 (ADA) is now prohibited. Under ADA an employer may 
not make medical inquiries about an applicant until a conditional offer has been extended. 
Once the offer has been tendered, an employer could have obtained medical, including ge­
netic, information about a job applicant. ADA did not prohibit obtaining genetic informa­
tion or genetic screening, nor did it prohibit an employer from requesting genetic testing 
once an applicant has been hired provided the testing is job related. and can be used for the 
purposes of job placement after a conditional job offer is made.
Most criteria for genetic screening programs indicate that participation should be volun­
tary, with informed consent in place. Genetic screening for these purposes cannot be sup­
ported at this time because of the current lack of linkage of causation of a given genetic 
polymorphism with a given occupational disease and its implications with regard to the 
Occupational Safety and Health Act (OSH Act of 1970) that the workplace be safe for all 
workers [OSHA 1980b].
Accurate genetic screening information may eventually be useful to workers considering 
employment options. Obtaining this information for the worker would become appropriate 
only after the screening tests have been validated regarding risk. Various ethical arguments 
have been advanced in the discussion of genetic screening, and a broad range of implica­
tions of genetic testing has been discussed in the literature and in this document, including 
the oversight of genetic testing laboratories.
The Ethical, Social, and Legal Implications of Genetics in the Workplace. A concern about 
the use of genetic information in occupational safety and health is that the emphasis in 
maintaining a safe and healthful workplace could shift from controlling the environment 
to excluding the vulnerable worker. This would be counter to the spirit and the letter of the 
OSH Act of 1970 [OSHA 1980b]. Actions that attempt to depart from providing safe and 
healthful workplaces for all should not be supported. Nevertheless, understanding the role 
of genetic factors in occupational morbidity, mortality, and injury is important and could 
lead to further prevention and control efforts. However, occupational safety and health de­
cision-makers, researchers, and practitioners may find that genetic factors do not contribute 
substantially to some occupational diseases. Environmental risk factors will probably al­
ways be more important for developing strategies for prevention and intervention in occu­
pational disease and ultimately for the reduction of morbidity and mortality. The challenge
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is to identify and apply genetic information in ways that will improve occupational safety 
and health for workers.
The use of genetic information in occupational safety and health research requires careful 
attention because of the real or perceived opportunities for the misuse of genetic informa­
tion. Society in general and workers in particular have concerns that discrimination and 
lack of opportunity will result from the inappropriate use of genetic information [MacDon­
ald and Williams-Jones 2002; Maltby 2000]. While only sparse or anecdotal information 
supports this contention, a wide range of workers, legislators, scientists, and public health 
researchers have concern that such discrimination could occur. Thus, GINA and other regu­
lations were passed to prevent the potential misuse and abuse of genetic information in the 
workplace. Examples of safeguards include rules and practices for maintaining privacy 
and confidentiality, prohibition of discrimination, and support of a worker’s right of self­
determination (autonomy) with regard to genetic information.
Many of these safeguards have been built into biomedical research in general, and occu­
pational safety and health research in particular, through guidance given in the Nuremberg 
Code [1949], the Belmont Report [1979], and the Common Rule (45 CFR* 46) [DHHS 
2005; CFR 2007], as well as in the National Bioethics Advisory Commission (NBAC) re­
ports [1999], the ADA [1990], Health Insurance Portability and Accountability Act (HIPAA) 
[1996] and GINA in 2008 [U.S. Congress 2008]. ADA and HIPAA provided some safe­
guards against the potential misuse of genetic information in the workplace before GINA 
was signed and in 2000, Executive Order 13145 was signed that prohibits discrimination in 
federal employment based on genetic information [65 Fed. Reg.T 6877 (2000)].
In summary, the use of genetic information in the workplace has the potential to affect 
every worker in the United States. This NIOSH document provides information on the 
scientific, legal, and ethical issues with regard to the use of genetics in occupational safety 
and health research and practice.
*Code of Federal Regulation. CFR in references. 
tFederal Register. See Fed. Reg. in references.
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G L O S S A R Y
Allele: The abbreviation for allelomorphs, meaning different forms of a gene or specific 
DNA (deoxyribonucleic acid) sequence that may be found in a population [Jorde et al. 
1997; Last 1988].
Analytical validity: The measure of how well a test predicts the disease genotype [SAC- 
GT 2000].
Base pair: Two complementary nucleotides linked by weak electrostatic bonds (hydrogen 
bonds). Electrostatic bonds between complementary single strands of DNA maintain the 
double helix structure of DNA [SACGT 2000].
Bioinformatics: The biotechnology revolution has created enormous quantities of data, 
especially in the areas of genomics, transcriptomics, and proteomics. Bioinformatics is the 
computer-based management, integration, and analysis of biotechnology data.
Biological variability: Variation in biological measurements. It can be subdivided into 
intraindividual variability, which is the difference within an individual over time, and in­
terindividual variability, which is the difference between individuals.
Biologically effective dose: The amount of a substance/chemical that reaches the target 
site for toxicity/disease.
Biomarker: Measurement made in biological tissues that give information about expo­
sure, disease or susceptibility.
Centromere: The condensed or constricted part of a chromosome, also known as the pri­
mary constriction. This is the structure responsible for chromosomal attachment to the 
spindle fibers during cell division that ensures that each daughter cell receives exactly half 
of the chromosomes.
Chemical base: An essential building block of DNA, one of four bases or nucleotides (ad­
enine [A], cytosine [C], guanine [G], and thymine [T]) [SACGT 2000].
Chromosomal aberration: Structural alteration of the chromosomes. Aberrations include 
breaks, deletions, insertions, translocations (of part of one chromosome to another chromo­
some), missing chromosomes (e.g., Turners), and extra chromosomes (e.g., trisomy).
Chromosome: Literally, “colored body” (Greek). A nucleic acid-protein complex contain­
ing a DNA molecule that codes for various genes. Humans have 23 pairs of chromosomes 
and inherit one of each pair from each parent.
Clinical utility: Assessment of the risks and benefits of a test to determine its value or 
usefulness for disease prevention, disease treatment, or life planning.
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Clinical validity: The measure of how well a test predicts the disease phenotype, including 
parameters such as positive predictive value and penetrance, environmental factors, and 
prevalence of the condition [SACGT 2000; Khoury et al. 1985].
Confounding: In epidemiology, a distortion of the exposure-disease relationship due to 
the effect of another variable (the confounder). A confounder must (1) be a risk factor for 
the disease, even among those not exposed, (2) be associated with the primary exposure of 
interest in the population from which the disease cases arose, and (3) not be an intermedi­
ate step in the causal pathway between the primary exposure of interest and the disease. 
Control of confounding, through study design or data analysis strategies, will reduce the 
impact of this bias [Rothman and Greenland 1998].
Copy number variant (CNV): A segment of DNA for which copy number differences 
have been observed when comparing two or more genomes. Normally, humans have two 
copies of each autosomal region. CNV can be caused by inversions, deletions, duplica­
tions, and translocations; and may be inherited or occur due to environmental exposures. 
CNV have been associated with a number of diseases.
Deoxyribonucleic acid (DNA): The hereditary material, a polymeric macromolecule com­
posed of sugar, phosphate, and the four chemical bases. The ordering of the bases provides 
the chemical code that governs all vital processes.
Diagnostic test: A tool used to ascertain current disease status.
DNA adduct: When a chemical attaches or binds to DNA or a DNA base modified by the 
covalent addition of an electrophile [Poirier and Weston 2002].
DNA strand break: The usual structure of DNA is a pair of complementary strands en­
twined in the form of a double helix. DNA damage can result from cleavage of one or both 
strands, either through interaction with toxic agents (chemicals or radiation) or through 
interaction with enzymes that modify DNA.
Effect modification: In epidemiology, a change in the size or magnitude of the exposure- 
disease relationship according to the value of another variable (the effect modifier). It is not 
a bias to be eliminated, but a finding to be reported as part of the effect measure.
Electrophile: In chemistry, is a chemical attracted to electrons and by accepting electrons 
from another chemical allows it to bond or attach to that chemical.
Epigenetics: The study of heritable changes in gene function that occur without a change 
in the sequence of DNA.
Gene: The fundamental physical and functional unit of heredity. A gene is an ordered 
sequence of nucleotides located in a particular position on a particular chromosome that 
encodes a specific functional product (i.e., a protein or ribonucleic acid [RNA] molecule).
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Gene-environment interaction: The combination of environmental factors and genetic 
factors to bring about a biological effect (disease phenotype). Six possible interaction mod­
els have been described: (1) neither the gene alone nor the exposure alone will result in 
disease, (2) a benign genotype occurs in the absence of a specific toxic exposure, (3) the 
risk of disease is higher in the presence of a specific genotype regardless of any type of 
exposure, although the risk of disease may be exacerbated in the presence of a specific 
exposure, (4) either the gene alone or the exposure alone may result in disease, (5) the pres­
ence of the gene decreases the effect of the exposure, and (6) the presence of the exposure 
decreases the effect of the gene [Khoury et al. 1993].
Gene-gene interactions: Interactions that occur when the combined effect of having cer­
tain alleles for specific genes is additive or multiplicative.
Genetic discrimination: The use of genetic information to exclude certain individuals 
from opportunities for employment, insurance, or reproduction.
Genetic exceptionalism: The view that genetic information can and should be differenti­
ated from other health information and afforded special protection [Kulynych and Korn 
2002; Murray 1997].
Genetic information: Narrowly defined, the results of DNA analysis; broadly defined, 
family health histories and the results of common laboratory tests for gene products as well 
as DNA test results [Kulynych and Korn 2002].
Genetic monitoring: The periodic evaluation of an exposed population, ascertaining 
whether an individual’s genetic material has been altered over time and thus indicating 
exposure and/or providing an early warning of possible health effects or outcomes [Schulte 
and Halperin 1987].
Genetic research: Evaluation of the role of specific genes in human disease or the effect of 
agents on DNA material or changes in gene expression. In the context of this publication, 
genetic research evaluates the role of specific genes, genetic damage, or changes in gene 
expression in occupational disease.
Genetic screening: A panel of genetic tests performed on one individual or a single genetic 
test applied in a population-based program [Press and Burke 2001; Parker and Majeske 
1996].
Genetic test: An assay used for the determination of the inherited genotype to identify 
specific alleles or mutations. Genetic tests can also be used for the determination of somatic 
changes that occur in the DNA, e.g., chromosomal breaks, rearrangements, or mutations.
Genome: The full complement of DNA that encodes all of the genes required for the struc­
ture and function of an organism. It has been estimated that about 20,000-25,000 human 
genes exist [Clamp et al. 2007].
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Genome-wide association study: An approach that involves rapidly scanning markers 
across complete sets of DNA or genomes of many people to find genetic variations associ­
ated with a particular disease.
Genomics: The study of genomes.
Genotype: The genetic constitution of an organism, as distinguished from its physical 
appearance or phenotype [DOE 2001]. The distinct set of alleles that an individual carries 
[SACGT 2000].
Hardy-Weinberg equilibrium: The principle that, in an infinitely large population and in 
the absence of mutation, migration, selection, and nonrandom mating, both gene and geno­
type frequencies are balanced according to the formulap2 + q2 + 2pq = 1.00, wherep  is all 
of the alleles that are homozygous and q is the frequency of other alleles at a genetic locus. 
Many loci have greater than two polymorphic alleles.
Heterozygous: Refers to an individual who has inherited different alleles at the same ge­
netic locus.
Hierarchy of controls: The principle that the best way to reduce worker exposure is to 
use a number of approaches that are designed to eliminate or minimize exposure. These 
include, in order of preference, elimination or substitution of the hazard, engineering con­
trols (such as isolation or ventilation), administrative controls, training in work practices, 
and personal protective equipment [Ellenbecker 1996].
Homozygous: Refers to an individual with two identical copies of a gene or an individual 
who has inherited identical alleles of a gene.
Linkage disequilibrium: Between genes close together on a chromosome, the co-inheri­
tance of particular alleles at each locus.
Locus (plural, loci): The position on a chromosome of a gene or other chromosome mark­
er; also, the DNA at that position. The use of locus is sometimes restricted to mean ex­
pressed DNA regions.
Medical monitoring: The ongoing performance and analysis of routine environmental or 
clinical measurements aimed at detecting changes in the environment or health status of an 
individual or specific population that are at a known risk for a disease [Last 1988].
Medical removal: Removal of a worker from a particular job task, title, worksite, or em­
ployment by an employer due to (1) a present medical condition or perceived susceptibility 
to a future medical condition believed to affect workplace performance negatively or (2) 
an exposure believed to negatively affect the worker’s current or future health or that of 
his/her children.
Medical screening: The presumptive identification of unrecognized disease or defect 
by the application of tests, examinations, or other procedures that can be applied rapidly. 
Screening tests distinguish apparently well persons who probably have a disease from
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those who probably do not and are a snapshot of the health of a person. A screening test is 
not intended to be diagnostic, although medical screening is performed for a clinical ap­
proach. Persons with positive or suspicious findings must be referred to their health care 
providers for diagnosis [Last, 1988].
Medical surveillance: Medical surveillance in the workplace is the overall process of 
ongoing, systematic collection, analysis, and interpretation of health data from workers. 
The goal is early recognition of trends and adverse health effects for prevention efforts. 
Included in medical surveillance is medical monitoring and medical screening.
Metabonomics: Investigations into the genetic underpinnings of metabolism.
Microarray: A set of microscopic molecular probes (nucleic acids or proteins/antibodies) 
that may be used to identify and quantify DNA, RNA, or proteins.
Micronuclei: Remnants of aberrant cell division that form small nuclear bodies that may 
contain chromosomes or chromosome fragments.
Monogenic disease: A disease determined by an allele at a single genetic locus.
Mutation: A change in the genetic material. Only changes in germ cells (ova and sperm) 
can be inherited. Changes in somatic cells (any cell in the body except germ cells) may 
lead to cancer.
Negative Predictive Value: The proportion of individuals who test negative and who will 
not get the condition.
Oncogene: An activated protooncogene. Oncogenes can promote or allow the uncontrolled 
growth of cancer cells.
Outlier: A test result quite different from the usual, typically a result that is more than two 
standard deviations from the mean of population test results.
Penetrance: The proportion of a population with a disease-related genotype that displays 
the phenotype (e.g., that develops the disease).
Phase I enzymes: Enzymes with broad substrate specificity that have the primary function 
of detoxification, usually by the addition of an oxygen molecule (e.g., cytochrome P450). 
However, these enzymes can inadvertently activate otherwise chemically inert toxincant to 
powerful electrophiles capable of forming adducts to DNA.
Phase II enzymes: Enzymes with narrow substrate specificity that reduce (epoxide hydro­
lase) or conjugate (glucuronosyl transferase) oxygenated chemical species. The primary 
function of phase II enzymes is detoxification; however, many have roles in the activation 
of procarcinogens.
Phenotype: The physical and biochemical characteristics of individuals as determined by 
their genotypes and by environmental factors [SACGT 2000].
Polygenic disease: A disease determined by alleles at multiple genetic loci.
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Polymerase chain reaction (PCR): The polymerase chain reaction is a method for the 
rapid amplification of specific segments of DNA. Specificity is accomplished through the 
use of primer molecules that are complementary to sequences that flank the region of DNA 
to be amplified. The reaction mixture is then subjected to thermal cycling. Since each new 
cycle produces more DNA as a template, the PCR product accrues exponentially. Thus, 
from 1 picogram (10-12 grams) of original template, 25 cycles will realize more than 10 
micrograms (10-5 grams) of PCR product.
Polymorphism: Literally, “many forms” (Greek). A locus where two or more alleles have 
gene frequencies greater than 0.01 in a population. For a given population, therefore, if 
at least 1% of genes (1 heterozygote in 50 people) harbor a DNA sequence variation, the 
variation is considered to be a polymorphism [Jorde et al. 1997].
Positive predictive value (PPV): The positive predictive value of a screening test is the 
proportion among those who test positive who truly are positive (true positives/(true posi­
tives + false positives)).
Protein adduct: An amino acid modified by covalent interaction with an electrophile.
Protein expression: The process by which transfer RNA (tRNA) translates messenger 
RNA (mRNA) to form proteins from amino acids.
Proteome: The full complement of proteins required for the structure and function of an 
organism.
Proteomics: The study of proteomes.
Protooncogene: Normal cell cycle regulatory genes that preserve cellular homeostasis. 
Mutations in protooncogenes can cause their activation, transforming them into oncogenes.
Reporter gene: In general, a reporter gene can give information about exposure, effect 
of exposure, or the expression of genes. Specific examples include (1) a gene in which 
mutations may be detected that signify carcinogenic or mutagenic exposure (hypoxanthine 
phosphoribosyltransferase [HPRT] and glycophorin A [GPA]), (2) a gene in which spe­
cific mutations suggest exposure to a specific carcinogen (codon 279 mutations of p53 in 
aflatoxin Bl-induced liver cancer), (3) a gene whose expression is induced in response to 
a specific environmental stimulus (alcohol induction of hepatic cytochrome P450, family
2, subfamily E, polypeptide 1 [CYP2E1]), and (4) a gene whose expression is under the 
control of an inducible promoter in an experimental situation (placing a gene adjacent to 
the metallothionine promoter allows induction by treatment with metal ions, e.g., Cd2+).
Resequencing: Repeating the sequence determination of a DNA fragment.
Restriction enzymes: Enzymes that constitute primitive defense mechanisms of bacte­
ria. Such enzymes recognize specific DNA sequences (usually 4-8 nucleotides in length). 
Upon binding to the recognition sequence, nuclease activity cleaves the DNA strands.
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Restriction fragment length: Restriction enzymes recognize specific sequences in poly­
morphisms (restriction fragment length polymorphism [RFLP]) to which they can bind and 
cause cleavage of the DNA. Therefore, these enzymes can be used to perform relatively 
crude interrogation of a DNA sequence. An enzyme recognizes a particular sequence of 
DNA bases and will cleave a segment of DNA at each position that this sequence appears. 
The DNA segment is cut into fragments that can be visualized by agarose gel electropho­
resis. In a DNA mixture containing different alleles, disruption of a restriction enzyme 
recognition site due to the nucleotide polymorphism results in variation in the size of the 
restriction fragments.
Ribonucleic acid (RNA): The nucleic acid polymers messenger RNA (mRNA) and trans­
fer RNA (tRNA) translate and transcribe the DNA code into peptides and proteins. RNA 
also functions as both regulatory molecules (rRNA) and as the genetic code in certain 
viruses.
Sensitivity: A measure of clinical validity: the proportion of truly diseased persons identi­
fied as diseased by a positive test result (true positives/(true positives + false negatives)) 
[Last 1988]. For analytical validity, sensitivity indicates how good the test is at identifying 
the marker or agent when present.
Sequencing: The determination of the order of the nucleotides (chemical bases) in a DNA 
or RNA molecule or the order of the amino acids in a protein [DOE 2001].
Single nucleotide polymorphism: A polymorphism resulting from a single base pair dif­
ference between alleles.
Sister chromatid exchange: Crossover between sister chromatids. This can occur either in 
the sister chromatids of a tetrad during meiosis or between sister chromatids of a duplicated 
somatic chromosome [Jorde et al. 1997].
Sister chromatids: The two identical strands of a duplicated chromosome joined by a 
single centromere [Jorde et al. 1997].
Specificity: A measure of clinical validity: the proportion of truly nondiseased persons 
identified as nondiseased by a negative test result (true negatives/true negatives + false 
positives) [Last 1988]. For analytical validity, specificity indicates how good the test is at 
correctly identifying the absence of the marker or agent.
Stochastic process: A sequence of events governed by probabilistic laws [Karlin and Tay­
lor 1975].
Susceptibility: The way individuals respond to occupational and environmental contami­
nants. It usually implies an indicator of degree of risk based on exposure and inherited 
factors.
Technical variability: Variation in results observed in laboratory measurements in the 
same sample over time.
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Toxicogenomics: The study of changes in expression of numerous genes or gene products 
due to toxicant-induced exposures.
Transcriptomics: The study of transcriptosomes.
Transcriptosome: The full complement of DNA transcripts (RNA molecules) required for 
the structure and function of an organism.
Transgenic animal: A genetically engineered animal that carries a gene or genes of an­
other species. Typically, a transgenic mouse or rat carries a human disease gene (e.g., cys­
tic fibrosis, Tay-Sachs disease, or one of the genes associated with breast cancer such as 
BRCA1).
Transitional study: A study that uses biomarkers and bridges the gap between laboratory 
and population-based studies. The goals of transitional studies may include characteriza­
tion and validation of biomarkers or optimizing the conditions for using the biomarker. 
Transitional studies differ from etiological research because the biomarker is generally the 
outcome or dependent variable as opposed to the disease [Schulte and Perera 1997].
Validation: The process by which a test’s performance is evaluated both in the labora­
tory (e.g., accuracy, precision, sensitivity, and specificity) and in the population (positive 
predictive value, penetrance, prevalence and other environmental factors) to evaluate the 
clinical utility of the test. Validation ensures that the test produces accurate and reliable 
data so that sound medical and health-related decisions can be made based on a test’s re­
sults [Lee et al. 2005].
Xenobiotic: A natural substance that is foreign to the body.
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INTRODUCTION
I n the past decade, remarkable advances 
have been seen in the technology of ge­
netic analysis as well as in the rapid ex­
pansion of its use, particularly in human 
studies and clinical medicine [Kelada et al. 
2003; Burke et al. 2002; Little et al. 2002]. 
Today it is possible to produce a complete 
record of an individual’s genetic makeup. 
Understanding the genetic components of 
disease and the interaction between genetic 
and environmental factors has increased, 
and the application of this knowledge to 
the workplace raises medical, ethical, le­
gal, and social issues [Clayton 2003; Ward 
et al. 2002; McCunney 2002; Christiani et 
al. 2001; Rothstein 2000a; Schulte et al. 
1999; Lemmens 1997; Barrett et al. 1997; 
Van Damme et al. 1995; Gochfeld 1998; 
Omenn 1982]. The scientific impact of ge­
netic information can be great, but that im­
pact can be intertwined with other conten­
tious workplace issues. Some of the medi­
cal, ethical, legal, and social issues need to 
be addressed soon because genetic infor­
mation is already being used in the work­
place [Khoury 2002; AMA 2004, 1999]], 
and legislation has been recently enacted 
in the U.S. [U.S. Congress 2008]. Debate 
continues about the use of genetic informa­
tion and the access to this information by 
employers, potential employers, insurers, 
and relatives of the workers being tested, 
and even about an individual’s rights to re­
ceive his or her own test results [Renegar 
et al. 2006; Mitchell 2002]. In some state 
statutes, genetic information is defined 
broadly. The laws extend beyond the results 
of deoxyribonucleic acid (DNA) analysis 
to encompass family health histories and
the results of common laboratory tests for 
gene products, such as messenger ribonu­
cleic acid (mRNA) or proteins [Kulynych 
and Korn 2002]. Various professional or­
ganizations and authoritative groups have 
begun to address the issues of genetics in 
the workplace [Genetics and Public Policy 
Center 2006; ACOEM 2005; ASCO 2003; 
CDC 2003; Goel 2001; NBAC 1999].
The purpose of this report is to consoli­
date the diverse literature and opinions on 
genetics in the workplace, to flag impor­
tant issues, and to provide some consider­
ations for current and future research and 
practice. Occupational safety and health 
professionals have a growing interest in 
understanding gene-environment interac­
tions at the mechanistic and population 
levels that may contribute to prevention 
and control strategies. The framework 
for considering the contribution of genet­
ics to occupational disease and injury can 
be seen in the exposure-disease paradigm 
that arose from the efforts of the National 
Academy of Sciences (NAS) in the 1980s 
[NRC 1987]. This framework (Figure 1-1) 
identified biomarkers to assess exposure, 
effects of exposure including disease, and 
susceptibility. Genetic biomarkers gener­
ally pertain to susceptibility. Biomarkers 
can complement traditional tools such as 
health and work history questionnaires, 
exposure measurements, death certificates, 
and job exposure matrices.
Biomarkers of exposure comprise several 
of the steps in the paradigm. Internal dose 
is that amount of agent that enters the body, 
while the biologically effective dose is the 
amount of agent that reaches the target site. 
For example, if an agent causes liver toxic­
ity, then the biologically effective dose is



















Figure 1-1. Continuum from exposure to disease. (Adapted from NRC [1987]; Schulte and 
Perera [1993].)
the amount of agent that reaches the liver. 
Early biologic effects may still be revers­
ible, and some effects may or may not be 
on the pathway leading to disease. Early 
biologic effects have been used as both 
exposure and disease biomarkers, bridg­
ing these two aspects. Altered structure or 
function describes the state before the dis­
ease is diagnosed, but during which chang­
es in the biological activity or structure 
may be present that could indicate early 
stage disease.
Susceptibility markers can be indicative of 
acquired or inherited susceptibility, but for 
the most part, the term has been used for 
inherited gene variants that may modify 
the effect of exposure and, therefore, the 
resulting consequences. Gene variants can 
modify various steps in the continuum 
from exposure to disease [Cherry et al. 
2002; McCanlies et al. 2002; Weston et 
al. 2002; Yong et al. 2001; Tamburro and 
Wong 1993; Kalsheker and Morgan 1990].
Genetic components can be found in all 
biomarker categories. For biomarkers of 
exposure, there is a rich history of research 
on xenobiotics binding with DNA or pro­
tein (called DNA or protein adducts) that 
indicate exposure [Groopman and Kensler 
1999; Gledhill and Mauro 1991; Perera and 
Weinstein 1982; Ehrenberg et al. 1974]. 
Biomarkers indicating the effects of expo­
sure range from somatic mutations to dis­
ease markers manifesting in chromosomal 
alterations to changes in gene expression 
[Boffetta et al. 2007; Rossner et al. 2005; 
Bonassi et al. 2004, 2000, 1995; Hagmar 
et al. 2004, 1998, 1994; Liou et al. 1999; 
Albertini and Hayes 1997].
It is possible to consider genetic research 
and its applications in terms of a matrix 
(Figure 1-2). The x-axis of the matrix de­
scribes where in the continuum between 
exposure and disease the investigation is 
focused. The y-axis shows the types of 
research or applications that could be con­
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ducted. These can range from assay devel­
opment to mechanistic studies to discov­
ery of gene function through etiological 
research. Increasingly, etiological research 
is being conducted using whole genomes 
as in genome-wide association studies. 
Transitional studies bridge laboratory and 
population-based studies by characterizing 
and optimizing biomarker measurements.
The matrix, itself, is filled with either spe­
cific genes or the genetic biomarkers of in­
terest for the type of study and where in the 
continuum the research interest lies. Once 
research is far enough along, applications 
such as interventions, risk assessments, 
and monitoring clinical trials can be con­
sidered.
Type o f 
research  
o r a p p lic a ­
tion
C o n tin u u m  fro m  exp o su res  to  d isease
Exposure ^  Internal dose











^  Prognostic 
significance
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Figure 1-2. Matrix of possible uses of susceptibility biomarkers.Note: The horizontal (x) axis 
indicates a continuum of biomarkers between exposure and resultant effects. At each arrow, a 
susceptibility biomarker can be considered to intervene.
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The work on chronic beryllium disease 
(CBD) is a good example of the contribu­
tion of genetics to occupational safety and 
health as it covers the gamut of basic re­
search using animal models, to population 
studies, to the development of policy. A 
transgenic animal is currently being evalu­
ated for a phenotype with characteristics of 
CBD. The animal model would be useful 
to develop and evaluate intervention strate­
gies. In addition, research was done to as­
sess the prevalence of genetic risk factors 
in workers exposed to beryllium [McCan- 
lies et al. 2007; Tinkle et al. 2003; Weston 
et al. 2002]. Tests to assess the risk due to 
major histocompatibility complex, class II, 
DP beta 1 (HLA-DPB1) polymorphisms 
have low positive predictive value (PPV) 
[Weston et al. 2002]. However, as research 
findings complete the matrix, this should 
provide valuable information about the 
development of an exposure recommenda­
tion that would protect all workers.
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G enetic information can reveal whether 
a change occurred in a person’s genet­
ic material (e.g., a change in one’s DNA, 
RNA, etc.; also known as acquired genetic 
effects) as a result of exposure to a harm­
ful agent. Genetic information can also 
indicate inherited characteristics, such as 
a gene that interacts with environmental 
agents to increase or decrease risk of dis­
ease. A distinction exists between genetic 
tests designed to detect genes and those that 
are designed to find changes in genetic ma­
terials [Van Damme and Casteleyn 2003; 
Schulte and DeBord 2000; OTA 1990]. 
Both kinds of genetic information—inher­
ited characteristics and changes in genetic 
material—will be discussed in this chapter.
2 .1  G e n e - E n v i r o n m e n t  
I n t e r a c t i o n s  in  O c c u p a t i o n a l  
S a f e t y  a n d  H e a l t h  R e s e a r c h
In the past, genetic information was rarely 
considered in epidemiological studies of 
occupational diseases, largely because there 
were no tools for precise measurement of 
genetic differences that might influence ex­
posure-disease relationships in subsets of 
the population. Historically, occupational
chemical exposures were so high that rea­
sonably valid studies of exposure-disease 
relationships could be performed even if 
they did not account for genetic variation 
[Schulte 1987]. However technology and 
information have progressed so that the 
relative influence of genetic factors on ex­
posure-disease relationships is relevant as 
variables in study design and analysis.
Interest in the role of genetic variants has 
emerged as a result of studies that have 
demonstrated variability in response to oc­
cupational exposures [Yucesoy and Luster 
2007; Godderis et al. 2004; Kline et al. 
2004; Thier et al. 2003]. The term “response 
variability” has been used to describe the 
differences in the type or magnitude of the 
biological effect that is due to intrinsic or 
acquired differences between individuals 
under identical exposure conditions. Vari­
ous factors contribute to response variabil­
ity from workplace or environment expo­
sures (see Figure 2-1) [Hattis and Swedis 
2001; Grassman et al. 1998].
One factor that contributes to that observed 
difference in response variability is indi­
vidual differences in the uptake of agents. 
Environmental monitoring may indicate 
identical exposure conditions, but what is 
actually absorbed into the body from that 
exposure may differ between individuals. 
Individual differences result from a range 
of factors that influence exposure uptake. 
Biological variability is one such factor. 
Biological variability can be further sub­
divided into interindividual variability, the 
difference between individuals, and intra­
individual variability, the difference within 
an individual over time.
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Genetic polymorphisms contribute to bio­
logic variability and hence may result in 
interindividual variability in the uptake of 
agents. For this reason, gene variants are 
important to study when trying to explain 
response variability. Our knowledge of the 
role of gene-environment interactions in 
occupational diseases has increased in the 
past few years. Mechanistic studies have 
focused on the role of specific genes in the 
development of disease. The majority of 
studies have investigated carcinogen expo­
sure and polymorphisms in the alleles of 
genes that code for enzymes involved in 
xenobiotic metabolism or biotransforma­
tion. Metabolism and transformation are 
intended to remove compounds from the 
body, but the process may result in the for­
mation of toxic metabolites. Differences in 
DNA coding result in biological variabil­
ity in enzymes, which ultimately affect the
biotransformation process. Mechanistic 
studies have consistently reinforced the 
hypothesis that the biologic variability ul­
timately affects disease risk by modifying 
the levels of toxic metabolites.
Table 2-1 lists research involving genetic 
polymorphisms and occupational/environ­
mental exposure. The trend in research to­
day is to evaluate multiple genes in a study 
rather than assess the role of single genes. 
In addition to carcinogenesis, there has 
been substantial focus on respiratory dis­
eases and allergic responses [McCanlies 
et al. 2003; Kalsheker and Morgan 1990; 
Brain et al. 1988; Rystedt 1985; Chan- 
Yeung et al. 1978]. Beyond that, studies 
on the gene-occupational environment in­
teraction for such conditions as diabetes, 
myocardial infarction, and immune func­
tion defects have been documented [Omori 
et al. 2002; Nakayama et al. 2002; Oizumi
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et al. 2001; Spiridonova et al. 2001; Alt­
shuler et al. 2000; Keavney et al. 2000; 
Fujisawa et al. 1996; Walston et al. 1995].
According to the Human Genome Project 
(HGP), which focused on the similarities 
of the human genome, the differences in 
the genome should be around for 0.1% 
[HGP 2009]. After publication of the hu­
man genome maps, greater variation was 
observed than expected. The National 
Institutes of Health (NIH) initiated the 
International HapMap Project in 2002. 
HapMap focused on single nucleotide 
polymorphisms (SNPs) and their pheno­
typic variation and relationship to disease. 
However, other variation exists in the ge­
nome structure including deletions, dupli­
cations, inversions and copy number vari­
ants (CNV). Redon et al. [2006] identified 
greater than 10% variation in the genome 
due to CNV after analyzing DNA from the 
HapMap Project. Others have reported a
0.4% variation in the genome of unrelated 
people with respect to CNV [Kidd et al. 
2008]. Since CNV can be altered with en­
vironmental exposures, the differences in 
reported variation in CNV may be due to 
somatic changes in the genome.
Genome-wide association studies have been 
used to identify specific points of varia­
tion (SNPs and CNV) in human DNA. By 
variation, it is possible to investigate dif­
ferences between people with a disease 
and those who are disease-free, thereby 
determining genetic factors that might be 
involved in specific diseases. Along with 
HapMap, databases exist on the Web that 
archive results from genome-wide asso­
ciation studies [Brookes et al. 2009; Wang 
WY et al. 2005; Becker 2004; IHC 2003].
A genetic power calculator has been de­
veloped to aid researchers in determining 
relationships between disease and genetic 
factors [Purcell et al. 2003]. In 2007, the 
National Institute of Environmental Health 
Sciences (NIEHS) began the Genes, Envi­
ronment and Health Initiative (GEI) [GEI 
2007]. One part of the program is the Ge­
netics Program, which includes a pipeline 
for analyzing genetic variation in popula­
tions with specific diseases. These kinds of 
tools and studies help scientists understand 
the complex interrelationships of diseases 
and the role of multiple genes in disease 
processes.
While mechanistic studies have estab­
lished the mechanistic plausibility that 
polymorphisms affect disease risk, detect­
ing such an effect in health research has 
been challenging. Over the last decade, 
many studies of gene-environment inter­
actions have been reported. Most of these 
studies did not find an association between 
genetic polymorphisms and disease risk, or 
the results could not be replicated. In gen­
eral, inadequate statistical power makes it 
difficult to detect an effect or association 
in occupational or environmental health 
research. This difficulty is compounded in 
gene-environment studies that require ad­
ditional attention to study design due to the 
increased number of variables under study. 
Factors related to study design may have 
made detection of an association difficult in 
early studies. Researchers have attempted 
to address the problem of insufficient pow­
er in the cancer area by developing larg­
er studies and combining studies [IARC 
1997; Rothman 1995]. Genome-wide as­
sociation studies using recently developed








Table 2-1. Research assessing the role of genetic polymorphisms in 
occupational disease: selected examples
Genetic Factors Exposure Disease/Injury References
NAT2 Aromatic amines Bladder cancer Ma et al. [2004]; Cartwright et al. [1982]
NAT2 Smoking
Benzidine
Bladder cancer Marcus et al. [2000a,b] 




Benzidine Bladder cancer Carreon et al. [2006a]
GSIM1 Smoking Lung cancer Sobti et al. [2004]
GSTT1, GSTM1, 
NAT2
Smoking Bladder cancer Hung et al. [2004b]
GSTT1 Ethylene oxide Bladder cancer Yong et al. [2001]
GSTM1, NAT2, 
NF2
Asbestos Mesothelioma Hirvonen et al. [1995]; 
Pylkkanen et al. [2002]
XRCC1, XRCC3, 
XPD, OGGI
Asbestos Mesothelioma Dianzani et al. [2006]









Table 2-1 (Continued). Research assessing the role of genetic polymorphisms in 
occupational disease: selected examples




Benzene Chronic benzene poisoning Chen et al. [2007]
OGGI Smoking (reactive oxygen 
species)
Lung Cancer Goode et al. [2002]
XRCC1 Smoking; ionizing radiation Breast cancer Goode et al. [2002]
TP53, CCND1, 
CDKN2A







Ionizing radiation Meningioma Sadetzki et al. [2005]
ALAD Lead Lead toxicity (nervous, 
hematologic, renal, reproductive 
systems)
Kelada et al. [2001]
HLA-DPB1 Beryllium Chronic beryllium disease McCanlies et al. [2003]








Table 2-1 (Continued). Research assessing the role of genetic polymorphisms in 
occupational disease: selected examples
Genetic Factors Exposure Disease/Injury References
PPAR-y
Calapain, PIR6.2
Impaired glucose tolerance Diabetes Altshuler et al. [2000] 
Stumvoll et al. [2005]
ADRB3 Body mass index (BMI) Diabetes Oizumi et al. [2001]; Fujisawa 
et al. [1996]; Walston et al. 
[1995]
ACE Total cholesterol, low-density 
lipoprotein cholesterol, and BMI
Hypertension; myocardial 
infarction
Spiridonova et al.[2001]; 
Keavney et al. [2000]
IL-3,1L-4R Allergens Asthma Cookson [2002]




Nakayama et al. [2002]
PONI Organophosphate pesticides Acute toxicity; respiratory 
effects
Battuello et al. [2004]; Cherry 
et al. [2002]
TNF-a Silica Silicosis McCanlies et al. [2002]
BRCA2, AR, 









Table 2-1 (Continued). Research assessing the role of genetic polymorphisms in 
occupational disease: selected examples
Genetic Factors Exposure Disease/Injury References
BRCA2, AR, 
CYP17 Electromagnetic fields Male breast cancer Weiss et al. [2005]
UGT2B7 Benzidine Bladder cancer Lin et al. [2005]
MPO, MnSOD Smoking, PAH Bladder cancer Hung et al. [2004a]
CYP2D6 Pesticides Parkinson’s disease Elbaz et al. [2004]
MnSOD, NQOl Pesticides Parkinson’s disease Fong et al. [2007]
SP-B Chromate Lung cancer Ewis et al. [2006]
large scale SNP platforms are capable of 
discovering loci associated with relative 
risks too modest to detect through small­
er studies [Hunter et al. 2007]. However, 
genome-wide association studies with re­
gard to common variants and disease have 
only moderate predictive power and col­
lectively only explain a small fraction of 
the genetic component of a disease [Gold­
stein 2009; Kraft and Hunter 2009]. The 
true impact of these types of studies may 
lie in their ability to identify new pathways 
of underlying diseases [Hirschhorn 2009]. 
Several aspects are still not resolved in the 
study of gene-environment interactions in 
the occupational setting. These include: 
errors of measurement, testing of multiple 
hypotheses, interactions, and Mendelian 
randomization [Vineis 2007].
In the area of cancer research, some exam­
ples of polymorphisms of biotransforma­
tion enzymes that have been widely stud­
ied include glutathione S-transferase M1 
(GSTM1), glutathione S-transferase theta 1 
(GSTT1), cytochrome P450, family 1, sub­
family A, (aromatic compound-inducible), 
polypeptide 1 (CYP1A1), N-acetyltrans- 
ferase 2 (arylamine N-acetyltransferase) 
(NAT2), and nicotinamide adenine di­
nucleotide phosphate (NADPH) dehydro­
genase, quinone 1 (NQO1). Consistently, 
the GSTM1null genotype has been shown 
to be a risk factor for tobacco-related lung 
cancer [Olshan et al. 2000]. This associa­
tion, like that of the association between 
GSTM1null and esophageal dysplasia [Roth 
et al. 2000], gives clues to the etiology of 
disease. Similarly, NAT2 is associated with 
arylamine-related bladder cancer [Marcus 
et al. 2000a], and NQO1 has been shown
to be important for benzene-associated 
leukemia [Rothman et al. 1997]. However, 
the contribution of these biotransformation 
genes to the overall risk of disease devel­
opment is small.
One example that illustrates the relative ef­
fects of genes, environmental exposures, 
and their interaction is the role of the pro- 
inflammatory cytokine tumor necrosis fac­
tor (TNF-a) in silicosis. The TNF-a-308 
polymorphism modifies the risk of silico­
sis among silica-exposed workers [Mc- 
Canlies et al. 2002; Yucesoy et al. 2001]. 
Two methods were used to determine the 
extent to which genetics contributes to 
the risk of disease beyond silica exposure. 
The predicted probabilities of disease were 
calculated for each individual and then 
ranked and categorized into exposure de­
ciles. Individuals in the highest exposure 
decile were at fourfold increased risk of 
developing silicosis compared with those 
in the lowest decile. However, when the 
comparison was restricted by genotype, 
individuals in the highest exposure decile 
who had TNF-a-308 were at eightfold risk. 
Using the second method, the investigators 
employed relative operating characteristic 
(ROC) curves to investigate the effect of 
genetic information on predicting whether 
an individual would have disease. No dif­
ference was seen when the curve generated 
using exposure alone was compared with 
that generated using both exposure and 
genetic data. The overall conclusion from 
this study was that while genotype plays a 
role in characterizing risk groups and dis­
ease mechanisms, the genotype is unlikely 
to be a predictor of disease for an individu­
al [McCanlies et al. 2002].
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2 .2  T h e  E f f e c t  o f  
O c c u p a t i o n a l  a n d  
E n v i r o n m e n t a l  E x p o s u r e s  
o n  G e n e t i c  M a t e r ia l
Damage to DNA or other hereditary mate­
rial of somatic cells can be used to evalu­
ate exposures and, potentially, disease risk. 
A variety of genetic biomarkers has been 
used to show exposure or effects from en­
vironmental or occupational exposures 
[Abdel-Rahman et al. 2005; Holeckova et 
al. 2004; Godschalk et al. 2003; Albertini 
et al. 2003; Medeiros et al. 2003; Toraason 
et al. 2001; Ewis et al. 2001; Lu et al. 2001; 
Wu et al. 2000]. An increasing number of 
studies has evaluated gene-environment 
interactions, but much more of the litera­
ture describes the effect of occupational 
exposures on genes and other genetic ma­
terial. The theoretical underpinnings of 
this research have grown out of the assess­
ment of workers and populations exposed 
to radiation from nuclear weapons and nu­
clear medicine techniques [Albertini 2001; 
Moore and Tucker 1999]. Somatic muta­
tions, DNA adducts and protein adducte, 
and cytogenetic changes have frequently 
been used as biological measures of expo­
sure and, in some cases, as biomarkers of 
effect. Radiation studies suggest a strong 
linear dose response correlation between 
exposure and observed mutation frequen­
cy. The evaluation of changes in genetic 
material is usually part of research studies 
that investigate the effects of exposure or 
can be part of periodic physical examina­
tions performed specifically for genotoxic 
agents in the workplace. Table 2-2 pres­
ents the types of genetic materials that have 
been used to assess exposure or effect.
Whether these changes are biomarkers of 
effect, and ultimately risk factors for dis­
ease, depends on the extent to which the 
association with the disease has been af­
firmed. While numerous cross-sectional 
studies have consistently identified cytoge­
netic changes associated with exposures to 
genotoxic substances or agents, only lon­
gitudinal analysis is best suited to identify 
which genetic biomarkers are risk factors 
for disease. For example, using prospec­
tive designs, an increase in chromosomal 
aberrations has been associated with an in­
creased risk of cancer development [Bof- 
fetta et al. 2007; Bonassi et al. 2007, 2004, 
2000; Rossner et al. 2005; Liou et al. 1999; 
Hagmar et al. 1998].
Gene activity also can be altered without 
changing the DNA sequence. Various epi­
genetic processes including methylation, 
acetylation, phosphorylation, ubiquity- 
lation, and sumolyation as well as chroma­
tin modification can affect gene activity. A 
wide variety of illnesses, behaviors, and 
health indicators have some level of evi­
dence linking them with epigenetic mecha­
nisms, including cancers, cognitive dys­
function, respiratory, cardiovascular, repro­
ductive, autoimmune and neurobehavioral 
illnesses [Weinhold 2006]. Heavy metals, 
pesticides, diesel exhaust, tobacco smoke, 
polycyclic hydrocarbons, hormones, radio­
activity, viruses, bacteria, and nutrients are 
known or suspected to influence epigenetic 
processes [Weinhold 2006]. While a com­
prehensive view of epigenetics in relation 
to occupational disease still has not been 
developed, a large role and further research 
is necessary since epigenetics may have a 
role in understanding occupational and en­
vironmental causes of diseases [Wade and 
Archer 2006].
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2 .3  E f f e c t  o f  G e n e s  o n  
B i o m a r k e r  M e a s u r e m e n t s  
a n d  U s e  in  R i s k  
A s s e s s m e n t s
Increasingly, sophisticated epidemiologi­
cal studies have been conducted using bio­
markers of both susceptibility and expo­
sure, including measurements of effect, to 
evaluate the exposure levels that cause ad­
verse effects among groups with differing 
susceptibility. For example, a study among 
physicians assessed how biomarkers of the 
biologically effective dose and polymor­
phisms of the metabolizing genes for glu­
tathione S-transferase (GST) interacted to 
predict smoking-related risk of lung cancer 
[Perera et al. 2003]. The study found that, 
among then current smokers, DNA adduct 
levels were associated with a threefold 
risk of lung cancer, after controlling for 
GST genotype. The GSTM1null/glutathione
S-transferase pi (GSTP1) Val genotype 
was associated with a fourfold risk of lung 
cancer overall, especially among former 
smokers, and did not vary by adjustment 
for adduct levels. Among people with lung 
cancer, adduct levels were significantly 
higher among then current and former 
smokers with the GSTM1 non-null/GSTP1 Ile 
genotype, suggesting a complex interac­
tion between genotype and adduct forma­
tion with smoking exposure.
Genetic susceptibility biomarkers have 
been used in risk assessment models to de­
termine the impact of the role of genetic 
polymorphisms of metabolism genes on 
risk estimates [El-Masri et al. 1999; Bois 
et al. 1995]. Susceptibility biomarkers 
may reflect variation in exposure, kinetics,
and effects and are therefore important to 
consider in risk assessments. To gauge the 
impact of genetic markers on risk assess­
ment, El-Masri et al. [1999] conducted a 
simulation study of cancer risk estimates 
for exposure to dichloromethane. The 
risk estimates were 23% to 30% higher 
when an effect-modifying polymorphism 
(GSTT1) was not included in the models. 
Mechanism-based modeling has the po­
tential to decrease uncertainties across and 
within species and exposure scenarios and 
to quantify pathways and complex rela­
tionships within gene networks [Toyoshiba 
et al. 2004].
An example of the utility of assessing the 
impact of genetic changes was illustrated 
by the International Agency for Research 
on Cancer (IARC) when the agency incor­
porated the alkylation and genotoxic ef­
fects of ethylene oxide in considering its 
carcinogenicity [IARC 1994]. With only 
limited epidemiological evidence of eth­
ylene oxide carcinogenicity in humans, 
IARC relied on supporting evidence that 
demonstrated this chemical causes a dose- 
dependent increase in macromolecular 
adducts and other biomarkers that reflect 
genotoxic damage. This conclusion was 
supported by a wealth of animal research 
linking ethylene oxide exposure to cancer.
2 .4  G e n o m i c  P r i o r i t i e s  a n d  
O c c u p a t i o n a l  S a f e t y  a n d  
H e a l t h
Advances in molecular genetics have re­
sulted in considerable progress in identify­
ing the genetic basis of diseases; however, 
the contribution of genetic information to
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preventing significant occupational health 
hazards has been limited. Many of these 
health hazards may not have a strong ge­
netic component. At some point, research 
priorities will need to be established so that 
resources are spent wisely on research to 
evaluate occupational and environmental 
health hazards in which genetic informa­
tion will contribute to understanding the 
etiology, mechanisms, or possible means 
of control of those hazards [Schulte 2007; 
Merikangas and Risch 2003].
Implications fo r Occupational Safety and Health 15
T a b le  2 - 2 .  G e n e t ic  b io m a r k e r s  o f  e x p o s u r e  o r  e f fe c t  o f  e x p o s u re :  s e le c te d  e x a m p le s
Genetic biomarkers Exposures* References
DNA Adducts Smoking Taioli et al. [2007]
PAH Peters et al. [2008]
Diesel exhaust Artl et al. [2007]
Hemoglobin Adducts (surrogates Acrylamide Hagmar et al. [2005]
for DNA adducts) Styrene Teixera et al. [2008]
1,3-Butadiene Boysen et al. [2007]
DNA Strand Breaks Roofing asphalt Toraason et al. [2001]
Antineoplastic drugs Marczynski [2006]
Deng H [2005]
Sister Chromatid Exchanges Anesthetic gases Bilban et al. [2005]
Gasoline Celi and Akbas [2005]
Styrene Teixeira et al. [2004]
Micronuclei Ionizing radiation Mrdjanovic et al. [2005]
Trivalent chromium Medeiros et al. [2003]
PAH Pavanello et al. [2008]
Styrene Migliore et al. [2006]
Chromosomal Aberrations Benzene Holeckova et al. [2004]
X-rays Milacic [2005]
Fenvalerate Xia et al. [2004]
Reporter Genes
Styrene Abdel-Rahman et al. [2005]
HPRT Radiation Jones et al. [2001]
GPA Pesticides Takaro et al. [2004]
Oncogene Mutations Arsenic Wen et al. [2008]
Coal emissions Keohavong et al. [2005]
Gene Expression Smoking Sexton et al. [2008]
Cisplatin Gwosdz et al. [2005]
Protein Expression Benzene DeCoster et al. [2008]
Pollution Joo et al. [2004]
*The exposures shown here are examples of the substances or agents studied and not a complete 
list.
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C H A P T E R
INCORPORATING  
G EN ETICS INTO 
OCCUPATIONAL 
HEALTH RESEARCH
A  major influence on genetic research 
in occupational health is the exponen­
tial increase in scientific advances brought 
about by the sequencing of the human ge­
nome and advances in molecular biology 
techniques. One such advancement is the 
polymerase chain reaction (PCR), which 
has been heralded as one of the most im­
portant scientific techniques in molecular 
biology because it allows the fast and inex­
pensive amplification of small amounts of 
DNA [NHGRI 2004]. Microarray technolo­
gies have allowed laboratories to study tens 
of thousands of genes and their expression 
products, which have greatly increased the 
number of genes that can be studied at the 
same time [Collins et al. 2003]. Restriction 
fragment length polymorphism (RFLP) 
uses restriction enzymes to cut a piece of 
DNA, resulting in varying fragments that 
can be used to identify gene variants.
Because of these scientific advances, ge­
netics has begun to transform research 
questions and study designs in the applied 
sciences of public and occupational health 
[Shostak 2003]. Genetic research studies 
provide new ways to study risks by evaluat­
ing genetic damage and gene-environment 
interactions. As discussed in Chapter 2, on­
going research focuses on damage to genet­
ic material, alteration of gene function, and 
interaction of genes with each other and 
with occupational/environmental factors
that increase or decrease risks. Initiatives 
by federal and other agencies have been 
created to further the science and improve 
communication of results.
In 1998, NIEHS initiated the Environ­
mental Genome Project (EGP). It has dual 
goals of providing information about how 
individual genetic differences affect dis­
ease from environmental agents, and in 
response to this information will propose 
appropriate environmental or public health 
policies [Dahl 2003]. EGP comprises five 
major research activities: (1) developing 
mouse models to determine the functional 
significance of genetic polymorphisms, 
(2) conducting resequencing and func­
tional analysis of polymorphic genes that 
are responsive to environmental insult, (3) 
developing a GeneSNP database that inte­
grates gene, sequencing information, and 
polymorphic data into gene models, (4) fo­
cusing on ethical, legal, and social issues to 
help understand the implications of genetic 
research, and (5) developing a collabora­
tive research program among multidisci­
plinary groups to plan novel and innovative 
molecular epidemiology studies of envi­
ronmental-induced diseases [EGP 2008]. 
Initiatives such as these can aid researchers 
and help address issues in genetic research. 
In addition in 2007, NIEHS launched the 
Exposure Biology Program (EBP), which 
will focuses on the development of tech­
nologies to measure environmental expo­
sure that interacts with genetic variation to 
result in human disease [EBP 2007].
The incorporation of genetics into occupa­
tional safety and health research generally 
requires collecting biological specimens 
from participating workers, analyzing those
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specimens, and developing test and study 
results. This is in some ways analogous to 
administering a test to a patient in a clini­
cal setting; however, the intent is usually 
different. That is, the use of a genetic test 
or assay in a research setting is to answer 
scientific questions and to obtain generaliz- 
able knowledge. Validated genetic factors 
can be used as independent and dependent 
variables or effect modifiers in animal and 
human studies. Ultimately, however, some 
of these research tests will be candidates 
for use in clinical settings. Hence, genetic 
research on workers may be seen as ex­
isting on a continuum between laboratory 
development and clinical use, as shown 
in Figure 3-1 [Schulte 2004; Burke et al. 
2002; Khoury 2002].
Issues of interpretation and communication 
of results are critical in workplace research 
involving genetics. Two types of results, in­
dividual or group, may be generated at dif­
ferent times and may have different mean­
ings. Most results to date in occupational 
safety and health have shown effects at the 
group level. Interpretation at the individual 
level is more complex as a variety of fac­
tors interplay with each other to affect risk. 
In addition, the interpretation of research 
results with respect to overall risk may be 
uncertain. The investigators may not know 
if the test or study results are meaningful or 
clinically relevant. Many times the purpose 
of the study is to evaluate the meaning of 
the test or assay, to learn about population 





Population- I Public Health PracticeBased
Research f t m
Testing;
Intervention
Genctics; Molecular Biology; 
Biochemistry; Analytical Chemistry
Figure 3-1. Continuum from basic science to medical and public health practice. 
(Schulte [2004].)
18 Genetics in the Workplace
3 .1  V a l i d i t y  a n d  U t i l i t y  I s s u e s  
o f  G e n e t i c  A s s a y s
Genetic assays or tests may have great val­
ue predicting disease risk factors and may 
establish a new approach in the primary 
prevention of many chronic diseases. Such 
tests could allow for the identification and 
elimination of environmental risk factors 
that lead to clinical disease among persons 
with susceptibility genotypes [Khoury and 
Wagener 1995]. Before such tests are used 
in practice, the tests need to go through a 
validation process (see Table 3-1). Valida­
tion ensures that the test produces accurate 
and reliable data so that sound medical or 
health-related decisions can be made based 
on this information [Lee et al. 2005].
Researchers may be learning about charac­
teristics of the assays under various condi­
tions and what the assays mean in relation 
to exposure, disease, susceptibility, or risk. 
Validation is a process rather than an end 
state. It is context-specific and pertains to 
the particular use of a genetic test. It in­
cludes analytical validity (whether the test 
accurately measures the specific genetic 
property of interest), clinical validity (what 
the test means in relation to exposure, 
health, and risk in populations or individu­
als), and clinical utility (whether the test is 
actually useful and feasible in clinical or 
population settings) [Burke et al. 2002].
Validity has been recently addressed by 
several groups [Constable et al. 2006; HGP 
2006; NCI 2006; Barker 2003; Burke et 
al. 2002; IPCS 2001]. A model process for 
evaluating data on emerging genetic tests 
was developed by the U.S. Task Force on 
Genetic Testing [1998]. More recently,
this process has been addressed by a col­
laborative group sponsored by the Cen­
ters for Disease Control and Prevention 
(CDC) [ACCE 2007; Burke et al. 2002]. 
This group, called the ACCE core group, 
takes its name from the four components 
of evaluation: analytical validity; clinical 
validity; clinical utility; and ethical, legal, 
and social implications and safeguards. The 
effort builds on a methodology described 
by Wald and Cuckle [1989] for evaluating 
screening and diagnostic tests. The ACCE 
process includes collecting, evaluating, in­
terpreting, and reporting data about DNA 
(and related) testing for disorders with a 
genetic component in a format that allows 
policymakers to have access to up-to-date 
and reliable information for decision­
making. The ACCE model contains a list 
of 44 questions, targeting the four areas of 
ACCE, to develop a comprehensive review 
of a candidate test for potential use [ACCE 
2007; Burke et al. 2002]. The International 
Programme on Chemical Safety (IPCS) 
discussed validation and the use of genetic 
markers in risk assessment, and the Nation­
al Cancer Institute (NCI) developed a list of 
questions to evaluate whether a genetic test 
is appropriate for screening purposes [NCI 
2006; IPCS 2001].
3.1.1 Analytical Validity
The first step in establishing validation of 
a test is analytical validity, which focuses 
on the ability of the test to measure accu­
rately and reliably the marker/genotype of 
interest. The four components of analytical 
validity are analytical sensitivity, analytical 
specificity, laboratory quality control, and 
test robustness [ACCE 2007; Burke et al.
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T a b le  3 - 1 .  C o n s id e r a t io n s  in  t h e  V a l i d a t io n  o f  G e n e t ic  T e s ts
Analytical Validity Clinical Validity Clinical Utility
Is the test qualitative or quantitative? How often is the test positive when 
the condition is present?
What is the natural history of the con­
dition?
How often is the test positive when 
the marker is present?
How often is the test negative when 
the condition is not present?
What is the impact of a positive (or 
negative) test on patient care?
How often is the test negative when 
the marker is not present?
Are there methods to resolve clinical 
false positive results in a timely man­
ner?
If applicable, are diagnostic tests 
available?
Is an internal quality control program 
defined and externally monitored?
What is the prevalence of the condi­
tion in this setting?
Is there an effective remedy, 
acceptable action, or other measur­
able benefit?
Have repeated measurements been 
made on specimens?
Has the test been adequately tested on 
all populations to which it may be of­
fered?
Is there general access to that remedy 
or action?
What is the within- and between-labo- 
ratory precision?
What are the positive and negative 
predictive values?
Is the test being offered to a 
socially vulnerable population?
If appropriate, how is confirmatory 
testing performed to resolve false 
positive results in a timely manner?
What are the genotype/phenotype re­
lationships?
What quality assurance measures are 
in place?
What range of patient specimens have 
been tested?
What are the genetic, environmental, 
or other modifiers?
What are the results of pilot 
trials?
How often does the test fail to give a 
usable result?
Do well-designed studies exist evalu­
ating the relationship between the 
marker and the condition?
What health risks can be identified for 
follow-up testing and/or intervention?
How similar are results obtained in 
multiple laboratories using the same 
or different technology?
What are the financial costs associ­
ated with testing?
How robust or rugged is the test? What are the economic benefits as­
sociated with actions resulting from 
testing?
What factors affect the test results? What facilities/personnel are avail­
able or easily put in place?
What educational materials have been 
developed and validated, and which 
of these are available?
Are there informed consent 
requirements?
What methods exist for long-term 
monitoring?
What guidelines have been developed 
for evaluating program performance?
What is known about stigmatization, 
discrimination, privacy/confidential­
ity, and personal/family social issues?
Are there legal issues regarding con­
sent, ownership of data, and/or sam­
ples, patents, licensing, proprietary 
testing, obligation to disclose, or re­
porting requirements?
What safeguards have been described, 
and are these safeguards in place and 
effective?
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2002]. Analytical sensitivity evaluates how 
well the test indicates the marker/genotype 
when it is present. Analytical specificity, on 
the other hand, evaluates the test to deter­
mine how well it identifies true negatives 
and false positives [Schulte and Perera 
1993]. Laboratory quality control evalu­
ates the test procedures to ensure they fall 
within the specified limits, and robustness 
measures the variability of the test mea­
surement under different analytical and 
preanalytical conditions.
3.1.2 Clinical validity
The second step in the validation process 
is to determine the clinical validity or the 
ability of the genetic test to detect or pre­
dict the associated condition (phenotype). 
The parameters of clinical validity include 
clinical sensitivity, clinical specificity, 
prevalence of the condition, positive and 
negative predictive value, penetrance, and 
modifiers of the condition, such as other 
genes and environmental factors. Clini­
cal sensitivity measures the proportion 
of the population that will get the condi­
tion when the test value is positive, while 
clinical specificity is the proportion of the 
population that will not get the condition 
when the test result is negative. Positive 
Predictive Value (PPV) is the proportion 
of individuals who will develop the disease 
given that they have the marker/genotype, 
while the negative predictive value is the 
proportion of individuals who test negative 
who will not get the disease [Weston et al.
2002]. Penetrance defines the relationship 
between the genotype and the phenotype, 
so that the expression of the genotype can
be determined and is broadly equivalent 
to the PPV [Constable et al. 2006]. Preva­
lence measures the proportion of individu­
als with the genotype who have or will get 
the condition. An additional factor in clini­
cal validity is heterogeneity—the same dis­
ease might result from the presence of any 
number of several different gene variants 
or totally different genes altogether [HGP 
2006]. Considerations for clinical validity 
include the design of the study, size of the 
population, type of test, and the endpoints 
measured [Constable et al. 2006]. For vali­
dation, data needed to establish the clinical 
validity of the genetic test must be collect­
ed under investigative protocols, the study 
sample should be drawn from a popula­
tion that is representative of the population 
for whom the test is intended, and formal 
validation needs to be established for each 
intended use of the test [HGP 2006]. Estab­
lishing clinical validity may take a lot of 
time and resources. Yang et al. [2000] es­
timated that for many adult onset diseases 
this process could take decades.
3.1.3 Clinical utility
Clinical utility addresses the elements that 
need to be considered when evaluating risks 
and benefits associated with the introduc­
tion of the genetic test into routine clinical 
practice. Three strategies are used to help 
determine whether a test has clinical utility. 
They are screening to detect early disease, 
interventions to decrease the risk of disease, 
and interventions to improve the quality of 
life. It is important to know the accuracy of 
the testing methods, the strength of the cor­
relation with the clinical phenotype and the
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condition, and the utility of the information 
[Ginsburg and Haga 2006]. Evaluating clin­
ical utility will require checks to ensure that 
due consideration is given to the complex 
array of factors that go into establishing 
clinical utility such as the predictive value, 
nature of the condition and associated so­
cial burdens, and the safety of the treatment 
and cost-effectiveness of the treatment. An 
example of a test that has clinical utility is 
blood cholesterol, which provides the indi­
vidual with valuable information that can 
be used for prevention, treatment, or life 
planning, regardless of results.
3.1.4 Validation of assays for 
evaluation of exposure or genetic 
damage
The first step in establishing the analyti­
cal validity of a method to test for genetic 
damage is characterization of the genetic 
biomarker of interest. Characteristics such 
as dose-response, biomarker persistence, 
interindividual and intraindividual vari­
ability, methodological variation, correla­
tion with other markers, and correlation 
with a critical response are crucial [Schulte 
and Talaska 1995; Vineis et al. 1993]. The 
establishment of a laboratory quality assur­
ance program is essential before any assays 
of genetic damage are used in research or 
practice. After analytical validity has been 
established, clinical validity must be de­
termined to demonstrate if the biomarker 
occurs in the population. Once the analyti­
cal and clinical validity are recognized, the 
risks associated with that biomarker at an 
individual level can be evaluated.
3.1.5 Validation of assays used to 
evaluate genetic polymorphisms
Genotyping assay results are subject to a 
variety of laboratory errors, such as mis- 
incorporation rate when using the poly­
merase chain reaction (PCR), differences in 
reagents, PCR artifacts, contamination by 
foreign DNA, and differences in efficiency 
of allele detection [Millikan 2002]. Dif­
ferences in interpreting genotyping results 
and errors contained in on-line genotyping 
databases are a source of variation. Errors 
can be found in many on-line databases, as 
not all sequence information or the order 
and location of all human genes have been 
confirmed. Differences in gene frequencies 
across populations in epidemiological stud­
ies can lead to small sample sizes and the 
subsequent lack of power. Deciding which 
genes and their variants to evaluate when 
studying disease-gene association in an 
epidemiological study can introduce bias 
because some genes may not be selected 
that may have a role in the disease or genes 
are selected that have no role in the disease 
[Peltonen and McKusick 2001]. Validation 
of a genetic test for worker populations is 
difficult, but has been demonstrated.
The PPV of any genetic test is dependent 
on the prevalence of the disease and ge­
netic trait in the population and the relative 
risk of disease for those carrying the trait 
[Khoury et al. 1993, 1985]. This issue has 
been demonstrated practically for HLA- 
DPB1 [Weston et al. 2002], which has been 
implicated as a susceptibility gene in beryl­
lium hypersensitivity and CBD [McCanlies 
and Weston 2004; Rossman et al. 2002; 
Saltini et al. 2001; Wang et al. 2001, 1999;
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Richeldi et al. 1997, 1993]. The prevalence 
of the genetic trait HLA-DPB1E69 for four 
major racial/ethnic groups in the United 
States was determined. Carrier frequencies 
ranged between 33% and 59%. Based on 
published studies, CBD disease prevalence 
among beryllium workers is 3% to 5% 
[Richeldi et al. 1997; Kreiss et al. 1996]. 
To estimate the PPV, investigators assumed 
a disease prevalence of 5% and odds ratios 
of 35 and 3 for CBD associated with inheri­
tance of HLA-DPB1E69 [Weston et al. 2002] 
and found that, for a genetic trait prevalence 
of 33% to 59%, the PPV for HLA-DPB1E69 
was 8% to 14% when the odds ratio was 
35 and 7% to 9% when the odds ratio 
was 3. The authors also assumed a higher 
prevalence rate of 15%, as might be seen 
in some higher-risk jobs, and the PPV for 
HLA-DPB1E69 was 25% to 43% when the 
odds ratio was 35 and 21% to 27% when 
the odds ratio was 3. Thus, for a tenfold dif­
ference of an odds ratio, a modest change in 
PPV was seen [Weston et al. 2002].
To date, many of the epidemiological stud­
ies to validate biomarkers of susceptibility 
have exhibited a high degree of heteroge­
neity in their results [Wenzlaff et al. 2005; 
Pavanello and Clonfero 2004; D’Errico et 
al. 1996]. In a review of four genetically 
based metabolic polymorphisms involved 
in the metabolism of several carcinogens, 
D’Errico et al. [1996] identified a range of 
methodological features that lead to discor­
dant results. These include a high propor­
tion of studies using prevalent cases, the 
frequent use of hospital controls, a low re­
sponse rate, the use of metabolic ratios as 
variables, and the lack of adequate adjust­
ment for covariates. In addition, such stud­
ies had small sample numbers and weak 
exposure characterizations [Vineis 1992].
3.1.6 Validation of multiple 
biomarkers
The use of multiple biomarkers has the 
potential to increase the understanding of 
exposure, disease, or susceptibility, but 
creates the challenge to combine the infor­
mation from individual markers and inter­
preting the overall combination of mark­
ers. This makes validation more difficult 
to accomplish since the complexity has 
increased. Therefore, how composite data 
will be analyzed and interpreted must be 
considered when a study is designed. Perera 
et al. [1992] demonstrated the benefits and 
extra knowledge that can be gained when 
they used a battery of biomarkers to assess 
genetic and molecular damage in residents 
of a polluted area of Poland. In this study, a 
common genotoxic model was used to pro­
vide a molecular link between environmen­
tal exposure and genetic alteration relevant 
to cancer and reproductive risk. Most of 
the biomarkers (carcinogen-DNA adducts, 
sister-chromatid exchanges, chromosomal 
aberrations, and ras oncogene overexpres­
sion) were related to levels of exposure to 
polycyclic aromatic hydrocarbons (PAHs) 
in the air.
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3 .2  C h a l l e n g e s  o f  G e n o m i c s  
a n d  R e l a t e d  R e s e a r c h  A r e a s
Technological developments, such as DNA 
and gene microarrays, and automated work 
stations capable of extracting, amplifying, 
hybridizing, and detecting DNA sequences 
will present a number of benefits and issues 
in studying genetic and environmental vari­
ables [NRC 2007; Christiani et al. 2001]. 
The benefits include the ability to study 
large numbers of genes, practically the 
entire human genome, in one study or ex­
periment and to have access to data banks 
containing further information on genomic 
DNA. The primary attendant issue with this 
technology includes heightened difficulties 
in analyzing and interpreting for research 
participants such large amounts of data [Er­
molaeva et al. 1998].
The area of genomics or the study of the 
expression of gene or gene products has 
grown exponentially and spun off a va­
riety of other related scientific areas such 
as toxicogenomics, proteomics (changes 
in cellular protein expression or function), 
metabonomics (changes in metabolites), 
and transcriptomics (changes in mRNA). 
One similarity among all of these fields is 
that large amounts of data are generated us­
ing high-throughput technologies, such as 
microarrays.
Toxicogenomics is the study of changes in 
expression of numerous genes or gene prod­
ucts due to toxicant-induced exposures. As 
our understanding grows, the science of 
toxicogenomics has become more useful 
in occupational and environmental health 
[Koizumi 2004; Tennant 2002; Henry et al.
2002; Nuwaysir et al. 1999]. Initially, toxi- 
cogenomics research has used various cell 
lines to understand the differences and sim­
ilarities between species so that the toxicity 
and changes in genes/gene products could 
be compared between animals and humans. 
A need exists for standardization of data 
collection from microarray experiments, 
optimization of information, and knowl­
edge management to make comparisons 
between studies easier and more accurate.
Proteomics is the sister technology to ge­
nomics [Kennedy 2002]. Genomics pro­
vides information about DNA and RNA, 
whether it is under- or overexpressed. Mes­
senger RNA is translated into proteins, 
which provide the structural and functional 
framework for cellular life. By studying 
proteins, we can see how a cell or organ re­
sponds to an insult. Proteomic researchers 
are also using high-throughput, sensitive 
technologies that can be used for protein 
identification and characterization.
Protein arrays along with genomic data 
can be used to better understand disease 
processes and mechanisms of toxicity and 
to develop biomarkers for diagnosis and 
early detection of diseases [Hanash 2003; 
Kennedy 2002]. The enthusiasm for this 
approach has been somewhat dampened 
because methodological and bioinformatic 
artifacts have been identified in some of 
the initial papers that suggested proteomics 
may be useful for disease diagnosis [Dia- 
mandis 2006]. Sample collection and stor­
age conditions may produce protein pro­
files that overshadow those generated by 
the disease. Further adding to the complex­
ity, just as most diseases are not caused by 
single genes, it is likely that a disease will
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Figure 3-2. Issues in microarray gene expression analysis and use. (Adapted from 
King and Sinha [2003].)
not be identified by a single protein, but by 
a protein profile as multiple pathways are 
involved in disease promotion/progression.
Microarray technologies for DNA and pro­
teins are the leading edge of efforts to use 
batteries of biomarkers to assess exposure, 
effect, or susceptibility. Making sense out 
of complex arrays of genetic expression 
data and multiple markers is difficult (see 
Figure 3-2) [King and Sinha 2001]. Much 
of the literature on the predictive value of 
diagnostic tests concerns a single test, with 
brief mention of multiple tests. Similarly, 
experience to address situations with mul­
tiple genes and environmental interactions 
is lacking. Koizumi [2004] described four 
ways DNA microarrays could be used in re­
search relevant to occupational health: (1) 
understanding the mechanistic background 
of health effects, (2) toxicity testing, (3) 
search of indicators for hazard prevention 
and health management, and (4) managing 
high-risk populations.
New technologies and approaches now al­
low researchers to focus more on studies
of gene-environment interactions that aim 
to describe how genetic and environmental 
occupational factors jointly influence the 
risk of developing disease [Hunter 2005; 
Christiani et al. 2001]. The study of gene­
environment interactions (1) allows for 
better estimates of population-attributable 
risk of genetic and occupational factors,
(2) strengthens associations between oc­
cupational risk factors and disease, (3) pro­
vides insight into mechanisms of action, 
and (4) provides new opportunities for in­
tervention and prevention [Hunter 2005].
The use of DNA microarrays is revolution­
izing genetic research. Microarrays have 
the ability to analyze gene expression pat­
terns, carry out genome-wide mapping, 
clone members of gene families within and 
across species, scan for mutations in inter­
esting genes, define genes controlled by 
particular transcription factors, being used 
for diagnostic purposes and have applica­
tion in risk assessments [Beaudet and Bel­
mont 2008; Travis et al. 2003; Blanchard 
and Hood 1996; Borman 1996]. The expec­
tation of researchers is that the expression of
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many thousands of genes will be measured 
before and after an exposure, although in 
the occupational setting, biomarkers are 
usually measured after exposure. These 
technologies will amplify the challenges in 
handling large amounts of data. Those chal­
lenges include data reduction, summation, 
analysis, and interpretation.
A challenge of array data analysis is that 
many early studies have shown that differ­
ent sets of genes are affected by similar ex­
posures. This finding may be due to a lack 
of standardization of approach in guiding 
analysis and interpretation. Studies where 
gene expressions are measured under dif­
ferent conditions need rules for determining 
what is an outlier (a potentially important 
deviation in expression). In the context of 
gene expression data, this is sometimes de­
scribed as the challenge of detecting a sig­
nal, a true difference in expression, amidst 
the noise of natural variability in gene ex­
pression. Whether variability for different 
genes can be expressed in the same scale 
of measurement needs to be determined 
[Wittes and Friedman 1999]. Replication 
is necessary to determine whether tested 
genes have the same natural scales of mea­
surement. Even if the same scale of mea­
surement is appropriate for different genes, 
the question arises as to whether the appro­
priate method has been used for detecting 
outliers [Wittes and Friedman 1999]. Chal­
lenges attending the interpretation of the 
deluge of data include identifying genes 
and their functions, identifying reproduc­
ible artifacts, and distinguishing homeo­
static from pathologic perturbations.
Different approaches have been suggested 
to analyze the large amount of gene expres­
sion information generated from microar­
ray experiments [IARC 2004]. Statistical
methods have been developed and refined 
for determining which genes, among the 
thousands on microarray chips, are differ­
entially expressed across experimental con­
ditions or biological states. Adjustments for 
multiple testing are necessary to balance 
the risks of type I and type II errors. Multi­
variate statistical analysis approaches, such 
as cluster analysis, are often then applied to 
discover groups of genes that have similar 
expression patterns on microarrays across 
different experimental conditions or bio­
logical states. These patterns are then ex­
amined to explore whether coexpression of 
the genes provides clues about their regula­
tion or their function.
A need exists for standardization of data 
collection from microarray experiments, 
optimization of information, and knowl­
edge management to make data exchange 
and comparisons between studies easier 
and more accurate. One approach to stan­
dardizing collection, analysis, and dis­
semination of microarray data was the 
development of the minimum-information- 
about-a-microarray-experiment (MIAME) 
guidelines [Brazma et al. 2001]. MIAME 
has six essential elements: (1) the study ex­
perimental design, or the set of hybridiza­
tion experiments as a whole, (2) the array 
design, or how each individual array and 
each element in the array is used, (3) the 
sample characteristics (which samples are 
used and how the samples are extracted, 
prepared, and labeled), (4) the hybridiza­
tion procedures and parameters, (5) mea­
surement (description and includes images, 
quantification, and specifications), and (6) 
normalization, control types, values, and 
specifications. This six-part approach has 
become the standard for some journal sub­
missions.
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The utility of microarray data will depend 
on our ability to interpret and communi­
cate the data. Ultimately, the goal is to inte­
grate this information into risk assessment 
[Ermolaeva et al. 1998]. In occupational 
and environmental health, a key decision 
will be when the technology will be mature 
enough for regulatory use [NAS 2003]. 
The NAS, in conjunction with a federal li­
aison group, identified four challenges to 
using toxicogenomic microarray data by 
government agencies: premature use of the 
data, data interpretation, communications, 
and information gaps [NAS 2003].
In addition to analyzing a gene for muta­
tions, the need to consider factors affecting 
gene penetrance and phenotypic expres­
sion, such as gene expression and environ­
mental covariates, still exists if genetic in­
formation is to be useful for environmental 
health research or risk assessment.
3 .3  T h e  R e l a t i o n s h i p  
B e t w e e n  G e n e t i c  a n d  
E n v i r o n m e n t a l  R i s k  F a c t o r s
Genetic factors may modify exposure-ef­
fect relationships. That is, the risk of effect 
or disease attributable to an occupational 
exposure can be decreased, unchanged, or 
increased depending on the form of interac­
tion (e.g., additive, multiplicative, or syn­
ergistic) between the gene variant and the 
occupational hazard [Poulter 2001]. This 
effect modification has both statistical and 
biological aspects. Statistically, the exami­
nation of the joint effects of two or more 
factors is often discussed and depends on 
the statistical method (e.g., multiplicative 
or additive) used to model the interaction. 
From a biological perspective, effect mod­
ification conceptually answers the ques­
tion of why only one of two similarly ex­
posed individuals develops a disease. The 
answer, in part, is variability in genetic 
makeup between individuals [Schulte and 
Perera 1993].
Gene-environment interactions are the 
combination of environmental exposures 
and genetic polymorphisms to bring about 
an effect. Ottman [1996] described six bio­
logically plausible models relating geno­
type to exposure (see Figure 3-3). The 
sixth model showed no interaction between 
a genetic biomarker and an occupational/ 
environmental risk for the disease. Models 
A through E in Figure 3-3 describe differ­
ent scenarios of gene-environment interac­
tions. In Model A, the genetic biomarker 
or genotype causes an increase in the envi­
ronmental risk factor, perhaps by increased 
absorption of the agent into the body. The 
genotype or genetic biomarker exacerbates 
the effect of the risk factor in Model B. For 
example, the genotype results in increased 
metabolism of a chemical so that greater 
levels of carcinogenic metabolites are 
formed. Alternatively, the genotype may 
result in a change in metabolism so that 
less carcinogenic metabolites are formed. 
In Model C, the exposure increases the ef­
fect of the genetic biomarker or genotype 
by causing increased or decreased gene ex­
pression. Both exposure and genotype di­
rectly increase the risk of disease in Model 
D. In Model E, the exposure and the genet­
ic biomarker both have the same effect on 
disease risk, either increasing or decreas­
ing that risk; for example, silica and TNF- 
a-308 are both risk factors for silicosis. 
Each of these models may lead to a different 
prediction about disease risk in individuals
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classified by the presence or absence of a 
high-risk genotype or environmental expo­
sure.
A case study of occupationally induced 
asthma is given as an example of some of 
the models. As with the case of silicosis, it 
appears that in occupationally induced asth­
ma, gene-environment interactions may be
important [Barker et al. 2003]. Genes can 
modify the risk of occupationally induced 
asthma in two ways. Genes may not have 
any effect on the disease, but may alter the 
response to the environmental exposure 
of the allergen (Model B), or they may be 
involved in the response to the allergen 
(Model E).
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C a s e  S t u d y  o f  O c c u p a t i o n a l l y  I n d u c e d  A s t h m a
Diisocyanates are low-molecular-weight chemicals known to produce occupational 
asthma. However, only 5% to 10% of those exposed develop disease [Piirila 
et al. 2001]. An example of how a gene may modulate a response is through 
biotransformation or metabolism of the xenobiotic. Glutathione S-transferases 
(GSTs) bind diisocyanates and their metabolites. This binding of the diisocyanates 
or their metabolites may alter the body’s response to the diisocyanate. Two studies 
of workers with diisocyanate-induced asthma were compared with an exposed, but 
asymptomatic, control group. Piirila et al. [2001] found that GST polymorphisms 
altered the response to exposure. GSTM1nul1 (one polymorphism of GST) nearly 
doubled the risk of developing diisocyanate-induced asthma. In a second study, 
Mapp et al. [2002] evaluated 92 workers who had toluene diisocyanate (TDI)- 
induced asthma and compared them with 30 asymptomatic exposed workers. They 
reported that workers with asthma with more than 10 years of exposure to TDI were 
less likely to have the GSTP1 (Val/Val) genotype, a second GST polymorphism. It 
appears that persons who are homozygous for these alleles have some protection 
against TDI-induced asthma.
In another example, for different genes, Wikman et al. [2002] investigated 
genotypes for the N-acetyltransferase-metabolizing enzymes in 109 workers with 
diisocyanate-induced asthma and 73 asymptomatic workers. The slow acetylator 
genotype for N-acetyltransferase 1 (arylamine N-acetyltransferase (NAT1) 
conferred a 2.5-fold increase in the risk of developing diisocyanate-induced asthma 
in general and a 7.8-fold increase in risk for TDI-induced asthma.
In the above example, genes modified the metabolism of the chemical exposure, 
which increased or decreased the risk of asthma. Genes can also modify the 
body’s immune response to the allergen in occupationally induced asthma. Human 
lymphocyte antigen (HLA) class 2 molecules have a crucial role in the immune 
response that occurs in occupational asthma. In one study, 67 workers with TDI- 
induced asthma and 27 asymptomatic controls were genotyped for three HLA class 
2 genes: DQA1, DQB1, and DRB1 [Mapp et al. 2000]. Asthmatics were found 
to have a significantly higher frequency of specific alleles for DQA1 and DQB1, 
while controls had higher frequencies of two other alleles for DQA1 and DQB1. 
Taylor [2001] reported that the HLA class 2 gene, DR3, was more prevalent in 
occupational asthma cases induced by acid anhydrides, suggesting that there 
may be a contribution of HLA class 2 molecules in individual susceptibility to 
sensitization and asthma induction.
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Interactions between independent causal 
factors are inevitably affected by expo­
sure response and latency relationships. 
The term “exposure response” refers to a 
response or effect seen at a given exposure 
level. The lower the exposure, the less the 
response or risk of disease and vice versa. 
Latency is the period of time between expo­
sure and the onset of the effect or disease. 
Failure to model dose-response and latency 
adequately can lead to bias in interaction 
estimates [Greenland 1993]. In addition, 
measurement errors, even if independent 
and nondifferential, can distort interaction 
assessment. Since both genetic and envi­
ronmental factors contribute to the etiology 
of most diseases, each may be expected to 
modify the effect of each other [Morgen­
stern and Thomas 1993].
3 .4  A n a l y t i c a l  
E p i d e m i o l o g i c a l  R e s e a r c h
Attention to the use of appropriate analyti­
cal epidemiological methods is critical for 
understanding the role of genetics in oc­
cupational disease. While many early stud­
ies were innovative, they were of limited 
value because issues of analytical validity 
of genotyping, possible selection bias, con­
founding, possible gene-environment and 
gene-gene interactions, and statistical inter­
action were inadequately addressed [Little 
et al. 2002]. Studies with conflicting find­
ings have been common; thus, the role of 
genetic factors in occupational disease and 
disorders is not as clear as it might be. Ge­
netic associations with disease or as effect 
modifiers in exposure response studies suf­
fer from a lack of a systematic approach.
Two CDC efforts have been initiated to 
address the problem. The first effort is the 
creation of the Human Genome Epidemiol­
ogy Network (HuGENet). Activities in this 
effort are to develop reviews of gene-dis- 
ease, gene-gene, and gene-environment in­
teractions systematically. Human Genome 
Epidemiology (HuGE) reviews were estab­
lished as a means of incorporating evidence 
from human genome epidemiological stud­
ies, i.e., population-based studies to deter­
mine the impact of human genetic variation 
on health and disease [Khoury and Little
2000]. These reviews are systematic, peer- 
reviewed synopses of the epidemiological 
aspects of human genes, including preva­
lence of allelic variants in different popula­
tions, population-based information about 
disease risk, evidence for gene-environ- 
ment interaction, and quantitative data on 
genetic tests and services (see Table 3-2) 
and are carried out according to specified 
guidelines [Khoury and Little 2000].
The other approach was a result of the CDC- 
National Institutes of Health (CDC-NIH) 
HuGE Workshop held in January 2001, 
which developed a standardized consen­
sus approach for reporting, appraising, and 
integrating data on genotype prevalence 
and gene-disease associations [Little et al.
2002]. A checklist (Table 3-3) developed 
during the workshop was intended to guide 
investigators in the preparation of manu­
scripts, to guide those who need to appraise 
manuscripts and published papers, and to 
be useful to journal editors and readers. The 
checklist was not meant to be exhaustive. 
For use in assessing the role of genetics in 
occupational disease, the list would need to 
be extended to specify the approach and as-
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T a b le  3 - 2 .  S e le c te d  H u G E  re v ie w s  [ H u G E N e t  2 0 0 9 ]
Genes Diseases Authors
GST Colorectal cancer Cotton et al. [2000]
NAT1 and NAT2 Colorectal cancer Brockton et al. [2000]
MTHFR Congenital anomalies Botto and Yang [2000]
HLA-DQ Diabetes Dorman and Bunker 
[2000]
GSTM1 and GSTT1 Head and neck cancer Geisler and Olshan 
[2001]
ALAD Lead toxicity Kelada et al. [2001]
NQO1 Benzene toxicity Nebert et al. [2002]
GSTM1 Bladder cancer Engel et al. [2002]
Lung Cancer Carlsten et al. [2008]
GST Ovarian cancer Coughlin and Hall [2002]
GJB2 Hearing loss Kenneson et al. [2002]
hMLHl and hMSH2 Colorectal cancer Mitchell et al. [2002]
APOe Cardiovascular disease Eichner et al. [2002]
AR Prostate cancer Nelson and Witte [2002]
HLA-DPB1 Chronic beryllium disease McCanlies et al. [2003]
MTHFR Leukemia Robien and Ulrich [2003]
CYP3A4 Breast and prostate cancer Keshava et al. [2004]
CTSD Alzheimer’s disease Ntais et al. [2004]
CYP17 Hormone levels Sharp et al. [2004]
ADH Head and neck cancer Brennan et al. [2004]
AR, PGR Ovarian cancer Modugno [2004]
MTHFR, MTR Colorectal neoplasia Sharp and Little [2004]
ERa and ER0 Osteoporosis Gennari et al. [2005]
ERCC2 Lung cancer Benhamou and Sarasin 
[2005]
CYP1B1 Breast cancer Paracchini et al. [2007]
GSTP1 Bladder cancer Kellen et al. [2007]
Lung Cancer Cote et al. [2009]
MPO G-463A Cancer Taioli et al. [2007]
NAT1 and NAT2 Bladder cancer Sanderson et al. [2007]
GST Hepatocellular cancer White et al. [2008]
E-cadherin Cancer Wang et al. [2008]
Adapted from Burke et al. [2002] and NCI [2006].
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T a b le  3 - 3 .  P ro p o s e d  c h e c k l is t  f o r  r e p o r t in g  a n d  a p p r a is in g  s tu d ie s  o f  ( i )  g e n o ty p e
p r e v a le n c e ,  ( i i )  g e n e -d is e a s e  a s s o c ia t io n s , a n d  ( i i i )  g e n e - e n v ir o n m e n t  in te r a c t io n s







1. Purpose of study Yesf Detect associations or 
estimate magnitude of 
association
Describe joint effects; 
test specific hypotheses 
about interaction
2. Analytical validity 
of genotyping
Types of samples used Yes For cases and for con­
trols
For cases and for con­
trols
Timing of sample col­
lection and analysis, by 
study group*
e.g., ethnic group e.g., cases vs. controls e.g., cases vs. controls
Success rate in extracting 
DNA, by study group*
e.g., ethnic group e.g., cases vs. controls e.g., cases vs. controls
Definition of the 
genotype(s) investigat­
ed; when there are mul­
tiple alleles, those tested 
for should be specified
Yes Yes Yes
Genotyping method 
used (reference; for 
PCR methods -  primer 
sequences*, thermocyle 
profile*, number of cy­
cles*)
Yes Yes Yes
Percentage of potentially 
eligible participants for 
whom valid genotypic 
data were obtained, by 
study group
e.g., ethnic group e.g., cases vs. controls e.g., cases vs. controls
If pooling was used, 
strategy for pooling of 





Yes Including blinding of 
laboratory staff
Including blinding of 
laboratory staff
Samples from each group 
of participants compared 
(e.g., cases and controls) 
included in each batch 
analyzed*
Yes
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3. Assessment of ex­
posures
Reproducibility and va- Yes
lidity of exposure docu-
mented
Categories or exposure Yes
scale justified
4. Selection of study
participants
Geographical area from Yes Yes Yes
which participants were
recruited
The recruitment period Yes Yes Yes
Recruitment methods for Yes
participants whose geno­
types were determined, 
such as random popu­
lation-based sampling, 
blood donors, hospital­
ized participants with 
reasons for hospitaliza­
tion
Definition of cases and 
method of ascertainment
Yes Yes
Number of cases recruit­
ed from families and 
methods used to account 
for related participants
Yes Yes
Recruitment rates Where possible by sex, 
age, and ethnic group
For cases and controls For cases and controls
Mean age (±SD) or age 
range of study partici­
pants, and the distribu­
tion by sex
Yes For cases and controls For cases and controls
Ethnic group of study 
participants
Yes
Similarity of sociodemo- Yes Yes
graphic (or other) char­
acteristics of participants 
for whom valid geno­
typic data were obtained 
with characteristics of 
participants for whom 
such data were not ob­
tained*
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If other than a case-fami­
ly control design, match­
ing for ethnicity, or ad­




Distinguish clearly a 
priori hypotheses and 
hypotheses generated
Yes Yes
If haplotypes used, spec­
ify how these were con­
structed
Yes Yes Yes
Number of participants 
included in the analysis, 
by cell numbers where 
possible
Yes Yes Yes
Method of analysis, with 
reference, and software 
used to do this
Yes Yes
Confidence intervals Of genotype frequency Of measures of associa­
tion with the genotype
For interaction analysis, 
2xK presentation used, 
or choice of stratified 
analysis justified
Yes
For interaction analysis, 
P value for interaction 
calculated and choice of 
Wald test or likelihood 
ratio test specified and 
justified
Yes
For interaction analysis, 
null interactions listed
Yes
Assessment of goodness 
of fit of the model used*
Yes Yes
f ”Yes” indicates essential aspects for reporting; text indicates inclusion with caveats.
*Additional information recorded (ideally in Web-based methods register), but not necessarily presented in 
journal article.
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sumptions for assessing gene-environment 
interactions and to specify quality charac­
teristics in the measurement of occupational 
and environmental exposures.
An international effort is underway to help 
understand the role of genomics in disease 
and to help solve the methodological prob­
lems that have been identified. This effort is 
called the “network of networks” [Semina­
ra et al. 2007; Ioannidis et al. 2006, 2005]. 
Groups of researchers (networks) exist that 
focus their research toward specific dis­
eases. The network allows for individual 
researchers to pursue their own hypotheses, 
but it can also facilitate researchers by im­
proving the quality of the studies through 
standardization of clinical, laboratory, and 
statistical methods. The Network of Inves­
tigator Networks helps to establish a road­
map for the conduct and translation of hu­
man genome research. The National Cancer 
Institute has funded different consortia of 
researchers to investigate specific cancers 
through their Epidemiology and Genetics 
Research Program.
3 .5  U s e  o f  B a n k e d  o r  S t o r e d  
S p e c i m e n s
Human biological material is an essential 
tool for genetic research in humans. De­
mand for human specimens is increasing as 
more genetic research is conducted [Ander­
lik 2003]. One of the biggest challenges in 
conducting human-based research is recruit­
ing participants and obtaining specimens. 
Large biobanks that contain stored speci­
mens have been suggested as a solution to 
the problem [Nederhand et al. 2003]. Other 
sources of biological material could be spec­
imens left over from other studies or even 
residual medical tissue that might remain 
after an operation, such as a biopsy. Tech­
nical issues present some challenges in us­
ing stored or banked samples. Specimens 
from epidemiological and biomarker stud­
ies are being collected by the thousands in 
ongoing studies. Little has been published 
on the selection and validation of the meth­
ods used to collect, prepare, preserve, and 
store these specimens [Holland et al. 2003]. 
Selection of these methods can affect the 
outcome of the study results and can even 
result in the specimens being useless for 
some analyses [Holland et al. 2003]. Devel­
opment of a good quality control program 
using standard operating procedures when 
handling or storing the samples can help to 
ease concerns about sample integrity. Be­
sides the technical issues surrounding stored 
or banked specimens, study design issues, 
such as selection bias, and ethical issues are 
also critical. These issues will be discussed 
in later chapters.
3 .6  C e l l  L i n e s  a n d  
T r a n s g e n i c  A n i m a l s
An alternative or complementary approach 
to epidemiology studies aimed at better un­
derstanding of disease pathologies in gene­
environment interactions is the use of cell 
lines and transgenic animals, coupled with 
DNA microarray technology. This technol­
ogy has expanded the field of genetic dis­
ease research to include evaluation of not 
just the gene, but also interindividual and 
intraindividual differences in gene expres­
sion. It is feasible to expose normal cells 
and tissues in vitro to chemicals or to com­
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plex mixtures of interest under controlled 
conditions and simultaneously to monitor 
exposure response by tens of thousands of 
genes. If this is done in the context of spe­
cific inherited genotypes of interest, then 
the underlying early exposure response can 
be identified.
The development of transgenic or geneti­
cally engineered animals is predicated on 
molecular epidemiological studies. These 
animals are widely used as basic research 
models to study the function of specific 
genes, the toxicity to specific chemicals, 
the result of a genetic change, etc. Candi­
date genetic traits or specific alleles can be 
introduced into an appropriate rodent mod­
el to predict or confirm other findings. In 
many cases, the animal will be susceptible 
to the disease/phenotype or partial pheno­
type only when the human homologue is 
present. These in vivo models, together 
with molecular epidemiological studies, 
are tools to understand disease pathobiol- 
ogy, develop prevention/intervention strat­
egies, and provide data that will help the 
Occupational Safety and Health Adminis­
tration (OSHA) develop better standards to 
protect workers.
3 .7  C o n s i d e r a t i o n s  in  t h e  
I n c o r p o r a t i o n  o f  G e n e t i c s  
In t o  O c c u p a t i o n a l  H e a lt h  
R e s e a r c h
The collection of genotype data from 
workers may yield new insights into re­
lationships between exposures, suscepti­
bility, and disease, assuming that the ana­
lytical validity of the genotyping, selection 
bias, confounding, and interaction (i.e.,
gene-environment, gene-gene, and other) 
are adequately addressed. The rights of 
workers who volunteer to participate in re­
search, including genetic research, must be 
protected. This protection must minimize 
the potential for misinterpretation, misuse, 
and abuse of genetic information by ad­
dressing issues such as privacy, confiden­
tiality, notification, and the implications of 
the results for workers and their families. 
Providing the worker with a clear explana­
tion of these and other aspects of a study 
during the informed consent process is the 
cornerstone of this protection.
The use of genetic biomarkers to improve 
the design and analysis of studies of occu­
pational and environmental determinants 
of disease may be one way to address the 
limitations of observational epidemiology 
that have been described [Davey Smith 
2001; Taubes 1995]. It is possible to ex­
ploit the random assignment of genes as 
a means of reducing confounding in ex­
posure-disease associations through the 
application of Mendelian randomization 
principles [Davey Smith and Ebrahim
2003]. According to Mendel’s second law, 
the random assortment of chromosomes at 
the time of gamete formation results in ran­
dom associations between unlinked loci in 
a population and is independent of occupa­
tional and environmental factors. This, in 
theory, would lead to a similar distribution 
of unlinked genetic loci in individuals with 
and without disease [Little and Khoury
2003]. However, there are caveats to this 
approach. Attention must be paid to study 
size, differences in patterns of linkage dis­
equilibrium, knowledge of candidate gene 
function, and the effect of population strat­
ification [Little and Khoury 2003]. Early
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results from HapMap indicate a tendency 
of certain areas of the human genome to be 
inherited in large blocks rather than inde­
pendent alleles [IHC 2005].
A rigorous study design can help to mini­
mize biological variation. The contribution 
of the variation in biological changes in 
an individual or among individuals can be 
factored in if the characteristics and con- 
founders of a genetic marker have been es­
tablished. Protocols should be established 
for the collection and documentation of the 
specimens. The timing of the collection of 
the specimen may be critical, depending on 
what the test is measuring. Protocols also 
need to be developed to establish trans­
portation and storage procedures in the 
preanalysis phase. It is generally accepted 
that specimens should be coded so that the 
identity, exposure status and disease status 
of the specimen donors are not known to 
the analyst. Questionnaires or interviews 
are needed to find out exposure details and 
about nonoccupational exposures that an 
individual might have, such as smoking, 
diet, or other lifestyle factors. It is criti­
cal in population validation that exposure 
assessment receive as much attention as 
marker measurement [Rothman 1995].
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C H A P T E R 4
HEALTH RECO RDS: 
A SO U RCE  
OF GENETIC  
INFORMATION
G enetic information may be included 
in the health records of workers [An­
derlik and Rothstein 2001; Rothenberg et 
al. 1997]. This information can be in the 
form of a family history, inferences based 
on early age of onset of diseases in fam­
ily members, a history of diseases with 
known strong genetic etiologies, or the 
results of physical examinations and com­
mon laboratory tests. This type of informa­
tion is often routinely reported by workers 
on job applications, health questionnaires 
for jobs, insurance applications and physi­
cals, and workers’ compensation forms.
Genetic information is a particularly sensi­
tive subset of health information, because 
it reveals distinctive and immutable attri­
butes that are not just personal but shared 
by family members as well [Hustead and 
Goldman 2002]. Employers and prospec­
tive employers, who obtain family health 
history, gain some insight, albeit limited, 
about a worker’s or potential worker’s ge­
netic make up, the genetic make up of his 
or her family members, and possibly his or 
her future health. However, the potential 
for misinterpretation and, hence, misuse of 
such information still exists.
The line between genetic and nongenetic 
information in health records is unclear. In 
existing and proposed legal statutes, the 
definition of genetic information may or 
may not include much of what is in health 
records other than that pertaining to ex­
plicit genetic tests [Hodge 1998]. Some 
statutes are underinclusive, limiting the 
definition of genetic information to DNA- 
based genetic test results. Other statutes 
are overinclusive and may include all types 
of genetic information as well as nonge­
netic health information [Hodge 1998]. A 
position statement of the American Col­
lege of Medical Genetics (ACMG) noted 
that definitions must be sufficiently broad 
to accommodate the wide range of what is 
known about classic single-gene disorders 
and the contribution of multiple genes to 
common, complex diseases [Watson and 
Greene 2001; Williams 2001].
Workers may benefit from a better under­
standing of how genetic information can 
be used in the workplace. This information 
may be used to aid potential employees
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in employment decisions when science is 
able to provide answers with greater cer­
tainty about potential risks given the expo­
sure in the prospective workplace. If work­
place exposures are not an issue, genetic 
discrimination still may be. Employers 
who learn about rare monogenetic diseases 
(e.g., Huntington’s disease) in a prospec­
tive worker’s family may conclude that 
the worker has an increased risk and may 
thus hesitate to hire him or her. In 2000, 
a U.K. government-appointed committee 
ruled that British life insurers could use 
the results of genetic tests for Huntington’s 
disease in underwriting life insurance poli­
cies [Aldred 2000]. However, due to fear 
of discrimination of those who test positive 
for Huntington’s, other countries have in­
troduced legislation that prevents insurers 
from either requiring genetic testing or of 
using the results of genetic testing to un­
derwrite medical, disability, or life insur­
ance policies.
4 .1  H e a l t h  I n q u i r i e s  a n d  
E x a m i n a t i o n s
The Americans With Disabilities Act of 
1990 (ADA) defined the kind of health in­
formation, including genetic, that an em­






In the preemployment, preoffer stage, the 
ADA prohibits health inquiries, including 
genetic inquiries and physical examina­
tions, prior to extending a conditional job
offer to an applicant [Langer 1996]. At the 
postoffer, preplacement stage, an employer 
could conduct unrestricted health inquiries 
or physical examinations, including genet­
ic testing and inquiry. However, under the 
proposed regulations for the Genetic In­
formation Nondiscrimination Act of 2009 
(GINA) [FRN 2009], employers will be 
prohibited from obtaining family medical 
history or genetic tests of job applicants 
after making a job offer. Similarly, em­
ployers will be barred from offering ge­
netic information through fitness for duty 
examinations.
4 .2  C o n f i d e n t i a l i t y ,  P r i v a c y ,  
a n d  S e c u r i t y
Health records of workers and job appli­
cants have been collected and maintained 
over time with different degrees of con­
fidentiality. Confidentiality describes the 
duties that accompany the disclosure of 
nonpublic information, such as the release 
of health history records to a third party 
within a professional, fiduciary, or contrac­
tual relationship [Anderlik and Rothstein 
2001]. In occupational health, traditional 
rules of confidentiality are often compli­
cated by the dual roles of a health care pro­
vider who is involved in relationships with 
both the worker and the employer [Tilton 
1996].
Underlying the responsibility of confiden­
tiality is the right to privacy. The concept of 
privacy is broad and subsumes at least four 
categories: access to persons and personal 
spaces, access to information by third par­
ties, third-party interference with personal 
choices, and ownership of materials and in­
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formation derived from persons [Anderlik 
and Rothstein 2001; Allen 1997]. Privacy 
is linked to autonomy or individual self­
governance, and it is an important theme 
in U.S. law and ethics [Beauchamp and 
Childress 1994].
A third concept, security, is related to con­
fidentiality and privacy. It refers to the 
measures taken to prevent unauthorized 
access to persons, places, or information 
[Anderlik and Rothstein 2001]. The mea­
sures used to achieve the goal of security 
depend on the context and the state of the 
technology.
With regard to the health records of work­
ers or job applicants, the issues of privacy, 
confidentiality, and security depend on a 
variety of factors. These include how the 
information is obtained, by whom, and for 
what purpose. Information can be records 
or test results, either of which may have 
genetic implications. A policy statement 
by the American College of Occupational 
and Environmental Medicine (ACOEM) 
asserts that the ethical standards of occu­
pational medicine practice mandate that 
employers be entitled to counsel about an 
individual’s medical work fitness, but not 
to diagnosis or specific details [ACOEM
1995]. Similarly, a position statement by 
the American Association of Occupational 
Health Nurses, Inc. (AAOHN), states that 
workers “should be protected from unau­
thorized and inappropriate disclosure of 
personal information” [AAOHN 2004b]. 
Protection of individual privacy and con­
fidentiality of health information are also 
addressed by both organizations in their 
codes of ethics [ACOEM 2005; AAOHN 
2004a].
Laws related to confidentiality of health 
information in the workplace are varied 
[Brandt-Rauf and Brandt-Rauf 1997]. 
ACOEM has endorsed a statement by the 
National Conference of Commissioners on 
Uniform State Laws that recommends “the 
development of uniform comprehensive 
legislation addressing the confidentiality 
of medical records...that encompass the 
treatment of employee medical informa­
tion in the workplace” [Brandt-Rauf and 
Brandt-Rauf 1997]. Prior to passage of the 
ADA, employers not covered by the Reha­
bilitation Act of 1973 could use health in­
formation, including genetic information, 
as justification for not offering an applicant 
a job. Up to that time, health information 
was by norm or law generally kept confi­
dential. However, depending on the rela­
tionship between the person who obtained 
the health history and the employer, a per­
son’s health records could be maintained in 
more than one location, including with the 
company physician, the human resources 
department, or a contract health care pro­
vider. Others, such as health and life insur­
ance providers, could also have access to a 
worker’s or job applicant’s health history. 
Prior to 1990, use of genetic information 
was permissible unless otherwise prohib­
ited by state law, either a disability nondis­
crimination law or a genetic nondiscrimi­
nation law.
The handling of health records in occupa­
tional health may be influenced by various 
federal and state regulations that govern the 
release of private health information in the 
workplace. Some of these statutes include 
the Uniform Health Care Information Act 
[1986], workers’ compensation statutes 
and case law [Workers’ Compensation
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Statutes 2007], the ADA [1990], the Drug 
Abuse Prevention, Treatment, and Reha­
bilitation Act [2007], and the Health In­
surance Portability and Accountability Act 
(HIPAA) (Public Law 104-191) [HIPAA
1996]. HIPAA permits a group health plan 
or health insurer to request genetic infor­
mation about an individual for treatment, 
payment, and health care operations, in ac­
cordance with HIPAA-compliant authori­
zations.
In 2000, the U. S. Department of Health 
and Human Services (DHHS) issued the 
Standards for Privacy of Individually Iden­
tifiable Health Information or Privacy Rule 
(45 CFR 160, 164) [DHHS 2007], which 
was amended in 2003 for compliance by 
April 14, 2003 [HIPAA 2005]. The rule 
imposed significant new documentation 
requirements on health care providers, 
particularly those who conduct clinical re­
search or provide health data to research­
ers. Providers were required to obtain writ­
ten consent covering the use or disclosure 
of personal health information.
The Privacy Rule did not replace or act 
in lieu of the DHHS protection of human 
participants regulations [DHHS 2007] and 
the Food and Drug Administration (FDA) 
protection of human participants regula­
tions (21 CFR 50, 56) [FDA 1999]. The 
Privacy Rule does not apply to research; it 
applies to covered entities, which research­
ers may or may not be. The Privacy Rule 
may affect researchers because it may limit 
their access to information, but it does not 
regulate them or their research per se [NIH
2004]. This rule sets minimum standards 
for how protected health information may 
be used and disclosed and what control
people have over their health information. 
For purposes of the Privacy Rule, genetic 
information is considered to be health in­
formation [NIH 2004].
4 .3  G e n e t i c  E x c e p t i o n a l i s m
“Genetic exceptionalism” is a term that de­
scribes the differentiation of genetic infor­
mation from other health information and 
the contention that it should be afforded 
special protection [Kulynych and Korn 
2002; Murray 1997]. However, definitions 
in state statutes vary widely and demon­
strate the practical difficulty of drawing 
operationally meaningful distinctions be­
tween genetic and other types of health in­
formation. Broader definitions may expand 
genetic information in the future [Burris et 
al. 2000]. A compilation of state statutes 
on genetic privacy and genetic information 
can be found at the National Conference of 
State Legislatures [2004] Web site (http:// 
www.ncsl.org/public/leglinks.cfm).
The concept of genetic exceptionalism is 
based on the implications that genetic in­
formation has for possible future illness of 
individuals as well as their family mem­
bers. However, treating genetic informa­
tion as distinct from health information 
may not be supportable because (1) genet­
ic information may significantly overlap 
with other health information, (2) the is­
sues underlying privacy and antidiscrimi­
nation protections for genetic information 
may apply equally to other sensitive types 
of health information (such as whether an 
individual is infected with the human im­
munodeficiency virus [HIV]), which may 
go relatively unprotected by comparison,
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and (3) the creation of significant protec­
tions for genetic information may foster a 
public perception that genetic information 
is something to hide rather than a valu­
able part of an individual’s clinical record 
[Hodge 1998]. Ultimately, most diseases 
have a genetic component.
The literature contains unresolved argu­
ments for and against claims of genetic ex- 
ceptionalism [Launis 2000; Strudler 1994]. 
Some have argued that whether genetic 
exceptionalism is a valid construct is sim­
ply not the right question [Press and Burke 
2001]. They argue that issues pertaining to 
genetic information should be viewed as 
central to and inextricably entwined with 
how disease, health prevention, and work­
place responsibility are considered. Ge­
netic information is risk factor information 
that, whether it needs special protection or 
not, is part of the constellation of factors 
that can be used to understand occupa­
tional risks. However, legislators and other 
policymakers have embraced the concept 
of genetic exceptionalism for pragmatic 
and political reasons [Rothstein 2005].
4 . 4  G e n e t i c  D i s c r i m i n a t i o n
Family history has long been viewed as an 
important factor in health diagnosis and 
treatment [Andrews 1997]. In 2000, the 
EEOC published “Policy Guidance on Ex­
ecutive Order 13145: To Prohibit Discrim­
ination in Federal Employment Based on 
Genetic Information” [EEOC 2000]. The 
Executive Order directs departments and 
agencies to extend to all of their workers 
the policy against genetic discrimination 
based on protected genetic information. 
The EEOC guidance directs that “protected
genetic information” includes information 
about genetic tests on individuals or their 
family members and family health history 
[EEOC 2000]. A broader discussion of ge­
netic discrimination appears in Chapter 7.
4 .5  T h e  H i s t o r i c a l  U s e  o f  
G e n e t i c  I n f o r m a t io n
Prior to the availability of genetic testing, 
genetic information was available and was 
used by clinicians, employers, health and 
life insurers, and researchers. Phenotypic 
traits, such as race, ethnicity, and sex, have 
been widely used as crude factors to ac­
count for the potential influence of genetic 
factors (among others) in clinical and epi­
demiological studies. Seventy years ago, 
investigators speculated that genetic traits 
might predispose some workers to occupa­
tional disease [Haldane 1938].
Concerns pertain to the repercussions of 
genetic information falling into the wrong 
hands and resulting in loss of health and 
life insurance, loss of employment, having 
a mortgage foreclosed or denied, or hav­
ing genetic information used in divorce 
and child custody cases, personal injury, 
or workers’ compensation suits. No solid 
source of empirical evidence documents 
how often or for what purpose employers 
have historically obtained or currently ob­
tain genetic information about job appli­
cants. A 1999 American Management As­
sociation (AMA) survey reported that 24% 
of major U.S. firms collected information 
about family health history [AMA 1999]. 
By 2004, this had decreased to 14.7% 
[AMA 2004]. Furthermore, 4.2% of the 
surveyed companies in 2004 used family 
medical history in their decisions to hire,
Implications fo r Occupational Safety and Health 4 3
assign or reassign, or retain or dismiss em­
ployees. Attention has also focused on the 
privacy rights of family members and on 
who owns family health history data ob­
tained from study participants [Renegar et 
al. 2001]. The issues involved are complex.
The American Society of Human Genetics 
(ASHG) [2000] has addressed the issue of 
family consent in research. ASHG believes 
that the determination about whether to 
collect family health history information 
represents more than minimal risk and af­
fects the participants’ rights and welfare 
and will have to be made in each case, as 
research protocols are reviewed at the local 
level. This determination will most likely 
be done by institutional review boards 
(IRBs). An IRB is a group that has been 
formally designated to review and moni­
tor biomedical and behavioral research 
involving human participants. An IRB per­
forms critical oversight functions to ensure 
research conducted on human participants 
is scientific, ethical, and legal. Most Fed­
eral government, academic and institu­
tional (hospitals) groups have IRBs that 
review research studies conducted by their 
staff. Commercial IRBs are also available 
for industry supported research or other 
groups that may not have their own IRB 
[Lemmens 2000]. Thus, IRBs are well po­
sitioned to address the question of whether 
collecting family history data indeed repre­
sents a violation of privacy of living rela­
tive about whom information is collected.
4 .6  T h e  U s e  o f  G e n e t i c  
I n f o r m a t io n  in  R e s e a r c h
Throughout U.S. history, health and oc­
cupational records and archival tissue of 
generations of workers have been an irre­
placeable source of new knowledge about 
occupational diseases and their prevention, 
control, and treatment. Medical knowl­
edge and occupational health cannot ad­
vance without ready, albeit controlled, 
access to health and occupational informa­
tion. Health records may be overlooked 
and overshadowed as sources of genetic 
information by the potential power of 
DNA testing to yield genetic information. 
However, increasingly, health records may 
contain information about tests conducted 
for diagnostic, therapeutic, predictive, or 
other purposes. As health knowledge about 
diseases and genetic factors increases, ge­
netic tests that were viewed as predictive 
may come to be considered diagnostic. As 
of 2008, use of genetic information con­
tained in health and other records has not 
been studied and reported in the scientific 
literature, but it appears, at this time, not to 
be a major source of health information for 
occupational research.
4 .7  G e n e t i c  I n f o r m a t io n  in  
t h e  A s s e s s m e n t  o f  C a u s a t i o n
Genetic information has been used retro­
spectively to assess causation in workers’ 
compensation or tort litigation [Schulte 
and Lomax 2003; Poulter 2001]. Many 
compensation or tort litigation cases that
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have invoked genetic susceptibility in rela­
tion to toxic or other causation have used 
the argument that genetics is an alternative 
explanation to the toxicant for the causa­
tion of disease and that a family history 
of the disease or condition in question is 
evidence of genetic predisposition [Poulter 
2001]. Counterarguments often invoke the 
absence of a family history, suggesting the 
absence of genetic expression in the ab­
sence of occupational exposure.
In some instances, genetic information may 
be used to apportion causation. The extent 
to which genetic information from a health 
record can be used to apportion causation 
will depend on the type of information in 
the record. Family history, genetic test re­
sults, or medical test results with genetic 
implications may all contribute to a causal 
analysis, but not to the same extent. Infor­
mation about mutations related to mono­
genic diseases that are highly penetrant 
may provide the strongest evidence for 
gene causation. However, most monogenic 
conditions are not work-related. In con­
trast, with less-penetrant polymorphisms, 
which may be involved in the activation 
or detoxification of workplace chemicals, 
the strength of arguments based on such 
information could be limited because of 
low relative and attributable risks related 
to the polymorphisms. [Kelada et al. 2003; 
Marchant 2003b; Marchant 2000].
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RESEA R CH  AND 
PRA CTICE
G enetic monitoring is the evaluation 
of an exposed population for genetic 
damage over time and involves the de­
tection of biomarkers of effect (see Table 
2-2). Genetic monitoring has been used in 
a variety of situations, particularly involv­
ing radiological and genotoxic chemical 
exposures. It is similar to other forms of 
biological monitoring [Ashford et al. 1990; 
Schulte and Halperin 1987]. Little infor­
mation is available about the recent use of 
genetic monitoring by companies. The last 
available information was a survey of For­
tune 500 companies conducted by the now 
defunct Office of Technology Assessment 
(OTA) in 1989. Only one company report­
ed current use of genetic monitoring [OTA 
1990]. Five companies reported past use, 
and two companies reported consideration 
of future use of genetic monitoring.
In public health, genetic monitoring has 
many of the same strengths and limitations 
as toxic exposure or health effects moni­
toring. The strengths of a monitoring pro­
gram include identifying a risk of exposure 
for a group or possibly for individuals to 
potentially hazardous substances, target­
ing work areas for evaluation of safety and 
health practices, and detecting previously 
unknown hazards. When genetic monitor­
ing is used to evaluate an exposure or the
effectiveness of safety and health practic­
es, a reduction in the genotoxic measure­
ments indicates a reduction in exposure. If 
the genetic monitoring assay is being used 
to determine a cancer risk, a reduction in 
genotoxic measurements may indicate a 
reduction in cancer risk, but only if that 
marker is in a relevant pathway for cancer. 
Genetic monitoring has its limitations, e.g., 
it will be uninformative if the exposures do 
not cause genetic damage. A number of 
confounders can also affect the results and 
produce large variations in measurements.
Genetic monitoring has been used to quan­
tify radiation exposures in military and 
civilian workers handling nuclear materi­
als in the United States and elsewhere in a 
research setting [Blakely et al. 2001; Jones 
et al. 2001; Moore and Tucker 1999; Men­
delsohn 1995; Langlois et al. 1987]. A case 
study of monitoring Chernobyl workers is 
presented.
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An estimated 600,000 to 800,000 workers in the former Soviet Union were 
potentially exposed to ionizing radiation as a result of cleanup activities 
after the Chernobyl nuclear power reactor accident in 1986. Approximately 
119,000 cleanup workers were monitored for radiation exposure using 
traditional badge monitoring methods, and those who were monitored in the 
2 years after the accident received an annual rate of exposure of about 0.75 
to 1.5 times the current annual U.S. exposure limit for workers exposed to 
gamma radiation.
A collaborative research program was established between U.S. and Russian 
scientists to evaluate the potential utility of persistent genetic biomarkers 
of exposure and damage among these badged workers. The goal of this 
research was to develop assays that could (1) estimate exposure, (2) indicate 
whether genetic damage had occurred that might lead to harmful health 
effects, and (3) estimate the relative biological effect of different types of 
radiation exposure. One potential public health use of such research is the 
ability to establish better regulatory standards by permitting the comparison 
of doses among populations from which standards may be derived (e.g., 
Japanese atomic bomb survivors versus nuclear workers) and by establishing 
the relative harm caused by different forms of radiation and different rates 
of exposure.
The studies conducted in the Chernobyl population have shown variability 
in their ability to assess genetic damage and to confirm the doses measured 
by badge readings (reviewed in Jones et al. [2002]). A study among 625 
cleanup workers and 182 controls from Russia compared three assays 
of genetic damage, including chromosomal aberrations measured by 
fluorescence in situ hybridization (FISH), HPRT mutation in lymphocytes, 
and two GPA-variant flow cytometry assays using erythrocytes [Jones 
et al. 2002]. Extensive analysis of other exposure and lifestyle attributes 
were included in the study. Results indicated that age, smoking, and other 
attributes and behaviors were related to markers of genetic damage. After 
adjusting for these factors, the FISH and HPRT assays indicated an average 
of 30% and 41%, respectively, greater genetic damage among cleanup 
workers than controls. The GPA assays showed no significant difference 
between cleanup workers and controls. The doses measured by badges 
were in general confirmed by the FISH chromosomal assay, and the effects 
measured appeared to persist over time. A number of technical problems 
have been raised by this research, including the assay sensitivity at lower 
doses, interactions with age and lifestyle factors, and technical difficulties 
and the high cost of these assays for use in epidemiological research.
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In the early 1960s, the Texas Division of 
Dow Chemical Co. initiated a compre­
hensive surveillance program for workers 
exposed to a variety of chemicals [Kilian 
and Picciano 1979]. The purpose of the 
program was to evaluate whether cytoge­
netic changes could be used to monitor for 
exposure to chemicals. The program con­
sisted of four parts: (1) periodic evaluation 
(health history, physical examination, and 
laboratory reports), (2) cytogenetic evalu­
ation by assessing chromosomal aberra­
tions, (3) conventional epidemiology such 
as morbidity and mortality, and (4) nested 
case-control studies to look at specific dis­
eases or conditions. Although this program 
was eventually phased out by the company, 
some results were achieved, such as the 
development of a comprehensive health 
questionnaire to determine confounders 
and interferences with cytogenetic results; 
the development of an education program 
to explain the program to the workers; the 
accumulation of a large database of cytoge­
netic results that could show temporal and 
seasonal variations of cytogenetic tests; 
and the confirmation that benzene and epi- 
chlorohydrin were genotoxic to workers 
who were exposed to either chemical [Le­
gator 1995].
Biomarkers of genetic exposure or damage 
can be sources of risk estimates to be used 
along with morbidity and mortality sta­
tistics. The use of well-validated genetic 
biomarkers has been advocated as a way 
to prioritize exposed individuals for more 
thorough medical monitoring [Albertini
2001]. However, one concern raised by 
critics of genetic monitoring is that the re­
sultant action will focus only on the worker 
and not on minimizing or eliminating the
exposure [Ashford et al. 1990; OTA 1990; 
Schulte and Halperin 1987]. Depending on 
the circumstances, both medical monitor­
ing of the worker and decreasing the expo­
sure may be warranted. The hierarchy of 
controls (Table 5-1) and the principles of 
the OSH Act require emphasis on chang­
ing the workplace environment to control 
occupational exposures at the source. Pri­
mary prevention tools are substitution or 
elimination of the agent, engineering con­
trols, training, administrative controls, and 
personal protective equipment [Ellenbeck­
er 1996; Halperin and Frazier 1985].
Secondary prevention includes medical 
monitoring and controlling other exposures 
that are likely to contribute to a health risk. 
Medical monitoring is one approach for 
detecting problems early enough to make 
a difference in the natural history or prog­
nosis of the health risk and may be justi­
fied if unidentified exposures exist or if ex­
posures cannot be adequately controlled. 
Genetic monitoring can be a tool used in 
primary or secondary prevention strategies 
to assess the efficacy of exposure or effect 
reduction.
In the course of genetic monitoring, indi­
vidual results have prompted a decision 
for further prevention measures such as 
medical removal—moving the worker to 
another job location where exposure is 
lower or absent. This has been practiced 
in conjunction with traditional biological 
monitoring, such as for blood lead and se­
rum and urinary cadmium [OSHA 2007a, 
2007b; 1974].
Genetic monitoring highlights confusion in 
the literature between group and individual 
risk assessment. Epidemiological research,
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1. Primary prevention: Eliminate or reduce exposure




• Personal protective equipment
2. Secondary prevention: Reduce the biological effects of exposure
• Medical monitoring
Pre-exposure screening 
Detection of effects following exposure 
test body burden 
test genotoxic effect
• Control of other chemical/agent exposures that may contribute to the genotoxic effect
3. Tertiary prevention: Reduce disease impact
• Medical removal
• Job reentry
*'Italicized text added to show how genetic monitoring could fit into the hierarchy. 
(Adapted from Halperin and Frazier [1985]; Plog and Quinlan [2002].)
including the validation of biomarkers of 
exposure and effect in a population, identi­
fies risks only for groups. It does not iden­
tify risks for specific individuals. Individ­
ual risk profiles could be constructed using 
exposure factors, data from tests on effects 
of exposure (such as genetic monitoring), 
and hereditary characteristics [Truett et 
al. 1967]. However, epidemiological data 
reports are still primarily based on group 
findings. Thus, what is available is the risk 
for a specific group with certain character­
istics in common, similar to life insurance 
company ratings of groups such as smok­
ers. In practice, the individual risk profiles 
could be useful for risk monitoring to iden­
tify highly exposed workers. A concern 
about this kind of risk profiling is the pos­
sibility of removing or excluding workers 
who fit the profile, rather than correcting 
environmental exposures.
5 .1  R e g u l a t i o n
Currently, no U.S. regulations mandate 
genetic monitoring, although medical sur­
veillance requirements are included in 17 
OSHA standards, but only 4 of these (arse­
nic, lead, cadmium, and benzene in emer­
gency exposure situations) require specific 
biological monitoring to determine ex­
posure. GINA does permit employers to 
engage in genetic monitoring provided it 
meets certain requirements such as provid­
ing clear written notice of the testing, that it 
be voluntary, why the testing is being done, 
employee consent is received and that the 
employee receives the results in such a 
way that the identity of specific individuals 
cannot be determined [FRN 2009].
Questions arise about whether genetic 
monitoring indicates a potential health
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problem, an existing health problem, or 
compensable damage [Schulte and DeBord 
2000]. Further work to understand and in­
terpret the science and public policy will 
help to answer these questions. No genetic 
monitoring assay has yet been fully vali­
dated to assess an individual’s risk of dis­
ease. Changes in chromosomal aberrations 
have been associated with increased risk of 
developing cancer. However, no individual 
risk for cancer development has been iden­
tified. As additional research is conducted 
and as understanding and recognition of 
genetic changes relevant to exposure and 
disease increase, genetic monitoring as­
says may be able to provide information 
about individual risks. With this increased 
knowledge, new opportunities for detec­
tion, prevention, and treatment of occupa­
tional disease may arise.
5 .2  C o n s i d e r a t i o n s  f o r  
G e n e t i c  M o n it o r in g
As with any medical monitoring program, a 
plan to delineate the objectives, scope, and 
resulting action of the program is needed. 
If genetic biomarkers are to be useful in 
the workplace, certain criteria need to be 
established. Examples of criteria proposed 
by Lappe [1983] and Murray [1983] are 
given in Table 5-2. Decisions need to be 
included in the plan, before implementa­
tion of monitoring, as to what will happen 
to workers with outlier results. The fol- 
lowup could range from repeat monitoring 
to diagnostic evaluation and may include 
environmental remediation or medical re­
moval.
Since many genetic biomarkers can be in­
fluenced by nonworkplace exposures, life­
style, and genetic makeup, genetic moni­
toring would be accompanied by a ques­
tionnaire to assess these exposures (which 
could include neighborhood ambient air, 
diet, hobby exposures, etc.). The goal of 
genetic monitoring would be to explain 
the implications of the monitoring results 
rather than to attribute them to some non- 
occupational exposure.
Consideration of what workers would be 
told about the monitoring plan, their test 
results, and what those test results mean is 
important for the well-being of the worker. 
The question of who will have access to ge­
netic monitoring data needs to be answered 
prior to implementation of any plan. Po­
tential participants would be informed of 
how their data would be protected from ac­
cess by others and how their data would be 
used.
Genetic markers of exposure or effect of 
exposure for occupational toxicants are not 
sufficiently validated at this time to permit 
their use in routine practice or regulation, 
except for genetic damage related to radia­
tion exposure. However, a growing body of 
data links genetic biomarkers and somatic 
mutations in reporter genes to cancer risks 
in groups of workers [Boffetta et al. 2007; 
Bonassi et al. 2007, 2004, 2000; Rossner 
et al. 2005; Liou et al. 1999; Hagmar et 
al. 1998]. The relevance of this risk to in­
dividuals in those groups with increased 
levels of genetic biomarkers has not been 
established and needs further study. At this 
time, insufficient evidence exists to support 
genetic biomarkers in routine occupational 
safety and health practice or regulation.
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However, the use of genetic biomarkers in 
research settings and in validation studies 
should continue to fill in those knowledge 
gaps and establish links between genetic 
biomarkers and occupational diseases, if 
they exist.
Table 5-2. Potential Criteria for Implementing 
Genetic Monitoring in the Workplace
• Use of validated genetic markers
• Clinical utility established
• Goals of the program specified
• Acceptance by population being monitored (informed consent)
• Established linkage to exposure or disease
• Protection of privacy and confidentiality
• Notification of participants
• Process for addressing results and outliers 
(Adapted from Lappe [1983]; Murray [1983].)
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C H A P T E R
THE TH EO RETICA L  
USE OF GENETIC  
SCREEN ING AND 
OCCUPATIONAL 
HEALTH PRACTICE
I n the workplace, genetic screening is 
the examination of the genetic makeup 
of workers or job applicants for certain 
inherited characteristics. This discussion 
of genetic screening is intended only for 
informational purposes and for stimula­
tion of discussion. Genetic screening is not
being recommended to inform employers 
in making employment-related decisions, 
and currently no test has been validated for 
genetic screening purposes in an occupa­
tional setting.
Theoretically, genetic screening in the 
workplace could be applied for two dis­
tinct purposes (Figure 6-1). First, workers 
or job applicants could be screened for the 
presence of genetically determined traits 
that would render them susceptible to a 
pathological effect if exposed to specific 
agents in the workplace. This information 
could also be used by the individual to 
make job-related choices. Second, work­
ers or job applicants could be screened to 
detect heritable conditions associated with
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6 .1  H i s t o r y
Haldane [1938] is generally credited as 
the first scientist to suggest using genetic 
screening to identify and exclude suscep­
tible workers from hazardous work envi­
ronments:
The majority of potters do not die 
of bronchitis. It is quite possible 
that if  we really understood the 
causation of this disease, we 
should find that only a fraction 
of potters are of a constitution, 
which renders them liable to it.
If so, we could eliminate potters’ 
bronchitis by rejecting entrants 
into the pottery industry who are 
congenitally disposed to it.
Later observations of the genetic makeup 
affecting an individual’s reactions to either 
a chemical agent or a drug were reported 
in the 1950s during the Korean War, when 
some American soldiers taking the antima- 
larial drug primaquine experienced acute 
hemolytic anemia. This was attributed to 
their carrier status for the gene for glucose-
6-phosphate dehydrogenase (G6PD) defi­
ciency. These soldiers were described as 
hypersusceptible [OTA 1990].
Schill [2000] describes the early history of 
genetic screening in the workplace:
G6PD is an enzyme necessary 
in the glucose metabolism of 
the red blood cell. Based on the
d iseases u n re la te d  to  o c c u p a tio n a l e x p o ­
sure [ O T A  1 9 9 0 ] .
experience of the soldiers in the 
Korean Conflict, it was postulated 
that individuals with a deficiency 
ofG6PD also would develop acute 
hemolytic anemia after exposure 
to chemicals such as aromatic 
nitro and amino compounds; 
arsine and related metal hydrides; 
lead and its compounds; and 
several dye intermediates 
[Rothstein 1984]. Stokinger and 
Mountain [1963]published one of 
the first scientific journal articles 
advocating the use of genetic 
screening to identify individuals 
who were hypersusceptible to 
certain chemicals because of 
their G6PD deficiency. By the 
early 1970s, genetic screening 
for hypersusceptibility had 
been proposed for additional 
conditions, such as sickle cell 
trait, alpha-1-antitrypsin (AAT) 
deficiency, and carbon disulfide 
sensitivity [Rothstein 1984].
The issue of genetic screening was first 
addressed by OSHA in the 1970s. At that 
time, OSHA promulgated 14 carcinogen 
standards that required a preassignment ex­
amination by a physician before a worker 
could be assigned to a job covered by these 
standards. The OSHA standards specify 
that the examination include a personal 
history of the worker, a family history, and 
the occupational background of the work­
er, including genetic and environmental 
factors [OSHA 1974]. No further guidance 
was developed, and initially the issue did 
not receive much attention [Schill 2000].
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Subsequently, in February 1980, after the 
publication of a series of articles in the 
New York Times on genetic testing in the 
workplace, the issue of using genetic fac­
tors in the carcinogen standards received 
greater scrutiny [Schill 2000]. In response, 
Dr. Eula Bingham, then Assistant Secretary 
of Labor for OSHA, issued a news release 
that stated, “There is absolutely no OSHA 
standard that requires genetic testing of any 
employee” [OSHA 1980b]. Bingham said:
Exclusion of workers as a result 
of genetic testing runs contrary 
to the spirit and intent of the 
Occupational Safety and Health 
Act of 1970. It wrongly puts 
the burden of controlling toxic 
substances on the worker who is 
denied employment because of a 
supposed sensitivity. Employers 
should make the workplace safe 
for all workers, rather than 
deprive some workers of their 
livelihood in the name of safety.
This announcement was followed by a 
directive from the OSHA Office of Com­
pliance Programs to OSHA enforcement 
staff in 1980. The directive stated in part, 
“These provisions [of the carcinogen stan­
dards and the OSHA cancer policy] do not 
require genetic testing of any employee 
[or] the exclusion of otherwise qualified 
employees from jobs on the basis of genetic 
testing” [OSHA 1980a]. Furthermore, the 
directive explained that taking a worker’s 
health history must be considered a “rou­
tine part of standard medical practice.. .de­
signed to identify factors important to the
employee’s general health status” [OTA 
1990; OSHA 1980a].
6 .2  P a s t  a n d  C u r r e n t  U s e  o f  
G e n e t i c  S c r e e n i n g
In the early 1980s, at the request of Con­
gress, OTA studied the role of genetic test­
ing in the prevention of occupational dis­
ease [OTA 1983]. As part of its evaluation, 
OTA surveyed U.S. industry, including 
utilities and unions, to determine the extent 
and nature of genetic testing (monitoring 
and screening) that was occurring in the 
workplace. The survey found that genetic 
testing had been used by 17 organizations 
in the previous 12 years, but only 5 of the 
17 were conducting such testing at the time 
of the survey. However, 59 organizations 
expressed interest in future use of genetic 
testing [OTA 1983].
A second study of genetic testing in the 
workplace was undertaken by OTA in the 
late 1980s. This study found that 12 com­
panies were using genetic monitoring or 
screening for research or some other rea­
son [OTA 1990]. Six companies reported 
that they anticipated future use of genetic 
monitoring or screening [OTA 1990].
A 1999 American Management Associa­
tion (AMA) survey on medical testing in 
the workplace found that 74% of 1,054 
responding companies required physical 
examinations of newly hired and current 
workers [AMA 1999]. This survey deter­
mined the frequency and types of genetic 
testing of job applicants and workers, 
as well as how the test results were used
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[Schill 2000]. Companies that tested used 
the results to hire applicants (6.7%), to as­
sign or reassign workers (7.3%), to retain or 
dismiss workers (1.7%), and in any regard 
(10.3%) [AMA 1999]. The AMA repeated 
this survey in 2004 and found that 63% of 
the 503 companies surveyed required some 
type of medical testing [AMA 2004]. Test­
ing categories included Huntington’s dis­
ease, family medical history, and suscep­
tibility to workplace hazards. The compa­
nies in the second survey indicated that the 
results from the aforementioned categories 
were used to hire job applicants (12.9%), 
assign or reassign employees (8.4%), or 
retain or dismiss employees (4.8%). The 
percentages from the second survey reflect 
slight increases from those of the first sur­
vey. However, since the companies were 
not identified in either survey, it is possible 
that different companies answered the two 
surveys so that the increases only reflect a 
difference in the respondents and not that 
more companies were beginning to use 
medical testing to make employment deci­
sions.
An example to illustrate the potential use 
of genetic screening may be seen in the 
case of beryllium workers. Research has 
demonstrated that workers with beryllium 
sensitivity and CBD were more likely to 
carry HLA-DPB1E69 than workers without 
these conditions, although the PPV was not 
very high. In the last few years, these find­
ings prompted a beryllium manufacturing 
company to initiate a pilot preemploy­
ment screening program for prospective 
workers [Bates 2001]. Prospective work­
ers were informed that a test for a genetic
marker that had been linked to CBD (HLA- 
DPB1E69) was available at no cost to them. 
Genetic counseling was provided by a uni­
versity-based genetic counselor through an 
800-number. The tests were performed at 
a university-based laboratory. The beryl­
lium manufacturing company paid for the 
testing and counseling, but did not receive 
identifiable individual results. Because of 
economic conditions in the beryllium in­
dustry at the time of the pilot project, the 
company hired few new workers so that 
relatively few individuals used the pro­
gram, and therefore it was suspended. In 
addition, evidence that an enhanced pre­
ventive model of workplace controls was 
effective in reducing exposure and rates of 
sensitization to beryllium resulted in less 
interest in the issue of individual suscepti­
bility conferred by genetic status.
Although currently no genetic screening 
tests have been validated for assessing the 
increased risk of susceptibility to work­
place hazards, it is anticipated that such 
tests will eventually become available for 
voluntary use. Genetic screening can offer 
some benefits, such as giving a person ad­
ditional information about whether a job 
may affect his/her health, as in the beryl­
lium case described above. At such time 
in the future, a test may be developed that 
would warrant its use to protect public safe­
ty. It has also been suggested that as genetic 
tests become more available in society, em­
ployers who fail to use them may be held 
liable for damages sustained by a worker 
whose genetic condition causes a lapse of 
consciousness or incapacity [French 2002]. 
This view has not been substantiated in the
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literature, nor is it plausible that a company 
would be held liable for genetic conditions 
of its employees. The implications are also 
not known if an employee knew about a 
genetic variation that could increase or de­
crease risk from exposure and failed to dis­
close that information to his employer.
6 .3  T e c h n i c a l  a n d  P u b l i c  
H e a l t h  I s s u e s  in  W o r k e r  
S c r e e n i n g
6.3.1 Reversing the hierarchy of 
prevention
Some proponents of genetic screening ar­
gue that, in a competitive business envi­
ronment, employers seek to use technical 
innovations, such as genetic screening, to 
select workers. Genetic factors already af­
fect employment options to the extent that 
they affect abilities. Ostensibly, organiza­
tions would use genetic screening to avoid 
placing hypersusceptible workers in haz­
ardous jobs. With these potential benefits, 
some have argued that companies have an 
obligation to screen [OTA 1990].
As described in Chapter 5, the occupation­
al safety and health community has estab­
lished a hierarchy of controls for prevent­
ing occupational disease and injuries [Hal- 
perin and Frazier 1985]. Genetic screening 
is not part of the hierarchy of controls. It 
involves evaluating workers prior to em­
ployment. An evaluation of health history 
is part of job placement decision-making. 
The addition of genetic screening to the 
process of job placement has the potential
to reverse the emphasis in the hierarchy of 
controls from changing the environment to 
changing (excluding) the workers [Schulte 
and Halperin 1987].
6.3.2 Uncertainty of the science 
and premature application of 
genetic screening tests
Various authoritative and scholarly groups 
have identified criteria for the use of ge­
netic tests [Genetics and Public Policy 
Center 2006; ACOEM 2005; ASCO 2003; 
CDC 2003; Goel 2001; NBAC 1999]. In 
addition to the ADA requirements that tests 
be job-related and consistent with business 
practice, as well as other civil rights stipu­
lations in legislation, there are the issues of 
the validity and utility of the tests, as well 
as ethical, legal, and social safeguards. In 
short, an adequate evidence base is need­
ed prior to the use of a genetic screening 
test. Until such a base is established, the 
test would not be ready for use in a worker 
population. In 2005, ACOEM concluded 
in its position statement on genetic screen­
ing in the workplace that “until extensively 
validated, genetic screening is a form of 
human investigation and subject to the ap­
propriate ethical and scientific controls.”
6.3.3 Published criteria for genetic 
screening
In anticipation of the eventual use of ge­
netic screening tests to determine the in­
creased risk of susceptibility to workplace 
hazards, the scientific community has been 
engaged in the discussion and consideration
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of potential criteria that would support the 
use of genetic screening for employers or 
workers to make employment-related de­
cisions. For example, the American Medi­
cal Association Council on Ethical and 
Judicial Affairs [1991] has suggested that 
genetic screening only be used if specific 
conditions could be met:
• The disease develops so rapidly that 
serious and irreversible illness would 
occur before monitoring of either the 
workers’ exposure to the toxic sub­
stance or the workers’ health status 
could be effective in preventing the 
harm.
• The genetic screening test is highly 
accurate, with sufficient sensitivity 
and specificity to minimize the risk 
of false negative and false positive 
results.
• Empirical data demonstrate that the 
genetic variation results in an unusu­
ally elevated susceptibility to occupa­
tional illness.
• Undue expense is needed to protect 
susceptible workers by lowering the 
level of the toxic substance in the 
workplace.
• Testing is not performed without the 
informed consent of the worker or 
applicant for employment.
Yesley [1999] also offered criteria to con­
sider regarding exclusionary employment 
policies based on genetic screening for oc­
cupational susceptibility:
• The relative and absolute risk of the 
disorder if an individual with the sus­
ceptibility mutation receives the occu­
pational exposure
• The accuracy of the genetic test in 
detecting the mutation
• The seriousness of the disorder
• The availability of treatments or pre­
ventives
• The practicability of eliminating the 
exposure from the workplace
Applying these criteria, Yesley [1999] pro­
vided three instructive examples: one that 
would reject the use of an exclusionary 
policy based on genetic screening, one that 
would support the use of an exclusionary 
policy, and one that would fall in the gray 
zone (Table 6-1). Other criteria may also 
include the public safety or worker safety 
aspects of a job. At present, however, ex­
clusionary employment-related policies 
based on genetic screening for increased 
risk to workplace hazards are not justified 
because science has not shown definitive 
linkage of genes and occupational illness. 
In addition, no genetic screening test with 
regard to an occupational illness has been 
validated.
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It is practical to eliminate the hazardous exposure.
A polymorphism does not substantially increase the risk from an 
occupational exposure.
The disorder is mild, slow to manifest, and treatable.
Gray zone •
•
A polymorphism confers susceptibility to an occupational expo­
sure, resulting in a serious but nonfatal disorder that will not 
manifest for several years and may be treatable.
The exposure can be eliminated at reasonable cost.
May be justified • A polymorphism in combination with an occupational expo-
sure commonly causes a fatal disorder that never occurs in the 
absence of the mutation.
• Control of the exposure from the workplace is not practicable.
Implications fo r Occupational Safety and Health 5 9
60 Genetics in the Workplace
C H A P T E R 7
THE ETHICAL, 
SO CIAL, AND LEG A L  
IMPLICATIONS OF 
G EN ETICS IN THE  
W O RKPLACE
A lthough genetic research is generally 
no different from many other types of 
biomedical research, the information ob­
tained in such research may have a greater 
potential for misinterpretation, misuse, and 
abuse. These same concerns also pertain to 
the use of genetic information in occupa­
tional health research and practice. This 
chapter highlights some of the ethical, le­
gal, and social issues related to genetics in 
the workplace.
It has long been known that there is a range 
of variability in human response to occu­
pational hazards, particularly chemical 
hazards. Genetic factors contribute to the 
variability and consequently may be use­
ful to consider in research and control of 
hazards [Marchant 2003b; Christiani et 
al. 2001; Neumann and Kimmel 1998]. 
“Susceptibility” is a term used to describe 
different ways that individuals respond 
to occupational and environmental con­
taminants. The concept of susceptibility 
in occupational safety and health should 
be framed within a public health context 
[Froines et al. 1988]. The basis for this 
framework is that workplace disease and 
injuries represent one of the largest groups 
of preventable conditions in public health, 
and the most effective strategies for the 
prevention of disease and injury are pri­
mary prevention strategies. Historically, 
excluding susceptible workers from expo­
sure has not been considered an element of 
primary prevention. The social history of 
regulation and practice has been to empha­
size control of the workplace and not the 
workers [Froines et al. 1988].
Identifying susceptible individuals or 
groups before exposure might enable those 
individuals to be protected. However, such 
policies might also result in discrimina­
tion and economic hardship independent 
of the disease that the policy was intended 
to prevent [Froines et al. 1988]. Further­
more, identification of susceptibility might 
be interpreted as a control strategy in itself, 
in conflict with historical values and ap­
proaches exemplified in the OSH Act. Em­
ployers may also face an ethical dilemma 
if they expose a known susceptible worker 
when the workplace exposure cannot be 
controlled enough to protect that worker 
[Froines et al. 1988].
The economic issues of employers and 
workers also influence the application of 
genetic susceptibility in occupational safe­
ty and health policies and practices. Em­
ployers face increasing health care costs, 
and often a small fraction of the worker 
population accounts for a large portion 
of the health care expenditures. There is 
a strong incentive for employers to try to 
reduce this fraction. From the workers’ 
perspective, current or prospective work­
ers’ livelihoods depend on having equal 
opportunities to obtain and keep jobs and 
to flourish in their work. Workers also have 
the expectation to be protected from work­
place harm and compensated for adverse 
health effects from work.
Implications fo r Occupational Safety and Health 61
In spite of the OSH Act and the historic 
view of workers’ compensation as a no­
fault system, companies may argue that 
their legal liability should be lessened be­
cause a worker’s genetic makeup contrib­
uted to a disease. This argument may be 
given more credence if the worker elected 
to take a genetic test that showed increased 
susceptibility, but chose to accept the job 
anyway. However, the dynamics involved 
in job selection are complex, and the OSH 
Act does not imply that susceptible work­
ers should be unprotected. How society 
will address the disease burdens and costs 
related to susceptibility will depend not 
only on economic analyses but also on pre­
vailing political views of distributive and 
social justice.
7 .1  F r a m e w o r k  f o r  
C o n s i d e r i n g  G e n e t i c  
I n f o r m a t io n
Genetics in the workplace can be consid­
ered according to three categories of use: 
research, practice, and regulation/litiga­
tion. All of the uses of genetic information 
in the workplace can be viewed through 
these three categories. To further explore 
these categories, they will be considered in 
terms of inherited genetic factors and ac­
quired genetic effects. This is a common 
classification scheme for genetic risks. 
Inherited genetic factors pertain to germ 
and somatic cell DNA transmitted through 
meiosis or mitosis. Acquired genetic ef­
fects involve modification of genetic mate­
rial over time and can include genetic dam­
age or expression as a result of workplace 
and environmental exposures.
The line between inherited genetic factors 
and acquired genetic effects, however, can 
be blurry in some areas, particularly those 
related to gene expression status such as 
transcriptomics, proteomics, toxicogenom- 
ics, and metabonomics. Table 7-1 identi­
fies some of the ethical, legal, and social 
issues for each use of genetic information.
7 .2  I n h e r i t e d  G e n e t i c  
F a c t o r s :  R e s e a r c h
Genetic factors are likely to be respon­
sible for some differential distribution of 
diseases among workers that cannot be 
accounted for by differences in exposures 
and lifestyle. [Neuman and Kimmel 1998]. 
It is clearly accepted that practically no oc­
cupational diseases are determined solely 
by either genes or environment. In the ear­
ly history of occupational epidemiology, 
genetic influences were considered only 
in terms of confounding by race and sex. 
Today as many occupational exposures are 
being controlled to lower levels, the under­
standing of genetic factors as sources of 
variability in risk estimates is increasing 
[Vineis et al. 1999; Neumann and Kimmel 
1998].
7.2.1 Safeguarding rights of 
participants in research
Genetic research involves human partici­
pants, and the rights of these participants 
require protection. The cornerstone of pro­
tecting the rights of research participants 
is the informed consent process, which 
is based on three historic documents: the
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Table 7-1. Framework for Considering Ethical, Legal, and Social Issues of Genetics 
in the Workplace With Respect to Sections in the Chapter
Types of genetic information
Uses Inherited genetic factors Acquired genetic effects
Research Section 7.2
• Validity and predisposition
• Safeguard rights of research 
participants
• Interpretation and 









• Prevention and diagnosis
• Job actions
• Autonomy, privacy, and 
confidentiality













• Premature use of genetic tests
• Apportionment of causation




• Use in risk assessment
• Impact on risk 
management
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Nuremberg Code [1949], the Belmont Re­
port [1979], and the Federal Policy for the 
Protection of Human Subjects, also known 
as the Common Rule [1999], which is 
codified at 45 CFR 46, Subpart A [DHHS
2005]. These documents form the basis for 
protecting the rights of participants in bio­
medical research.
A broad spectrum of opinion exists about 
what obtaining informed consent entails 
and when it is achieved [Clayton 2003; 
Schulte et al. 1999; Samuels 1998a; Hunter 
and Caporaso 1997; Schulte et al. 1997]. 
Some believe that for genetic data (bio­
markers) whose meaning is not known at 
the time of the study, a participating work­
er in an occupational study cannot give 
truly informed consent [Samuels 1998a]. 
This interpretation implies a much higher 
standard for genetic biomarker informa­
tion than for other information routinely 
obtained by questionnaires, environmen­
tal monitoring, or record linkage. Until 
there is determination of predictive value 
and course in the natural history, such ge­
netic biomarkers are clearly only research 
variables with no clinical meaning, and 
participants should be made aware of this. 
The extent to which a biomarker has been 
validated (i.e., quantitatively linked to risk 
of disease at the group or individual level) 
should be clearly described to potential re­
search participants. With regard to inform­
ing participants of risks, general practice 
has been to identify only medical risks; 
however, it has been argued that truly in­
formed consent should include reference 
to non-medical risks that might affect par­
ticipants. For example, study participants 
may be informed that they carry a genetic
mutation that puts them at increased risk 
of subsequently developing cancer given a 
particular exposure. Participants in occu­
pational genetic studies consent to provide 
the specimens and corollary demographic 
and risk factor information and, hence, co­
operate in the specified research. The par­
ticipant generally does not consent or im­
ply consent to distribution of the data in a 
way that identifies him or her individually 
to any other parties, such as employers, 
unions, insurers, credit agencies, lawyers, 
family members, public health agencies, 
etc. [Schulte et al. 1997].
Many of the ethical concerns that have 
arisen with single-gene studies will be 
exacerbated as investigators conduct ge­
nome-wide association studies (GWAS) in 
large cohorts or in combinations of cohorts 
[IHC et al. 2007; Hinney et al. 2007; Na- 
hed et al. 2007; Weir et al. 2007]. The util­
ity of the GWAS approach will be maxi­
mized because the genetic data are posted 
in widely accessible databases [Couzin and 
Kaiser 2007]. While such approaches may 
be powerful research tools and resources, 
they have the potential to allow an individ­
ual in the database to be identified. Conse­
quently, the privacy of individuals in such 
large databases is in jeopardy. Underlying 
the privacy issues is the nature of the origi­
nal informed consent, the safeguards in 
the database assembly procedures, and the 
limitations on the use of the database by 
other investigators. In addition to privacy 
and consent issues is the potential for de­
veloping premature and unvalidated clini­
cal guidance based on findings of GWAS 
or the use of such findings in litigation or 
criminal proceedings.
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The broad range of opinion of profes­
sional organizations and scholarly groups 
is that genetic testing in research or prac­
tice should only be conducted when it is 
voluntary and given with informed consent 
[ACOEM 2005]. One question that arises 
with genetic testing for research in the 
workplace is whether a prospective or cur­
rent worker can freely give consent. The 
power dynamics of a workplace are such 
that consent could easily be pressured or 
coerced even if coercion is not intentional 
[Samuels 1998b].
Genetic research has some special aspects 
that relate to the informed consent process. 
New technologies may come into existence 
after the specimens have been collected 
and informed consent has been obtained. 
Ethical issues for stored specimens relate 
to whether (1) consent was originally giv­
en to store the samples, (2) the consent was 
generic or specific to the original hypothe­
sis, (3) the original consent obtained would 
meet consent standards at the time speci­
men use was contemplated, and (4) results 
might pertain to family members who were 
not part of the informed consent process 
[Schulte et al. 1997]. Obtaining reconsent 
is difficult for several reasons: study par­
ticipants are hard to recontact, bias may be 
interjected into the study if a high propor­
tion of the participants deny reconsent, and 
if reconsent is needed for every new test 
then a continual process of reconsent may 
be necessary as new assays are developed. 
Development of common informed con­
sent language to allow testing of specimens 
using yet-to-be-developed tests is not like­
ly to be successful. Informed consent usu­
ally limits testing to the specific hypothesis
at hand. What has been successful is add­
ing language to informed consents to al­
low storage of specimens to address future 
questions related to the specific disease at 
hand as opposed to storage of samples to 
address any hypothesis. The emergence of 
commercial tissue banks may help to alle­
viate the issue in that few restrictions may 
exist to limit hypothesis testing. However, 
broad social and policy questions surround 
these commercial banks with respect to 
informed consent, privacy, and the poten­
tial for genetic analysis to generate a large 
amount of information from a small speci­
men [Rothstein and Knoppers 2005; An­
derlik 2003].
Some investigators have drafted language 
to ask for consent to anonymize any un­
used specimens. Anonymization may al­
low the investigator to use those specimens 
for other testing or methods development. 
Anonymization comes with a price, how­
ever, in that valuable information about the 
person who donated the specimen, such as 
exposure or work history, may be lost. In 
addition, anonymization does not allow 
the investigators to notify the participants 
if a clinically relevant finding is observed, 
since the identity link between the speci­
men and its donor has been destroyed.
7.2.2 Interpreting and 
communicating the results of 
occupational genetics 
research
Three issues merit consideration in the 
interpretation and communication of the 
results of genetic research. These are the 
realization that (1) epidemiologic results
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are group risks and not individual risks,
(2) a statistically significant genetic fac­
tor may not be biologically significant, and
(3) the results of many small studies of ge­
netic polymorphisms have not been repli­
cated [Schulte 2004]. Many gene disease 
association studies represent new findings 
and have not been replicated by other in­
vestigators; and therefore, do not offer a 
clear clinical interpretation [Renegar et al.
2006]. Heeding these issues, a CDC mul­
tidisciplinary group [Beskow et al. 2001] 
using expert opinion, as well as federal 
regulation, the National Bioethics Advi­
sory Commission’s (NBAC) report on re­
search involving human biological materi­
als [NBAC 1999], and the relevant litera­
ture suggested that participants not be told 
of information that has no direct clinical 
relevance. However, occupational studies 
differ from population-based studies in the 
sampling frame used and the types of inter­
vention available. In occupational settings, 
“clinical relevance” could be defined as 
whether participants could take reasonable 
preventive or medical action based on the 
results. In the workplace, these reasonable 
actions could include various engineer­
ing, administrative, or behavioral controls 
[Weeks et al. 1991]. Clearly, where valid 
risks to workers are found in studies, noti­
fication is warranted.
7 .3  I n h e r i t e d  G e n e t i c  
F a c t o r s :  P r a c t i c e
7.3.1 Prevention and diagnosis
Genetic tests have been shown to be use­
ful for various nonoccupational diseases in 
terms of disease diagnosis and individual
risk assessment and provision of preven­
tive services [Grody 2003; Burke et al.
2002]. Thus, they are becoming a part of 
general medical practice. The extent to 
which they will impinge on practice re­
lated to the workplace and workers is not 
known. Whether such approaches will be 
useful for occupational disease also is not 
known. If genetic tests are to be useful in 
occupational health, a process is needed so 
that evidence-based integration of data for 
the development of guidelines for disease 
prevention and health services occurs such 
as the guidelines that have been suggested 
for general clinical and public health prac­
tice [CDC 2007]. CDC established the 
Evaluation of Genomic Applications in 
Practice and Prevention (EGAPP) Working 
Group in 2005 to support the development 
of a systematic process to assess the avail­
able information regarding the validity and 
utility of emerging genetic tests for clinical 
practice. In 2007, EGAPP announced their 
first evidenced-based recommendation on 
the testing for cytochrome P450 polymor­
phisms in patients undergoing treatment 
for clinical depression using serotonin re­
uptake inhibitors. The EGAPP recommen­
dation was to not conduct genetic testing 
at this time as the weight of evidence did 
not support the need for testing [EGAPP
2007]. Since the first evidenced based rec­
ommendation in 2007, five additional rec­
ommendations have been made.
In the future, the practice of occupational 
medicine may occur against the backdrop of 
individualized or personal medicine. At the 
least this may involve the need to consider 
an individual’s genetic profile in the con­
text of occupational exposures in terms of 
risk and prevention. The pressures to con­
sider genetics and occupational exposures
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may grow as pharmacogenetic assessments 
become more common in medical practice 
[Rothstein 2003]. The question that arises 
is whether this information should be used 
in making workplace decisions.
Genetic tests for more than 1,400 clinical 
diseases are available, with approximately 
300 more in the research and development 
stage [GeneTests 2009]. Laboratories per­
forming genetic testing receive oversight 
under the Clinical Laboratory Improve­
ment Amendment of 1988 (CLIA). CLIA 
was enacted to ensure and improve the ac­
curacy and reliability of medical testing. It 
imposes basic requirements that address 
personnel qualifications, quality control 
and assurance, and degree of skill to per­
form and interpret. Specialty areas have 
been identified for which targeted require­
ments are determined. To date, no specialty 
area for genetic testing has been formed to 
tailor the requirements for genetic testing 
laboratories for the explosion of new tests 
and technologies currently in use [Javitt
2006]. One aspect of CLIA is proficiency 
testing. Only a few organizations offer pro­
ficiency testing for genetic tests and then 
only for a few of the genetic tests avail­
able [Javitt and Hudson 2006]. Genetic 
testing laboratories are left to determine 
their proficiency for themselves. It has 
been reported that for those laboratories 
that do perform proficiency testing also re­
port fewer deficiencies and thus fewer ana­
lytical errors [Javitt and Hudson 2006]. In 
addition, research laboratories are exempt 
from CLIA regulations provided they do 
not give individual results for the purposed 
of diagnosis, treatment or prevention of 
diseases [Renegar et al. 2006].
The FDA does not generally regulate in 
-house developed tests. A few free-stand­
ing test kits are available and the FDA 
does review the clinical analytical valid­
ity and labeling claims [Javitt 2006; Javitt 
and Hudson 2006]. FDA also regulates a 
small subset of genetic tests known as in 
vitro diagnostic multivariate index assays. 
However, the majority of genetic tests are 
not affected by this regulation [Javitt 2006; 
Javitt and Hudson 2006] CLIA does not 
explicitly specify how accurate in-house 
tests need to be. Recently, several compa­
nies have begun offering genomic scans 
[Hunter et al. 2008]. These genomic scans 
do not fall under FDA or CLIA oversight, 
since the companies make the disclaimer 
that results should not be used for making 
medical decisions. In addition, the analyti­
cal validity, clinical validity and clinical 
utility have not been determined for these 
genomic scans [Hunter et al. 2008]. The 
proliferation of direct to consumer testing 
runs the risk of misleading consumers by 
providing inaccurate results thus under­
mining consumer confidence in genetic 
testing [Javitt and Hudson 2006].
7.3.2 Genetic screening and job 
actions
The capacity of the human body to respond 
to chemical exposure and physical agents 
varies from one individual to another. To 
some extent this is due to genetic charac­
teristics which, in principle, could become 
part of employment testing known as ge­
netic screening. Genetic screening is the 
examination of the genetic makeup of em­
ployees or job applicants for certain inher­
ited traits. The actual use of genetic assays 
or tests of workers in job offering or place­
ment is believed to be rare, but the avail­
able data to assess such activity are weak
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[AMA 2004]. However, with the passing 
of GINA, the use of genetic information in 
employment decision is prohibited. Still it 
is useful to reflect on the concerns about 
using genetic information in work-related 
actions. This will be discussed further in 
this chapter. In 2009, the EEOC published 
proposed regulations regarding GINA’s 
employment provisions. Title I and II of 
GINA establish legal protections from 
discrimination based on genetic informa­
tion. Title II focuses on the workplace and 
prohibits employers, unions, employment 
agencies, and labor-management training 
programs from using genetic information 
in connection with employment decisions, 
bars intentional collection of genetic in­
formation regarding job applicants and 
employees, imposes confidentiality and 
record keeping requirements and prohibits 
retaliation [FRN 2009]. These regulations 
are expected to be effective November 21, 
2009.
The respective roles of genetic and envi­
ronmental factors in disease differ greatly 
[Grassman et al. 1998; Brain et al. 1988]. 
The certainty with which genetic charac­
teristics can be used to predict a disease 
with or without an occupational exposure 
also varies widely [Lemmens 1997]. De­
termining the correct mix of genetic and 
environmental factors and the attendant 
risks is a complex endeavor fraught with 
many uncertainties. Therefore, the ability 
of employers or workers to make informed 
employment-related decisions based on 
genetic and environmental factors is lim­
ited by the degree of certainty about the 
relative roles of these factors. Predictions 
of risk that are highly uncertain will under­
mine claims of rights to freedom and well­
being.
The degree of certainty in genetic screen­
ing has ethical implications. If employers 
or workers make employment decisions on 
the basis of tests with low predictive value, 
workers may be harmed or resources may 
be wasted. Genetic screening is less useful 
if the screening occurs after the exposure 
rather than before the worker begins the 
job and has exposure. The extent to which 
occupational safety and health investiga­
tors and practitioners are certain about the 
meaning of genetic information will in­
fluence the nature of communications to 
workers, employers, and others.
Another issue is that in today’s workforce, 
workers are not always employees of the 
companies, but rather are contract, tempo­
rary, or subcontract workers. These work­
ers do not have the same benefits and may 
be subject to differing philosophies regard­
ing genetic information, testing, and the 
ramifications of that information.
The interpretation of information about a 
potential worker’s health risk was seen in 
the case of Echazabal v. Chevron when the 
Supreme Court ruled that employers do 
not have to hire a person with a disability 
(in this case hepatitis C) if they believe the 
person’s health or safety would be put at 
risk by performing the job [NCD 2003]. In 
this case, the job involved working around 
chemicals in a refinery. The case illustrates 
the potential for discrimination against 
employees who might be identified at in­
creased risk through genetic screening or 
from genetic information in their medical 
records [Kim 2002].
6 8 Genetics in the Workplace
Four objectives of genetic screening have 
been identified: (1) to ensure appropriate 
placement at the jobsite, (2) to exclude 
job applicants with increased susceptibil­
ity to disease, (3) to set limit values for 
more susceptible subgroups, and (4) to 
provide individual health counseling [Van 
Damme et al. 1995]. In general, pre- and 
postemployment nongenetic testing is a 
relatively common practice in selection 
and placement in the workplace. Suscep­
tibility, however, is the result of a variety 
of genetic and nongenetic factors. Despite 
the profound advances in understanding 
the human genome, there are still no ge­
netic tests that have been fully validated 
for use to screen perspective employees 
for occupational disease risks. Moreover, 
much controversy surrounds the practice 
of genetic screening, including such issues 
as the poor predictive value of the tests 
[Holtzman 2003; Van Damme et al. 1995]. 
Genetic polymorphisms may be unevenly 
distributed in the population among dif­
ferent ethnic groups [Rebbeck and Sankar
2005]. Thus, racial or ethnic discrimination 
could be a consequence of inappropriate 
use of genetic screening, which might be 
aimed at excluding workers at employment 
examination [Van Damme et al. 1995]. In 
the practice of occupational medicine, ge­
netic information has been used selective­
ly, mostly as derived from medical history, 
in job placement or diagnosis [AMA 2004, 
1999; Staley 2003].
Of special concern for researchers and 
practitioners is how to communicate genet­
ic screening results. Condit et al. [2000] 
suggested three goals for communication 
about genetics: (1) the focus should be on 
the health and well-being of the individual,
(2) individual rights for free choice should 
be actively protected, and (3) stigmatiza­
tion associated with specific genetic char­
acteristics should be avoided.
The ethical issues of genetic screening of 
job applicants or workers have been as­
sessed from various points of view. Ge­
netic screening bears on the fundamental 
interests of workers, employers, and soci­
ety [Gewirth 1998]. Various ethical issues 
of genetic screening have been addressed 
in the literature, including the certainty 
of the interpretation of genetic informa­
tion, autonomy, privacy, confidentiality, 
discrimination, and stigmatization. Some 
authors argue against genetic screening in 
the workplace because of ethical concerns. 
Others argue that screening is supportable 
with appropriate safeguards [MacDonald 
and Williams-Jones 2002; Maltby 2000; 
Bingham 1998; Van Damme et al. 1995; 
Ashford et al. 1990; Gewirth 1986; Mur­
ray 1983]. In a review of the use of genetic 
information in the workplace, it was found 
that genetic screening should only be done 
with the consent of the worker with the 
worker controlling access to that infor­
mation [Geppert et al. 2005]. In addition, 
genetic testing should only be done when 
the information was required to protect the 
safety of that worker or other workers.
Genetic screening has been assessed by 
the European Group on Ethics in Science 
and New Technologies [EGE 2003], which 
concluded that the use of genetic screening 
in the context of the medical examination, 
as well as the disclosure of results of pre­
vious genetic tests, is not ethically accept­
able. Furthermore, EGE found that, to date, 
there is no proven evidence that the exist­
ing genetic screening tests have relevance
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or reliability in the context of employment. 
Generally, genetic screening tests still have 
uncertain predictive value [EGE 2003].
Most of the research to date has focused on 
just a few genetic polymorphisms. Work­
place decisions based on such research 
would not yet be scientifically support­
able, since few of these polymorphisms 
have been found to be definitive causative 
factors for occupational diseases. The at­
tributable risk or proportion of risk as a 
result of a susceptibility-conferring geno­
type generally only reaches a level above 
25% when the relative risk is about 5 and 
the frequency of the genotype is 10% or 
greater [Holtzman and Marteau 2000]. 
Previous studies of genetic polymorphisms 
have generally failed to identify groups 
of individuals with a relative risk greater 
than 3 [Holtzman and Marteau 2000]. One 
of the few exceptions found to date is the 
beryllium example, where a ninefold dif­
ference was found in risk of chronic be­
ryllium disease for those who carried the 
HLA-DPB1E69 marker, which is present in 
about 40% of the population [McCanlies et 
al. 2002]. Hseih et al. [2007] reported a 13­
fold increased risk of liver fibrosis among 
vinyl chloride exposed workers with CY- 
P2E1 c2c2 genotype. The tendency to 
reduce complex biological and social oc­
cupational phenomena to a single genetic 
cause and the small attributable risks that 
have been assessed reduce the confidence 
that most polymorphisms studied thus far 
would be defensible for genetic screening 
[Vineis et al. 2001].
Genetic screening information may be use­
ful to inform potential employees of job 
risks if that information is not available
to employers in individually identifiable 
form. While, in principle, it seems useful 
that prospective employees would benefit 
from information about potential risks, the 
attendant problems are not without impact. 
Using such a test, many false positive find­
ings could occur resulting in people mak­
ing employment decisions based on flawed 
information. Second, the difference be­
tween voluntary anonymous screening and 
mandated screening of individually identi­
fiable applicants by prospective employers 
is huge with regards to what is known and 
not known about the relevance of genetic 
testing for occupational diseases. In con­
trast, if the test had a high (>90%) predic­
tive value, would an employer have an ar­
gument for the right to use it in employee 
selections? An American Management As­
sociation survey of medical testing in the 
workplace conducted in 2004 found that 
some companies have used susceptibility 
to workplace hazards as a reason to hire, 
assign or reassign, dismiss, or retain em­
ployees [AMA 2004]. However, the em­
ployee may also benefit from the knowl­
edge of genetic tests results by deciding 
whether to take a job or stay in a job. Deci­
sions can be made regarding health or the 
need for increased medical monitoring.
7.3.3 Autonomy (self­
determination), privacy, and 
confidentiality
Some observers believe that the central 
ethical question is whether using informa­
tion obtained in genetic testing violates 
the rights of current or prospective work­
ers [Bingham 1998]. In this view, genetic
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screening interferes with an individual’s 
right to self-determination regarding em­
ployment if the employer uses genetic 
screening information for employment-re­
lated decisions. A small survey of workers 
found that workers had a strong interest in 
learning about personal genetic informa­
tion and also felt that it needed greater pro­
tection, because of concerns about misuse, 
than general medical information [Roberts 
et al. 2005]. Safeguards have been called 
for to protect against the release and mis­
use of genetic information. It has been ar­
gued that genetic privacy has intrinsic val­
ue as a facet of autonomy and that respect 
for autonomy implies a duty to respect the 
genetic privacy of others [Anderlik and 
Rothstein 2001]. However, a different view 
holds that employers have interests (or re­
sponsibilities) to protect the well-being of 
their workers by using genetic screening 
information to select and place workers 
[French 2002; Krumm 2002; Anderlik and 
Rothstein 2001]. Employers have used this 
justification to support medical screening 
in general. Two federal class action law­
suits have been brought to the EEOC with 
regard to preplacement nerve tests to ex­
clude workers with abnormal results. Al­
though nerve testing is not a genetic test, 
the premise is the same. The EEOC lost 
both of these cases, so in essence, the prac­
tice is currently legal under federal law 
(EEOC v. Rockwell International Corp., 
60 F. Supp 2d 791 (N.D. Ill. 1999), aff’d, 
243 F.3d 1012 (7th Cir. 2001); and EEOC 
v. Woodbridge Corporation, 124 F. Supp 
2d 1132 (W.D. Mo. 2000), aff’d, 263 F.3d 
812 (8th Cir. 2001)) [French 2002].
7.3.4 Stigmatization and 
discrimination
Identifying prospective or current work­
ers with genetic risk factors may have a 
psychological and economic impact on in­
dividuals and groups [Marteau and Rich­
ards 1996; Billings et al. 1992]. Workers 
who are labeled as having an undesirable 
genetic trait may also have the mistaken 
impression that this trait puts them at risk 
from many or all exposures. Racial or eth­
nic groups who may already be burdened 
by discriminatory practices may be further 
burdened if they appear to have an inordi­
nate frequency of various traits [Wiesner 
1997].
Potential abuses and untoward effects of 
genetic screening are a concern. Genetic 
screening involves obtaining DNA, usually 
from a blood specimen, followed by the 
analysis of the DNA for genetic sequences, 
variants, polymorphisms, mutations, and 
deletions. Genetic screening creates infor­
mation about a person that indicates, or ap­
pears to indicate, either the possibility of 
health risks from workplace exposures or 
the possibility of health effects unrelated to 
work. The findings of such tests are gener­
ally reported as a probability or possibility 
of occurrence.
Depending on who possesses genetic in­
formation and how they act, the potential 
abuses and untoward effects of genetic 
information about workers can include 
discrimination in employment and health 
and life insurance, labeling, individual and 
group stigmatization, and family disrup­
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tion. While little evidence exists to support 
these contentions, many professional or­
ganizations and authoritative committees 
give strong credence to the possibility of 
these effects and advocate safeguards to 
protect against them [Watson and Greene 
2001; U.S. Task Force on Genetic Test­
ing 1998; ASHG 1996; ACOEM 1995]. 
A government-appointed committee in the 
United Kingdom did approve the use of ge­
netic test results for Huntington’s disease 
by British life insurance providers [Aldred
2000]. A U.S. health insurance provider 
has recommended its own guidelines for 
accessing genetic tests that include not us­
ing genetic test results to classify groups 
for the purpose of providing health cover­
age [Aetna 2002]. The general consensus 
is that at the present time the social conse­
quences of revealing genetic screening test 
results may outweigh the benefits of valid 
and meaningful tests.
7 .4  I n h e r i t e d  G e n e t i c  
F a c t o r s :  L i t i g a t i o n  a n d  
R e g u l a t i o n
7.4.1 Litigation
One of the first workplace areas where ge­
netic information has been used is work­
ers’ compensation. Even though traditional 
workers’ compensation is a no-fault system 
under which an employer takes a worker 
“as he or she is,” there is still potential for 
ethical and legal issues to arise involving 
genetic information. In the United States, 
there is no legal prohibition against in­
cluding any medical or genetic tests in the 
independent medical examination that is
routine in workers’ compensation cases 
[Rothenberg et al. 1997]. In addition, in­
formed consent for such testing is not re­
quired. By extension, genetic information 
may also be used as proof of causation in 
toxic injury litigation. However, “analysis 
of the role of genetic factors in multiple 
cause cases requires statistical and mecha­
nistic data about how the genetic and toxic 
risks combine to cause disease” [Poulter
2001].
One example of the use of genetic infor­
mation in a fault-based workers’ compen­
sation case involved genetic factors linked 
to occupational carpal tunnel syndrome 
[Schulte and Lomax 2003]. Railroad work­
ers who filed for compensation under the 
Federal Employees Liability Act were test­
ed for a genetic characteristic believed to 
predispose them to carpal tunnel syndrome. 
However, the genetic test had not been val­
idated for this use. Second, unresolved is 
the question of whether society should use 
genetic testing for a susceptibility genotype 
to apportion causation. This question raises 
the issue of whether immutable traits be­
yond a worker’s control should be factored 
into a claim of work-relatedness of a dis­
ease. In the above case, if it was found that 
genetic predisposition was a factor in the 
disease and not just occupational exposure, 
then the liability would have been reduced. 
The EEOC filed suit challenging the use 
of genetic testing in this case. In the settle­
ment of EEOC v. Burlington North Santa 
Fe Railway Co. (CA 02.C0456) Burling­
ton North was required to suspend genetic 
testing, could not analyze the results from 
any previous genetic testing, and could not 
analyze any blood specimens previously 
obtained [EEOC 2001].
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Indeed in some jurisdictions (various states 
such as Iowa, Wisconsin, New York, and 
New Hampshire), consensual genetic test­
ing is allowed in compensation cases. In 
the United States, most workers’ com­
pensation statutes permit medical testing, 
including genetic testing, to ascertain the 
medical condition of the claimant and the 
potential work-relatedness of the claim 
[Schulte 2004]. However, various U.S. 
organizations do not generally condone 
genetic testing without informed consent 
[ACOEM 2005].
Genetic information is also likely to be 
used in toxic tort lawsuits by both plain­
tiffs and defendants [Marchant 2003b]. In 
such cases where courts require that plain­
tiffs prove the defendant’s actions double 
the background risks (i.e., relative risk 
greater than 2.0) to satisfy the “more likely 
than not” standard of causation, genetic in­
formation could be used to segment most 
populations and identify a subgroup with 
a particular genetic polymorphism with a 
relative risk greater than 2.
7.4.2 Differences in genetic 
susceptibilities and inclusion 
in risk assessments
Risk assessments are conducted to help 
decision-makers to determine the risk of 
exposure and risks to health. Despite fa­
miliar examples of interindividual vari­
ability, as well as emerging advances from 
molecular genetics, the potential applica­
tion of such information to risk assessment 
has rarely been attempted [NRC 2007; 
Malaspina 1998]. Few examples exist of 
the incorporation of genetic information 
in quantitative risk assessments. The OSH 
Act stipulates that no worker should suffer
impairment from work; however, occupa­
tional standards are clearly set at levels that 
include residual risks. Hypersusceptibility 
has never been a major factor in determin­
ing permissible exposure levels [Hornig 
1988].
In risk assessment, genetic information 
may replace default assumptions when 
specific information regarding exposure, 
absorption, toxicokinetics, and species ex­
trapolation is unavailable or limited [Ponce 
et al. 1998; Marchant 2003b]. Although 
examples of how genetic biomarker infor­
mation can be used in risk assessments are 
limited [Dourson et al. 2005; Toyoshiba 
et al. 2004; El-Masri et al. 1999; Ponce 
et al. 1998; Hattis 1998; Bois et al. 1995; 
Hattis and Silver 1993], a general frame­
work can be adduced [NRC 2007]. Genetic 
biomarkers can be used to stratify risks and 
identify high-risk subgroups. They also 
can be used to develop mechanism-based 
models for risk assessment [Toyoshiba et 
al. 2004].
Various technical questions abound about 
the use of genetic factors in risk assess­
ment and need to be considered. For in­
stance, does the tenfold uncertainty factor 
traditionally used to account for interindi­
vidual variability within the human popu­
lation adequately describe the observed 
variability of response and susceptibility? 
Does the conservative default assumption 
used in cancer risk assessment account for 
interindividual variability relative to hu­
man exposure to carcinogens?
Genetic information has been used in risk 
assessment models to determine the impact 
of the role of metabolic polymorphisms on 
risk estimates [El-Masri et al. 1999; Bois 
et al. 1995]. While genetic information has
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the promise of more refined risk assess­
ments through identification of gene-gene 
and gene-environment interactions, there 
is danger that various ethical and social is­
sues will arise. These include stigmatiza­
tion, discrimination, and the interpretation 
that removing a susceptible person from 
the exposure scenario without reducing ex­
posure opportunities will reduce risk effec­
tively, when it may not on a comparative 
basis [Holtzman 2003; Vineis et al. 2001; 
Ashford et al. 1990].
7.4.3 Regulation
Regarding the use of genetic information in 
occupational safety and health regulations, 
there are no examples of where such infor­
mation is required. Genetic advances push 
at the historic boundaries of the OSH Act. 
The act mandates standards and rules to as­
sure “to the extent feasible...that no em­
ployee will suffer material impairment of 
health or functional capacity.” This raises 
the question of whether workers who could 
be defined by certain genetic polymor­
phisms as “hypersusceptible” should have 
special protections [Marchant 2003b]. The 
implementation of these protections raises 
a host of questions and issues regarding 
privacy, discrimination, and responsibil­
ity [Bergeson 2003]. Will employers have 
a duty to warn individuals with a genetic 
susceptibility for a specific workplace ex­
posure? (See Marchant [2003b] for a more 
detailed discussion of these issues.)
Some genetic testing laboratories are using 
“direct to the consumer” advertisement to 
publicize their testing capabilities [Hunter 
et al. 2008; Javitt and Hudson 2006]. These
40 plus companies offer a variety of ser­
vices such as being able to determine your 
ethnicity, to determining which sports your 
child may be better at to a dating service 
based on your genes. Most companies do 
not offer testing directly to the public. The 
underlying criticism is that consumers may 
be misled and not able to fully and correct­
ly interpret the results and understand all of 
the implications with regard to their health. 
Access to clinical genetic testing is cur­
rently regulated by state laws. Some states 
allow consumer-requested genetic testing, 
while other states prohibit any medical 
testing unless requested by a physician. 
These “direct to consumer” companies 
by-pass state laws as they make no claims 
about their use for medical treatment.
7 .5  A c q u i r e d  G e n e t i c  
E f f e c t s :  R e s e a r c h
There is an extensive scientific literature 
assessing the impact of environmental 
hazards on genetic material [Hagmar et al. 
2004; Bonassi et al. 2004; Jones et al. 2002; 
Albertini 2001; Toraason et al. 2001]. For 
the most part, this has involved assessment 
of cytogenetic effects (e.g., effects on chro­
mosomes) and changes in various reporter 
genes such as GPA and HPRT, mutations, 
and the formation of DNA and protein ad- 
ducts following exposure to electrophilic 
chemicals or ionizing radiation [Perera et 
al. 2003; Kelada et al. 2003; Phillips 2002; 
Albertini 2001; Groopman and Kensler 
1999; Vineis et al. 1990; Ehrenberg et al. 
1974]. The objectives of much of this re­
search were to determine if genetic dam­
age did occur and if it could lead to harm­
ful health effects [Bonassi et al. 2004].
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Much of the newer DNA and expression 
technologies, including toxicogenomics, 
transcriptomics, proteomics, and meta- 
bonomics, are means to assess acquired 
genetic effects [NRC 2007; Wang Z et al. 
2005; Toyoshiba et al. 2004; Waters et al. 
2003; Christiani et al. 2001]. These ap­
proaches allow for assessing the expression 
of many thousands of genes before and af­
ter exposure. Implicit in these approaches 
is that effects of xenobiotics can be detect­
ed in expression of genes. Critical in us­
ing this technology will be bioinformatics, 
the ability to analyze and interpret the vast 
amounts of data that arise from the stud­
ies. Such interpretation is quite difficult be­
cause many factors affect gene expression, 
and there is need to distinguish adaptive 
or homeostatic responses from pathologic 
ones. If a pattern from high throughput 
(e.g., microarrays) can be validated as a 
biomarker of effect, it may be used as an 
independent or dependent variable in etio- 
logic or intervention research and as evi­
dence of harm in workers’ compensation or 
tort litigation [Segal et al. 2005; Marchant 
2003a, 2003b]. These patterns could also 
be used in standards as biological exposure 
indices.
The informed consent issues raised in sec­
tion 7.2 for research involving banked 
specimens and inherited genetic factors 
also pertain to research on acquired genet­
ic effects. Proteomic, toxicogenomic, and 
transcriptomic research may occur with 
specimen banks previously collected. Indi­
viduals who participate in such banks may 
only be able to give broad, general con­
sent. Pertinent to this discussion are issues 
of privacy and confidentiality in the use of 
banked specimens in research [Rothstein 
and Knoppers 2005].
7 .6  A c q u i r e d  G e n e t i c  
E f f e c t s :  P r a c t i c e
The ascertainment of acquired genetic dam­
age information in occupational safety and 
health practice would generally occur in 
the form of genetic monitoring. However, 
the fact that it involves preclinical somatic 
genetic effects often leads to its consider­
ation as a somewhat different form of mon­
itoring. Genetic monitoring is similar to bi­
ological monitoring, but instead of merely 
assessing exposure, it assesses the effects 
of exposure. At present, the results of ge­
netic monitoring can only be interpreted on 
a group level; they have not been validated 
as individual risk predictors [Van Damme 
et al. 1995]. If high-throughput expression 
technologies become candidates for use in 
genetic monitoring, the issues of standard­
ization, validation, and interpretability will 
have to be overcome since these will be 
much greater than with a single test.
7 .7  A c q u i r e d  G e n e t i c  
E f f e c t s :  R e g u l a t i o n  a n d  
L i t i g a t i o n
Currently, no U.S. regulations require ge­
netic monitoring of workers. In part, this is 
because questions arise about whether ge­
netic monitoring indicates exposure, a po­
tential health problem, or a compensable 
injury [Schulte and DeBord 2000].
The gene expression technologies have 
been viewed as potentially providing use­
ful data for group risk assessment; how­
ever, there are numerous interpretive ques­
tions, as summarized by Freeman [2004],
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regarding the use of data from microarray 
experiments by regulating agencies.
• How does a regulator deal with risk 
assessment data that scientists are 
often unable to interpret—data that 
some companies are anxious to submit 
and others to withhold?
• How does this same regulator evaluate 
information that is produced without 
a universally recognized standard for 
laboratory protocols or data formats?
• Should companies submit all data 
voluntarily without knowing whether 
regulators will be able to understand 
it, and, if so, exactly how they will use 
it?
• What if data that cannot be inter­
preted now are later shown to indi­
cate toxicity, perhaps at a low level 
that could not be detected in animal 
testing [Freeman 2004]? The critical 
issue in using genomics data is that if 
and when it is interpretable in terms 
of population risks, what will be the 
regulatory focus if sensitive sub­
groups are identified? Will controls 
be required to protect these groups, or 
will risk management strategies, such 
as communications, be applied [Free­
man 2004]?
Data from gene expression technologies 
may contribute to understanding the im­
pact of interindividual variability in risk 
assessments. Hattis [1998] has described 
examples that show various possibilities 
for improving quantitative risk assessment 
of both cancer and noncancer effects of en­
vironmental and occupational exposures 
with the aid of human data on interindi­
vidual variability. He argues that improve­
ments would be possible if interindividual 
variability data were collected more sys­
tematically by investigators and if previ­
ously collected individual data were made 
more readily available. In general, there 
appears to be a strong consensus among 
risk assessors that reducing the uncertainty 
associated with our understanding of hu­
man variability will improve risk assess­
ment [Hattis and Swedis 2001; Bailar and 
Bailer 1999; Grassman et al. 1998].
In the short term, transcriptomics, pro- 
teomics, and metabonomics will probably 
be of most value for the hazard identifica­
tion aspect of risk assessment [Morgan et 
al. 2002; Faustman and Omenn 1996]. If 
gene expression technology is to enter the 
mainstream of the risk assessment process, 
protocols for assays to confirm selected 
biochemical responses will need to be de­
veloped as regulatory requirements [Mor­
gan et al. 2002]. Various uncertainties ex­
ists that limit confidence in and utility of 
risk assessment in general for informing 
regulatory decisions. These include issues 
in extrapolating from animals to humans, 
high to low doses, the shape of the dose- 
response curve, and estimating workplace 
levels of exposure. Genetic expression 
data may be useful in addressing these is­
sues [Marchant 2003a].
Genetic expression data potentially may 
be used to quantify or address exposure 
in litigation [Marchant 2003 a]. Critical in 
this regard is the timing of these expres­
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sion changes, the linkage to a particular 
exposure, recovery for latent risks, and 
decisions on interventions such as medi­
cal monitoring [Marchant 2003 a]. The key 
feature for any of these uses is that the ge­
netic expression tests be validated for the 
specific use being considered.
One potential outcome of genetics research 
in general, and occupational toxicogenom- 
ics research in particular, is the potential to 
transform current conceptions of “risk” and 
“injury” in the law of toxic torts [Grodsky 
2007]. As more is learned about acquired 
genetic effects, such as those related to 
gene expression, preclinical changes will 
be detected before classical clinical symp­
toms occur. The question has been raised 
whether plaintiffs exposed to toxic hazards 
and placed at significant risk of disease, yet 
perhaps not physically “injured,” should 
be entitled to some form of legal remedy 
[Grodsky 2007]. This contention hinges on 
the evidence base regarding the validity of 
preclinical change to predict or lead to dis­
ease. Blurring of the risk and injury con­
cepts may lead to ambiguity about the ap­
propriate public health action or legal rem­
edies. Where science can not only identify 
such conditions but possibly treat them at 
the molecular level, a case can be made for 
the need for medical monitoring and pos­
sibly treatment of individuals to prevent or 
minimize the ultimate effect. This concept 
is not new to the occupational safety and 
health field, but has been advocated for 
workers determined by epidemiologic re­
search to be members of high-risk groups, 
such as asbestos workers [Samuels 1998b]. 
This was termed “high-risk management.” 
If new genetic and genomic technologies
and research enable the identification of an 
expanding progression of biologic effects 
between a chemical (or other workplace) 
exposure and fully developed disease, 
there is the expectation of new legal claims 
by such workers [Grodsky 2007]. The oc­
cupational safety and health community 
may have to apply high-risk management 
concepts to these groups of workers. This 
would mean considering appropriate risk 
communication, biological monitoring, 
medical screening, and risk management 
issues [Schulte 2005; Samuels 1998b].
Another way to communicate results to 
workers is through group presentations 
that stress the overall results and how they 
fit in with current research knowledge. 
Such presentations provide a forum for 
questions and discussions about the issues, 
as well as education about interpretation 
of results. In the beryllium example, some 
workers with chronic beryllium disease 
do not have the HLA-DPB1E69 gene, and it 
is important to emphasize to workers that 
absence of the high-risk marker does not 
mean absence of risk for disease. In other 
words, good workplace hygiene is still es­
sential. Care also must be taken to ensure 
that workers are not inadvertently identi­
fied when presenting group results through 
too much detail in tables and examples.
7 .8  T h e  A d e q u a c y  o f  
S a f e g u a r d s  t o  P r o t e c t  
W o r k e r s  A g a i n s t  M i s u s e  
o f  G e n e t i c  I n f o r m a t io n
Rothstein [2000b] reviewed the laws re­
lated to genetic nondiscrimination.
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As of October 2000, about half of the 
states have enacted laws prohibiting genet­
ic discrimination in employment. President 
Clinton signed a similar Executive Order 
applicable to federal employees on Febru­
ary 10, 2000 (Executive Order No. 13145) 
[65 Fed. Reg. 6877 (2000)]. The laws are 
directed at two perceived problems: (1) em­
ployers responsible for employee and de­
pendent medical expenses, either through 
commercial insurance or self-insurance, 
have a great economic incentive to exclude 
presumed high-cost future consumers of 
medical resources [EEOC 1995] and (2) 
individuals who are at a genetic risk of 
disease will be discouraged from undergo­
ing genetic testing if they think that their 
current or future employers would have 
access to the results of the tests or other 
genetic information [Yesley 1999].
Regarding safeguards in genetic research, 
Anderlik and Rothstein [2001] presented 
the following discussion:
Although the rules for the new 
science are not yet fixed, we find 
some areas of consensus. First, 
privacy is too large an issue to 
be solely the responsibility of 
geneticists, or any other group.
The involvement of ethicists, 
social scientists, lawyers, and 
representatives of affected 
communities in appropriate 
cases is an important protection 
against the errors of judgment 
that may result from narrowness 
of perspective. Without public 
participation, there is a very
real risk that the public will 
turn against genetic research if 
projects come to light that violate 
public expectations of protection 
of privacy and autonomy.
Second, individuals and 
organizations working in the field 
of genetics should add privacy 
protection to the checklist of items 
to be reviewed at each stage of a 
project, from conception through 
ongoing monitoring.
Third, although laws protecting 
the privacy of health information 
and prohibiting genetic 
discrimination are in place in most 
jurisdictions, there are gaps in 
these laws and in the social safety 
net. Public fears of irrational 
and rational discrimination in 
insurance are not unjustified, 
and scientists eager to recruit 
participants for genetic research 
will have to address these fears.
Researchers are not regulated directly un­
less they fit the HIPAA definition of health 
care providers. In addition, the key provi­
sion of HIPAA affecting research permits 
covered entities (such as health care pro­
viders) to use or disclose protected health 
information for research purposes without 
authorization by the research participant. 
There are, however, limited safeguards for 
research participants. Before information 
can be used or disclosed in this manner, 
the covered entity must obtain a written 
waiver of authorization from an IRB or a 
privacy board for each research protocol.
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This requirement applies to all research for 
which a covered entity serves as a conduit 
of protected health information, regardless 
of funding source.
The federal government offers some ad­
ditional confidentiality protection for fed­
erally funded research under 301(d) and 
308(d) of the Public Health Service Act 
[FDA 2007]. Assurance under 308(d) pro­
tects both the individual and the institution, 
while a certificate of confidentiality under 
301(d) protects only the individual in the 
research study. These protections limit dis­
closures of information that are permitted 
under the Privacy Act, such as routine or 
court-ordered disclosures without the con­
sent of the respondent [NIH 2007]. These 
additional protections under 301(d) and 
308(d) are generally reserved for data col­
lection of sensitive information.
Unfortunately, as long as legal protections 
remain imperfect, one of the principal 
tasks for researchers committed to ethical 
conduct will be educating potential partici­
pants about the harms that may be associ­
ated with participation in genetic research. 
Before educating potential participants, 
however, genetic researchers need to con­
sider the societal aspects of their research. 
For better or worse, privacy will be as im­
portant to genetic researchers as pedigrees, 
polymorphisms, and proteomics.
In summary, genetic information has the 
potential to improve employee health and 
reduce worker disability. State and Federal 
laws have been passed to protect individu­
als against using genetic information for 
discriminatory practices. Some concerns
still remain with regard to autonomy, pri­
vacy, stigmatization and clinical relevance. 
At this time, genetic screening in the work­
place is not recommended as currently no 
genetic test has been validated for an oc­
cupational disease.
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